REGISTER RAKA ZA SLOVENIJO CANCER REGISTRY OF SLOVENIA EPIDEMIOLOGIJA IN REGISTER RAKA EPIDEMIOLOGY AND CANCER REGISTRY Poročilo RR št. 46 Report No. 46 LJUBLJANA 2007 INCIDENCA RAKA V SLOVENIJI CANCER INCIDENCE IN SLOVENIA ISSN 1318-2471 02 40 Uredniški odbor / Editorial Board Maja Primic Žakelj, glavna urednica / editor-in-chief Matej Bračko Marko Hočevar Vera Pompe–Kirn Primož Strojan Vesna Zadnik Branko Zakotnik Tina Žagar Osebje Registra raka / Staff of the Cancer Registry Maja Primic Žakelj, vodja / head Barbara Babuder Mojca Brus Andrej Kirn Andrej Krašovec Neža Milčič Darja Strle Fani Škrlec Nataša Šturm Tina Žagar, mlada raziskovalka / junior researcher Računalniška obdelava / EDP analysis Jurij Modic Vesna Zadnik Tina Žagar Priprava za tisk in tisk / Typesetting and printing Tiskarna knjigoveznica Radovljica d.o.o. Izdal / Published by Onkološki inštitut Ljubljana / Insitute of Oncology Ljubljana, Slovenia Direktor / Director Zvonimir Rudolf Naslov / Correspondence to Maja Primic Žakelj Onkološki inštitut Ljubljana /Institute of Oncology Ljubljana Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenia Telefon / Phone: + 386 (1) 5879 563 E-pošta / E-mail: register@onko-i.si Spletna stran / Web site: http://www.onko-i.si/rrs/ http://www.onko-i.si/crs/ Nasvet za citiranje / Recommended reference Incidenca raka v Sloveniji 200 . Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2007.4 Cancer incidence in Slovenia 200 . Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2007.4 Vse pravice pridržane. All rights reserved. VSEBINSKO KAZALO / CONTENTS Stran / Page Uvod in pojasnila Introduction and Comments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 Tabela A Breme raka - Slovenija 2004 Table A Cancer burden - Slovenia 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16 Tabela B Prevalenca glede na obdobje opazovanja - Slovenija, 31. 12. 2004 Table B Prevalence by period of observation - Slovenia, December 31, 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16 Tabela C Stabilnost podatkov - število in odstotek novih primerov raka, prijavljenih po izdaji letnega poročila, po obdobju - Slovenija, 1965–2003 Table C Data stability - number and percentage of new cases reported after the publication of annual reports, by time period - Slovenia, 1965–2003. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16 Tabela D Opazovana in napovedana incidenca raka - Slovenija, 1995–2007 Table D Observed and predicted cancer incidence - Slovenia, 1995–2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .17 Slike / Figures 1 Najpogostejše rakave bolezni po spolu - Slovenija 2004 The leading cancer sites by sex - Slovenia 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . .18 2 Odstotni delež vseh rakov po starostnih skupinah in spolu - Slovenija 2004 Percentage distribution of all cancer sites by age groups and sex - Slovenia 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .19 3 Odstotni odklon grobe incidenčne stopnje raka po statističnih regijah od povprečne Percentage deviation of crude cancer incidence rate in statistical regions from . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 4 Groba in kumulativna letna incidenčna stopnja vseh rakov po spolu - Slovenija 1950–2004 Crude and cumulative annual cancer incidence rate for all sites by sex - Slovenia 1950–2004 . . . . . . . . . . . . . . . . . . . . . 20 5 Groba letna incidenčna stopnja izbranih rakov po spolu - Slovenija 1950–2004 Crude annual cancer incidence rate for selected primary sites by sex - Slovenia 1950–2004 . . . . . . . . . . . . . . . . . . . . . . . . . 21 6 Debelo črevo (C18), moški - Slovenija, 2000–2004 Colon (C18), males - Slovenia, 2000–2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 7 Debelo črevo (C18), ženske - Slovenija, 2000–2004 Colon (C18), - Slovenia, 2000–2004females 23 8 Rektosigmoidna zveza in danka (C19–C20), moški - Slovenija, 2000–2004 Rectosigmoid junction and rectum (C19–C20), males - Slovenia, 2000–2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 9 ženskeRektosigmoidna zveza in danka (C19–C20), - Slovenija, 2000–2004 Rectosigmoid junction and rectum (C19–C20), females - Slovenia, 2000–2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 10 Dojka (C50), ženske - Slovenija, 2000–2004 Breast (C50), females - Slovenia, 2000–2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 11 Maternični vrat (C53), ženske - Slovenija, 2000–2004 Cervix uteri (C53), females - Slovenia, 2000–2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 12 Relativno 5-letno preživetje bolnikov s 95 % intervalom zaupanja z izbranimi raki po spolu, zbolelih v letih 1995–1999 in 2000–2004 5-year relative survival with 95% confidence interval for selected cancer sites by sex 28 Cancer Incidence in Slovenia 2004 3 Institute of Oncology Ljubljana, Cancer Registry of Slovenia slovenske - Slovenija 2000–2004 average - Slovenia 2000–2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . in periods 1995–1999 and 2000–2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Tabele / Tables 1 Prebivalstvo po starosti in spolu - Slovenija, 30. 06. 2004 Population by age and by sex - Slovenia, June 30, 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 2 Prebivalstvo po statističnih regijah in spolu - Slovenija 30. 06. 2004 Population of Slovenia by statistical regions and by sex - Slovenia, June 30, 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 3 Število novih primerov raka, število in odstotek mikroskopsko potrjenih primerov, število in odstotek primerov, ugotovljenih z drugimi preiskavami in število in odstotek registriranih samo iz zdravniških poročil o vzroku smrti, po lokaciji in spolu - Slovenija 2004 Total number of new cancer cases, number and percentage of microscopically confirmed cases, number and percentage of cases confirmed by other investigations, and number and percentage of cases registered from death certificates only, by site and by sex - Slovenia 2004 32 4a Število novih primerov raka po lokaciji (MKB–10), spolu in starosti - Slovenija 2004 Number of new cancer cases by site (ICD-10), by sex and by age - Slovenia 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 4b Število novih primerov raka po lokaciji (MKB–8), spolu in starosti - Slovenija 2004 Number of new cancer cases by primary site (ICD–8), by sex and by age - Slovenia 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . 42 5 Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter kumulativna stopnja (KS) po lokaciji in spolu - Slovenija 2004 Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex - Slovenia 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45 6a Število novih primerov raka po statističnih regijah, po najpogostejših lokacijah in spolu - Slovenija 2004 Number of new cancer cases by health regions by most frequent sites and by sex - Slovenia 2004 . . . . . . . . . . . . . . 52 6b Starostno standardizirana incidenčna stopnja raka po statističnih regijah, po najpogostejših lokacijah in spolu - Slovenija 2004 Age standardised cancer incidence rate by statistical regions, by most frequent sites and by sex - Slovenia 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 7 Število histološko (H) in citološko (C) potrjenih novih primerov raka po histološki vrsti in lokaciji - Slovenija 2004 Number of histologically (H) and cytologically (C) confirmed new cancer cases by histological type and by site - Slovenia 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 8 Število primerov ne-Hodgkinovih limfomovpo lokaciji, spolu in starosti - Slovenija 2004 4 Incidenca raka v Sloveniji 2004 Onkološki inštitut Ljubljana, Register raka za Slovenijo Total number of non-Hodgkin's malignant lymphomas by site, by sex and by age - Slovenia 2004 . . . . . . . . . . . . . . . . 63 9 Število novih primerov raka po bolnišnicah ugotovitve diagnoze ter število in odstotek primerov, napotenih na Onkološki inštitut Ljubljana (OI) - Slovenija 2004 Number of new cancer cases diagnosed by reporting hospitals, and number and percentage of cases referred to the Institute of Oncology Ljubljana (IO) - Slovenia 2004 . . . . . . . . . . . . . . . . . . . . . . 64 10 Število in odstotek novih primerov raka (brez registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu - Slovenija 2004 Number and percentage of new cancer cases (without cases registered from death certificates only) by stage, by site and by sex - Slovenia 2004 66 11 Število umrlih za rakom po lokaciji, spolu in starosti - Slovenija 2004 Number of cancer deaths by site, by sex and by age - Slovenia 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70 12 Število vseh živih bolnikov z rakom po spolu in izbrani primarni lokaciji - Slovenija, 31. 12. 2004 Prevalence of cancer patients by sex and by selected primary site - Slovenia, December 31, 2004 . . . . . . . . . . . . . . . 75 Izbor publikacij / Selected publications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . UVOD Register raka za Slovenijo (Register) je eden najstarejših populacijski registrov v Evropi. Ustanovljen je bil leta 1950 na Onkološkem inštitutu v Ljubljani kot posebna služba za zbiranje in obdelavo podatkov o incidenci raka in preživetju bolnikov z rakom. Pred letom 1950 so bili populacijski registri raka le v Hamburgu, na Danskem in v Veliki Britaniji. Od ustanovitve do leta 1975 je Register vodila pokojna profesorica dr. Božena Ravnihar, dolgoletna direktorica Onkološkega inštituta. Njeno delo j nato prevzela profesorica dr. Vera Pompe Kirn, ki je do leta 2003 skrbela za nadaljnj uveljavljanje Registra v domačem in mednarodnem merilu. Tega leta je On ološki inštitut dobil nov statut, ki je združil Register z Enoto za epidemiologijo v enotno služ raka. V njej so poleg Registra še bolnišnični register Onkološkega inštituta, oddelek za epidemio- logijo, kjer tečejo epidemiološke raz Register organiziranega presejanja za raka materničnega vratu (ZORA), kjer je tudi koordinacija državnega programa prese- janja za raka materničnega vratu. e e k bo Epidem-iologija in register iskave, in Prijavljanje raka je že od ustanovitve Registra v Republiki Sloveniji obvezno in zakonsko predpisano (Ur. l. SRS, št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS, št. 9/92 in št. 65/00). Zbrani podatki so podlaga za ocenjevanje bremena rakavih bolezni v državi, za načrtovanje in ocenjevanje onkološkega varstva na področju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za načrt vanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska oprema, posteljne zmogljivosti), ter za klinične in epidemiološke raziskave v Sloveniji in v sklopu širših mednarodnih raziskav. Populacijski register raka opravičuje svoj obstoj, če se zbrani podatki tudi redno obdelujejo, objavljajo in uporabljajo. Ena izmed stalnih oblik vračanja obdelanih informacij so letna poročila. Ker je virov o INTRODUCTION The Cancer Registry of Slovenia (Registry) is one of the oldest population based registries in Europe. It was founded in 1950 at the Institute of Oncology Ljubljana (Institute) as a special service for collecting and processing data on cancer incidence and cancer patients' survival. Before 1950, population based registries existed only in Hamburg, Denmark and in Great Britain. From its foundation and until 1975, the Registry was headed by the late Professor Božena Ravnihar who was also general director of the Institute for almost 20 years. At the Registry she was succeeded by Professor Vera Pompe-Kirn, who carried on her work until 2003 and contributed a lot to the further development of the Registry as well as its recognition at the national and international level. In 2003, a new Statue was adopted by the Institute that enacted the merging of the Registry and Epidemiology Unit in a single service, Epidemiology and Cancer Registry. The new service comprises, besides Cancer Registry of Slovenia, also the hospital-based Cancer Registry of the Institute, Epidemiology Unit for epidemiologic studies and Cervical Cancer Screening Registry (ZORA), a unit that is also in charge of coordinating the nationally organised cervical cancer screening programme. Notification of cancer has been compulsory in Slovenia since the foundation of the Registry and prescribed by law (Official Gazette of SRS, No. 10/50, No. 29/50, No. 14/65, No. 1/80, No. 45/82, No. 42/85; Official Gazette of RS, No. 9/92 and No. 65/00). The data collected serve as the basis for assessing the cancer burden in the country, for programming and evaluating primary prevention, diagnosis, treatment and rehabilitation, planning facilities and funding needed for cancer control (personnel, equipment and hospital capacities) as well as for clinical and epidemiological research in Slovenia and in international multicentric studies. The existence of a population-based cancer registry is justified only by regular processing, publishing and using the data collected. The Registry's Annual Reports are one of the Cancer Incidence in Slovenia 2004 5 Institute of Oncology Ljubljana, Cancer Registry of Slovenia informacij več, je čas, potreben za dokončanje zbirke, povezavo in objavo podatkov pri nas in po svetu daljši, običajno 2 do 3 leta. Sedanje poročilo prikazuje podatke o novih pri incidenco pričakujemo leta 2007, dodajamo s posebno statistično meto Register je prva letna poročila izdajal že v letih 1953-57 za leta 1951-55. Prva analiza podatkov za leto 1950 je bila objavljena v 1951. Podatki za leta 1957-71 so bili objavljani v periodičnih publ ikaci ja in v . Od leta 1965 so bili podatki spet redno objavljani v posebnih letnih poročilih z naslovom ), in sicer v slovenskem in angleškem jeziku. Za vsebino publikacije skrbi uredniški odbor, v katerem smo zbrani specialisti raznih vej onkologije. Glede na želje in pripombe uporabnikov letna poročila iz leta v leto dopolnjujemo, vendar skrbimo za to, da so objavljeni podatki iz leta v leto primerljivi. Incidenca raka je po svetu zelo različna, za raziskovanje teh razlik pa so ključni kakovostni podatki. Prav zato so bili in so naši podatki o incidenci raka zanimivi tudi za svet. Leta 1957 je izšlo prvo obsežnejše poročilo za leta 1950-55 v angleščini. Podatke za leta 1956- 60, 1961-65, 1968-72, 1973-76, 1978-81, 1982-87, 1988-92 in 1993-97 so objavili tudi v vseh osmih zvezkih knjige na agencija za raziskovanje raka. Podatki o incidenci in umrljivosti za rakom so vključeni tudi v mednarodne podatkovne baze preživetje slovenskih bolnikov pa je obdelano v mednarodnih študijah in podatke v Registru obdelujemo in pojasnjujemo v skladu s trenutno perečo problematiko v Sloveniji, z lastnim ra- ziskovalnim programom in s predlogi merih, registriranih v letu 2004. Za osnovno informacijo o tem, kakšno do ocenjeno napoved za leto 2007. h Svetovne zdravstvene organizacije (1965-77) in (1978-2003 tudi ki jo izdaja Mednarod Zbrane Zdravstvenem vestniku leta Epidemiological and Vital Statistics World Health Statistics Report Rak v Sloveniji Incidenca raka v Sloveniji Cancer Incidence in Five Continents, EUROCIM, GLOBOCAN, ACCIS, EUROCARE II EUROCARE III. regular ways of disseminating information. Because of a variety of data sources, data collection, their linking and publication is rather time consuming (with us and elsewhere) and usually takes two to three years. As preliminary information on expected incidence in 2007, predicted numbers and rates are presented in this report. The first annual reports of the Registry for the period 1951-55 were issued during the years 1953-57. The first data analysis for the year 1950 was published in in 1951. The data for the period 1957-71 were appearing in the periodicals and both edited by World Health Organization. From 1965 onwards, the data have been appearing regularly in special bi- lingual (Slovene-English) annual reports, first entitled (1965-77), and then (1978- 200 ). The editorial board, responsible for the contents of the report, consists of experts of different specialties in oncology. Our endeavours have always been directed towards further improvement of these publications, by taking into account as much the requests and comments of the users as the comparability of the data from year to year. There are great differences in cancer incidence among different populations and to evaluate them, good quality data are needed from different parts of the world. That is why our data on cancer incidence have always been interesting also for professional publ ic abroad. In 1957, the f i rs t comprehensive report, covering the period 1950-55, was issued in English under the title The data for the periods 1956-60, 1961-65, 1968-72, 1973- 76, 1978-81, 1982-87, 1988-92 and 1993-97 were published in all eight volumes of the issued by International Agency for Research on Cancer. The data on cancer incidence and mortality are also included in international databases The survival of Slovenian cancer patients is analysed in the international studies and The data collected have been processed in accordance with the current problems in Zdravstveni vestnik Epidemiological and Vital Statistics Report World Health Statistics Report Cancer in Slovenia Cancer Incidence in Slovenia Cancer in Slovenia 1955. Cancer Incidence in Five Continents EUROCIM, GLOBOCAN, ACCIS EUROCARE II EUROCARE III. , . 3 6 Incidenca raka v Sloveniji 2004 Onkološki inštitut Ljubljana, Register raka za Slovenijo uporabnikov. Izsledke objavljamo v člankih v domačem in tujem strokovnem in poljudnem tisku. Izdane so tudi tri knjige Seznam drugih pomembnejših del, objavljenih v zadnjih petih letih, je v dodatku na koncu poročila. Letošnje poročilo je v celoti dostopno v elektronski obliki na spletni strani Onkološkega inštituta Osnovni vir podatkov so prijavnice rakave bolezni. Registru jih pošiljajo iz vseh bolnišnic in diagnostičnih centrov v Sloveniji, iz ordinacij osnovnega zdravstvenega varstva pa le izjemoma, če bolnik ni napoten na nadaljnje preiskave in/ali zdravljenje. Dodatni vir podatkov so zdravniška poročila o vzroku smrti in obdukcijski zapisniki z diagnozo maligne bolezni. Zbiranje podatkov za to letno poročilo smo zaključili 31. marca 2007. Zanesljivost podatkov osvetljujeta dva kazalca: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež raka, registriranega samo iz zdr vniških poročil o vzroku smrti (tabela 3). Majhen delež primerov, prijavljenih po izdaji letnega poročila v raznih časovnih obdobjih kaže, da do izdaje poročila registriramo večino novih primerov raka (tabela C). Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, označene v tabelah s šifro 234.0 (karcinom in situ). Primerjava s podatki za obdobje 1961-92 tako ni možna. Po 10. reviziji MKB so vse intraepiteljiske spremembe matrničnega vratu uvrščene v šifro D06. Od leta 1995 registriramo tudi prijavljene intraepitelijske karcinome mehurja in maligne melanome Clark I. : . a Zemljevidi incidence raka v Sloveniji 1978- 1987, Preživetje bolnikov z rakom v Sloveniji 1963-1990 in Preživetje bolnikov z rakom v Sloveniji 1983-1997 http://www.onko-i.si/rrs. GRADIVO IN METODE Slovenia, as well as with respect to our research program and suggestions from our users. These data are published in national and foreign medical literature and as publications for lay readers. Three special publications are The list of other relevant publications is at the end of this report. The current annual report is available in pdf format on website of the Institute of Oncology: The main sources of data are notifications gathered from all hospitals and diagnostic centres in Slovenia, exceptionally also from primary health care centres in case the patient was not referred for further diagnostic investigations. This information is completed by death certificates and autopsy protocols stating cancer diagnosis. The collection of data for the current report was completed on March 31, 2007. The reliability of information can be assessed by two parameters: the percentage of microscopically (histologically or cytologi- cally) confirmed cases and by the percentage of cancer cases registered on the basis of death certificates only (Table 3). The small and stable proportion of cases registered after the publication of annual reports shows that the majority of cases are reported to the Registry by the time of the publication of annual reports (Table C). In 1993, compulsory registration of all cervical intraepithelial dysplasias classified as CIN III was introduced (code 219 according to ICD-8). Till then, only carcinoma in situ (code 234.0) was registered. Thus, the comparison with the data for the period 1961-1992 is not possible. According to ICD-10, al l cervical intraepithelial neoplasms (in situ and CIN III) are coded as D06. Since 1995, the number of all reported intraepithelial carcinomas of Atlas of Cancer Incidence in Slovenia 1978-1987, Cancer Patients' Survival in Slovenia 1963-1990 and Cancer Patients' Survival in Slovenia 1983-1997 http://www.onko i.si/crs. . - MATERIAL AND METHODS Cancer Incidence in Slovenia 2004 7 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Za razvrščanje neoplazem po lokacijah Register od leta 1997 uporablja do takrat pa je uporabljal osmo. Za vse, ki želijo primerjati podatke iz prejšnjih poročil, je dodana tabela 4b. Klasifikaciji različno uvrščata bolezni med maligne, zato število novih primero Prav pri uvrščanju med maligne bolezni je treba opozoriti še na klasifikacijo za morfologijo neoplazem, za katero uporab- l jamo mor fološki del Mednarodne klasifikacije bolezni za onkologijo, od poročila za leto 2001 tretjo izdajo. V tej izdaji je spet nekaj sprememb, tudi katere histološke vrste sodijo med maligne. Po tretji reviziji so med maligne uvrščene kronične mieloproliferativne bolezni in mielodispla- stični sindromi (sedaj v topografski šifri C96.7). V skladu novimi pravili tudi mejno malignih ovarijskih tumorjev ne uvrščamo več v kategorijo C56, pač v D39.1. Opozarjamo še, da so v tabeli 7 histološke vrste razvrščene po tretji reviziji morfološkega dela Mednarodne klasifikacije bolezni za onkologijo in združene v drugačne skupine kot v poročilih za leto 2000 in leta pred njim. V tabeli 6 smo do leta 2002 prikazovali podatke po devetih zdravstvenih regijah. V skladu z Uredbo o standardni klasifikaciji teritorialnih enot - SKTE, ki predpisuje sistematiko členitve ozemlja Slovenije na enajstih ravneh, smo se odločili, da v tej tabeli in regijskih primerjavah uporabimo raven SKTE-3, 12 statističnih regij. Po potrebi pa podatke lahko še vedno posredujemo do ravni upravnih enot. Za napoved incidence v letu 2007 je uporabljena metoda po Dybi in Hakulinenu, ki je primerna za oceno incidence v krajšem časovnem obdobju, saj upošteva samo obdobje diagnoze in starost; pri napovedih za daljša časovna obdobja je treba upoštevati tudi vpliv rojstne kohorte. 10. revizijo Mednarodne klasifikacije bolezni, poškodb in vzrokov smrti, v raka po obeh klasifikacijah ni enako. z pa the bladder and all malignant melanomas Clark I have been registered. Since 1997, cancer sites are coded according to the 10th revision of the (ICD- 10); before, the 8 revision was used (ICD-8). As in earlier reports, Table 4b contains also the data coded according to the 8th revision in order to allow the comparison with the earlier reports. There are differences in coding neoplasms as malignant or benign according to both classifications, so, according to the two classifications, the number of new cancer cases is not equal. When classifying tumours as malignant, the behaviour digit of the morphology code of the third edition of is used in the current annual report. In this edition, some changes were introduced in terms of morphology and behaviour code. According to this classification, chronic myeloproliferative disorders and myelo-displastic syndromes are classified as malignant (topography code C96.7), while ovarian tumours of borderline malignancy are currently coded as D39.1 (and not C56). It should be noted that in Table 7 the morphology codes are grouped in different categories as in reports 2000 and previous and are adapted to the third revision of morphology part of International Classifica- tion of Diseases for Oncology. Till report 2002, the data in Table 6 have been presented by 9 health regions. The new law on regional division of Slovenia introduced the system of eleven levels, and health regions are not official units. So, 12 statistical regions have been chosen to present the data in Table 6 since 2003 report. The method by Dyba and Hakulinen was used for predictions. It is suitable for predictions in shorter time period, taking into account period of diagnosis and age structure of population. For long-term predictions the cohort effect should be included also. International Statistical Classification of Diseases and Related health Problems International Classification of Diseases for Oncology th 8 Incidenca raka v Sloveniji 2004 Onkološki inštitut Ljubljana, Register raka za Slovenijo DEFINICIJE Incidenca Prevalenca roba incidenčna stopnja starostno specifična stopnja Starostno standardizirana stopnja Kumulativna incidenčna stopnja pomeni število vseh v enem koledarskem letu na novo ugotovljenih primerov raka v točno določeni populaciji. V incidenco ne štejemo novih primarnih rakov parnega organa iste lokacije, če je bila histološka vrsta obeh rakov, npr. leve in desne dojke, enaka. Prav tako v incidenco ne štejemo novega pojava raka iste histološke vrste na istem organu, npr. multiple lezije v debelem črevesu. V incidenco so vključeni primeri bolezni bolnikov s stalnim bivališčem na območju Republike Slovenije, ne glede na t , kje so bili ti bolniki zdravljeni. je število vseh živih bolnikov z rakom na določen datum ne glede na leto diagnoze. je število novih primerov na 100.000 oseb opazovane populacije, pove to relativno število v posamezni petletni starostni skupini. Če analiziramo incidenco v daljšem časovnem obdobju (če se starostna struktura prebivalstva v času spreminja) ali če primerjamo incidenco med populacijami z različno starostno strukturo, je potr uporabiti eno od metod starostne standardizacije. je teoretična incidenčna stopnja, pri kateri predpostavimo, da je starostna struktura opazovane populacije enaka starostni strukturi v standardni populaciji. verodostojnejšo primerjavo incidenčnih in umrljivostnih stopenj z državami v Evropi ali po svetu pri eposredni metodi starostne standardizacije uporabili svetovni standard, v tabeli 6b pa je za primerjavo incidenčnih stopenj med slovenskimi statističnimi regijami za standard uporabljena starostna struktura prebivalcev Slovenije ob popisu leta 2002. (v zadnjem stolpcu tabele 5) je petkratna vsota starostno specifičnih incidenc na 100 prebivalcev posameznih petletnih starostnih skupin do 74. leta starosti. Je neposredna, na dejansko populacijo posamezne petletne starostne skupine standardizirana incidenca ali o ebo Na slikah 6-11 smo za n G DEFINITIONS Incidence Prevalence Crude incidence rate age specific rate The age-standardised rate The cumulative incidence rate The cumulative risk is the number of newly diagnosed cancer cases in a defined population, reported to the Registry for a given calendar year. New primary cancers of the same histology in paired organs, e. g. on the left and right breast, are not comprised in the incidence figures, neither are any new cancers of the same histology appearing in the same organ, e.g. multiple lesions of the colon. The incidence includes only the data on patients with permanent residence in Slovenia, regardless of the place of treatment. is the number of all surviving cancer patients, irrespective of the year of diagnosis. is the number of new cases per 100,000 population, while the expresses this relative number in an individual five-year age group. When analysing the incidence rate within longer time period (if the age structure of population changes) or comparing the incidence between populations with different age structure, age standardisation is needed to adjust the rate for the effect of age. is a theoretical incidence rate assuming that the age structure in the observed population is the same as in the standard population. In Figures 6-11, the World standard population was used in direct standardisation for better comparison of Slovenian data with those from other countries in the World, while in table 6b the standard is age structure of Slovnian 2002 census population. (the last column in Table 5) is five times the sum of the age-specific incidence rates per 100 population, calculated over five-year age groups up to the age of 74 years. It is a directly age-standardized rate with the same population size in each age group, or as an approximation to the cumulative risk. is the risk an individual would have of developing the disease in Cancer Incidence in Slovenia 2004 9 Institute of Oncology Ljubljana, Cancer Registry of Slovenia približek kumulativnemu tveganju. nem starostnem obdobju, npr. do 74. leta starosti (če, seveda, ne umre prej zaradi drugih vzrokov). Kumulativno stopnjo računamo na 100 in jo izražamo v odstotkih. Kumulativna stopnja raka dojk pri žensk 7,2/100 pomeni, npr., da bo verjetno 7,2 % deklic, rojenih leta 2004 (ali ena od 14 do 75. leta starosti zbolelo za rakom dojk. Kumulativno incidenčno stopnjo smo uporabili za prikaz časovnega trenda incidence, kot je za Slovenijo prikazan na spodnjem delu slike 4. Primerjava oblike krivulj grobih in kumulativnih stopenj na sliki 4 kaže, da povečevanja incidence raka ne moremo pripisati le staranju prebivalstva RS, ampak da k temu prispevajo še drugi nevarnostni dejavniki. pomeni razmerje med opazovanim preživetjem proučevane skupine in preživetjem, ki bi ga pričakovali pri enako stari skupini istega spola v slovenski populaciji. Je približek preživetja bolnikov v primeru, da bi upoštevali kot vzrok smrti samo Izračunano je s paketom relsurv v programu R. prikazujejo osnovne podatke o bremenu raka v Sloveniji: število vseh zbolelih in umrlih za rakom v letu 2004, prevalenco in najpogostejše rakave bolezni po spolu. V je prikazana incidenca in povprečna letna incidenčna stopnja vseh in izbranih rakov v dveh 5-letnih obdobjih 1995- 1999 in 2000-2004. Pomembne so kjer smo tokrat dodali še 95-odstotni napovedni interval. opozarja na različno breme raka v raznih življenjskih obdobjih. Rak je skoraj izjema pri mladih do 19 let. Manj kot 3 % vseh rakov je med 20. in 34. letom starosti, ko je pri moških najpogostejši rak mod, pri ženskah pa rak materničnega vratu. Medtem ko Kumula- tivno tveganje je verjetnost posameznika, da zboli za rakom v izbra ah izbranega raka. , Relativno preživetje Tabeli A, B in slika 1 abeli D napovedane vrednosti za leto 2007 Slika 2 POJASNILA t question during a certain age period if no other causes of death were in operation. The cumulative rate is expressed per hundred (per cent). Thus, the cumulative rate (0-74) of 6.4/100 for breast cancer in females means that 6.3% of women (each l6th woman) are expected to develop breast cancer by their age of 75. The cumulative rate was used to present the incidence time trend in the lower part of Figure 4. The comparison of the curves of crude incidence per 100 000 population and cumulative incidence rates in Figure 4 indicates that the increasing cancer incidence rate in both sexes cannot be attributed only to the aging of population, but also to additional risk factors. Cumulative rate is used also in cancer maps. is the ratio of the observed actual survival and the survival that is, in the observation period, expected in general population of Slovenia with respect to age and sex. It is approximation of cancer cause specific survival. It has been calculated with the package relsurv in the programme R. present the basic data on cancer burden in Slovenia: the number of new, deceased and prevalent cancer patients in 2004 and the most frequent cancer sites by sex. In incidence and average crude incidence rate in two 5-year periods (1995-1999 and 2000-2004) is presented together with predicted values for 2007 toigether with 95% prediction interval. points to the different proportion of cancer in different age groups. Cancer is more an exception till the age of 19, and less than 3 percent of all cancer is in the age group 20-34, where the most frequent is testicular cancer in males and cervical in females. The proportion of new cancer patients is a bit higher among females in the age group 35-49, while this ratio is reversed between the age of 50-74 years. After the age of 75, there is again a higher proportion , Relative survival Tables A and B and Figure 1 Table D, Figure 2 COMMENTS 10 Incidenca raka v Sloveniji 2004 Onkološki inštitut Ljubljana, Register raka za Slovenijo med 35. in 49. letom zboli za rakom nekaj več žensk kot moških, se med 50. in 74. letom to razmerje obrne; delež zbolelih je spet večji med ženskami po 75. letu starosti, tudi zato, ker je njihova pričakovana življenjska doba daljša. Na je prikazan odstotni delež, za katerega posamezne statistične regije odstopajo od slovenskega povprečja v obdobju 2000-2004. Med najbol j obremenjenimi izstopajo Osrednjeslovenska, Obalno-kraška in orenjska regija. Ti podatki so pomembni za načrtovanje zdravstvenih zmogljivosti. Starostno standardizirane incidenčne stopnje ( ) kažejo, da je velik del razlik med regijami posledica različne starostne strukture njihovih prebivalcev. kažeta trende incidence vseh in izbranih rakov po spolu. Pri grafičnih prikazih so v eno skupino združeni rak debelega črevesa in danke in v drugo rak ust, žrela in grla (glava in vrat). so pomembnejši epi demiološki podatki o raku debelega črevesa, rektosigmoidne zveze in danke, dojk in materničnega vratu. Podatki so izhodišče za vrednotenje učinkovitosti presejalnih programov. Zaenkrat v Sloveniji teče le organiziran presejalni program za raka materničnega vratu ZORA, v letu 2007 bomo postopno uvajali organiziran program za raka dojk DORA, v skladu z evropskimi priporočili pa se načrtuje tudi presejanje za raka debelega črevesa in danke. Z verodostojnejšo primerjavo incidenčnih in umrljivostnih stopenj z državami v Evropi ali po svetu smo pri uporabili svetovni standard. Ker je v tem standardu delež starejšega prebivalstva relativno manjši kot v slovenskem prebivalstvu, so te stopnje večinoma manjše od grobih. prikazuje bolnikov z vsemi in izbranimi raki, zbolelih v letih 2000-2004. Za primerjavo so dodani podatki o bolnikih, zbolelih v letih 1995-1999. Pri moških se je skupno preživetje povečalo za 8 %, delno tudi na račun boljšega prijavljanja raka prostate nižjih stadijev, ki imajo boljšo prognozo, saj je pri tej bolezni preživetje navidezno večje kar za 14 %. sliki 3 tabela 6b Sliki 4 in 5 slikah 6 do 11 Slika 12 relativno 5-letno preživetje G Na - a neposredni metodi starostne standardizacije of cancer among females, also because of their longer life expectancy. In the percentage deviation of crude incidence rate in 12 statistical regions from Slovenian average incidence rate in 2000-2004 is presented. The highest incidence rates are in Osrednjeslovenska, Obalno-kraška and Gorenjska region. While these data are important for planning health care facilities, the age standardised rates in Table 6b indicate, that the majority of these differences are due to different age structure of population in these regions. show the incidence trends for all and selected cancers by sex. In graphical presentations, colon and rectal cancers are grouped in one category as colorectal, as well as oral, pharyngeal and laryngeal cancers as head and neck. show some important epide- miological data on cancers of colon, rectosigmoidal junction and rectum, breast and uterine cervix. These data are important for evaluation of screening programmes. In Slovenia currently cervical cancer screening is the only organised screening programme (Programme ZORA), in 2007 a gradual introduction of organised breast cancer screening is planned (Programme DORA) and it is hoped that colorectal cancer screening will also start soon. In these figures, direct age standardization using the World standard population was applied for valid comparison of incidence and mortality rates with other countries. As in this standard, the proportion of older population is relatively smaller as in slovenian population, these rates are in general lower than crude ones. of all and selected cancer sites in patients diagnosed in 2000-2004 is presented along with the same survival in patients, diagnosed in 1995-1999. In all male cancer patients the relative five-year survival increased for 8%, partially also due to better registration of prostate cancer cases with less advanced stage at diagnosis, who have better prognosis, as in these patients, the survival. In these patients the five-year relative survival increased for 14%. Nine-percent better five- Figure 3, Figures 4 and 5 Figures 6-11 In figure 12, 5-year relative survival Cancer Incidence in Slovenia 2004 11 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Za 9 % boljše preživetje bolnikov z rakom debelega črevesa in danke je gotovo realno, posledica boljšega odkrivanja, večje kakovosti zdravljenja in več sistemskega zdravljenja. Pri ženskah je skupno preživetje večje za 4 %. Tudi pri njih je za 8 % boljše preživetje pri bolnicah z rakom debelega črevesa, za 6 % pa se je izboljšalo preživetje bolnic z rakom dojk. prikazujejo podatke o prebivalcih in incidenci raka v Sloveniji leta 2004 po spolu, starosti, lokaciji, histološki vrsti in stadiju bolezni ob diagnozi, o incidenci po statističnih regijah ter podatke o številu novih primerov raka, ugotovljenih v tem letu po posameznih bolnišnicah, število smrti za rakom po spolu, starost i in lokaci j i ter prevalenco najpogostejših rakov. prikazujemo, na kakšen način je bila postavljena diagnoza registriranim novim primerom raka. Od 10.625 leta 2004 na novo registriranih primerov raka je bila pri 92,6 % diagnoza potrjena mikroskopsko (histološko ali citološko), pri 6,1 % z drugimi preiskavami, 1,3 % primerov pa smo registrirali samo na osnovi zdravniškega poročila o vzroku smrti , ki je že več let podoben, kaže bolnike, ki verjetno zaradi starosti ali napredovale bolezni niso bili zdravljeni v bolnišnici. Kakšna je bila morfološka slika malignomov pri 9.837 primerih, pri katerih je bila diagnoza potrjena mikroskopsko, kaže V njej so posebej primeri, ki so potrjeni histološko (90,6 %) in tisti, ki so bili potrjeni samo citološko (9,4 %). Po 8. reviziji MKB, po kateri so raki razvrščeni v je novih primerov raka 10.570. Razlika za 55 primerov je posledica novega razvrščanja neoplazem glede na tretjo izdajo morfološkega dela Mednarodne klasifikacije bolezni za onkologijo. prikazuje grobo in starostno specifično incidenčno stopnjo na 100.000 prebivalcev ter kumulativno stopnjo na 100. Število vseh novih primerov raka iz leta 2004 je preračunano na število prebivalcev R Slovenije na dan 30. junija 2004. je število novih primerov vseh in izbranih rakov prikazano po statističnih regijah. Te številke so pomembne za načrtovanje zdravstvenih zmogljivosti. Tabele tabeli 3 tabela 7. tabeli 4b, Tabela 5 tabeli 6a V . Ta zadnji odstotek V year relative survival of colorectal cancer patients is real, reflecting earlier diagnosis and better surgical and medical oncology treatment. In all female cancer patients the five-year relative survival increased for 4 %. In colon cancer patients the relative survival increased for 8% and in breast cancer patients for 6%. show the data on population and on cancer incidence in Slovenia in 2004 by sex, age, primary site, histology, stage of the disease at diagnosis, on the incidence in the individual statistical regions, and on new cancer cases diagnosed in the current year in different hospitals in Slovenia, on deaths and on prevalence of most frequent cancer sites. In data on basis of diagnosis of new cancer cases that were registered in 2004 are presented. From 10,625 new cancer cases, in 92.6% the diagnosis was confirmed microscopically (by histology or cytology), in 6.1% with other investigations and 1.3% was registered from death certificate only. This letter percentage has been similar for several years and represents those patients that, due to advanced age or disease have not been treated in the hospital. The morphology of tumours in 9,837 cases, diagnosed microscopically, is presented in In this table, cases confirmed by histology (90.6%) and by cytology only (9.4%) are presented separately. In the diagnoses are coded according to the 8 revision of International Classification of Diseases. According to this classification, 10,570 new cancer cases were registered. The difference of 55 cases is due to new morphology classification of the third revision of International Class- ification of Diseases for Oncology. shows crude and age specific incidence rate per 100,000 population and cumulative rate per 100. For calculation of crude rate, the Slovenian population census on June 30, 2004 was used. In the number of new cases of all and selected cancer sites by different statistical regions is presented. Tables Table 3, Table 7 Table 4b, Table 5 Table 6a, . th 12 Incidenca raka v Sloveniji 2004 Onkološki inštitut Ljubljana, Register raka za Slovenijo V starostno standardizirana incidenca kaže, da so razlike med regijami tudi posledica različnega deleža starejših. kaže starostno porazdelitev ekstranodalnih in nodalnih lokacij ne- Hodgkinovih malignih limfomov. Ker je število ekstranodalnih lokacij majhno, so prikazane le absolutne številke. Iz je razvidno, kje vse bolnikom postavijo diagnozo. Tako kot že vrsto let, polovica od vseh bolnikov z rakom, ki jim diagnozo postavijo v slovenskih bolnišnicah ali jih tam tudi začnejo zdraviti, v nadaljnjem poteku bolezni pride na posvet ali na zdravljenje na Onkološki inštitut. prikazuje porazdelitev bolnikov po stadiju, v katerem je bila bolezen odkrita. Uporabljena je poenostavljena opredelitev stadijev, ki upošteva vse preiskovalne metode, vključno operacijo; če bolnik ni bil popre j zdrav l jen, tud i obdukc i jo. Uporabljamo in navajamo jo zato, ker so podatki o stadiju bolezni po klasifikaciji TNM na prijavnicah pogosto pomanjkljivi. Poenostavljena opredelitev stadijev pri solidnih tumorjih praviloma sledi klasifikaciji TNM. V omejeni stadij je razvrščena bolezen, kjer je tumor označen kot Tl in T2 (razen pri dojki, malignem melanomu in ščitnici, jer so vključeni tudi tumorji T3, in materničnem vratu, telesu in sarkomih, kjer so vključeni le tumorji T1) in pri kateri niso prizadete regionarne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionarne razširitve je bolezen, kjer je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi regionarne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V stadiju oddaljene razširitve pa je tista bolezen, pri kateri so zasevki že v oddaljenih ali organih (M1). Maligni limfomi so opredeljeni po klasifikaciji Ann-Arbor. V so uradni podatki o umrljivosti za rakom. Tabelo so pripravili na Inštitutu za varovanje zdravja RS. prikazuje prevalenco vseh in pogostejših rakov na dan 31. 12. 2004 tabeli 6b Tabela 8 tabele 9 Tabela 10 tabeli 11 Tabela 12 k bezgavkah These numbers are important for planning health care facilities. The age standardised rates in Table 6b indicate that the majority of the differences are due to different age structure of population in these regions. Age distribution of extranodal and nodal sites of non-Hodgkin malignant lymphomas is presented in Owing to a small number of extranodal sites, only the absolute numbers are given. From it is evident, in which hospitals cancer cases are diagnosed. Observations of many years show that half of the patients diagnosed or initially treated in regional hospitals are later on referred to the Institute of Oncology Ljubljana. A simplified definition of stages at diagnosis is presented in The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is considered as well. The simplified stage definition is used because, in cancer notification forms, the data on stage according to TNM Classification System are often lacking. However in solid tumours, the simplified stage definition often follows the TNM Classification. Localised stage includes all cancers where the tumour has been classified as T1 and T2 (except in breast, malignant melanoma and thyroid cancer, where T3 is also included, and uterine cervix, uterine corpus and sarcomas, where T1 only is included), where neither regional node involvement nor distant metastases are found (N0, MO). The regional stage includes tumours classified as T3 and T4 (exceptions already ment ioned) and/or regional node metastases (N1), if no metastases in distant lymph nodes or organs (M0) are found. The disease with metastases in distant nodes or organs is classified as the remote stage (M1). Malignant lymphomas are classified according to Ann-Arbor System. Official data on cancer mortality are given in The table has been prepared at the Institute of Public Health of the Republic of Slovenia. Data on prevalence of all and most frequent cancers on December 31, 2004 are presented in Table 8 Table 9 Table 10 Table 11 Table 12 . . . . Cancer Incidence in Slovenia 2004 13 Institute of Oncology Ljubljana, Cancer Registry of Slovenia 14 Incidenca raka v Sloveniji 2004 Onkološki inštitut Ljubljana, Register raka za Slovenijo ZAHVALA Zdravniki, medicinske sestre in admini strativno osebje iz slovenskih bolnišnic in drugih zdravstvenih ustanov so Registru pošiljali Prijavnice s podatki o novih bolnikih z rakom in njihovi nadaljnji usodi in nam pomagal i dopoln jevat i pr i jave z manjkajočimi informacijami. Vsaj polovico podatkov, obdelanih v tem poroči lu, sta pr ispeval i sodelavki Bolnišničnega registra Onkološkega inštituta v Ljubljani Ana Dotzauer in Maruška Ferjančič. Naše delo bi bilo bistveno težje brez dolgoletnega sodelovanja s Centralnim Registrom prebivalstva RS, z Inštitutom za varovanje zdravja RS in Statističnim uradom RS. Vsem imenovanim in tudi drugim, ki so kakorkoli prispevali, da smo lahko prikazali rezultate našega dela v tem poročilu, se - najlepše zahvaljujemo. Uredniški odbor ACKNOWLEDGEMENT Physicians, nurses, and administrative staff from Slovenian hospitals and other health institutions have provided the data on new cancer patients and their medical history as well as helped us in obtaining additional information when needed. Our co-workers at the Hospital Registry of the Institute of Oncology, Mrs. Ana Dotzauer and Maruška Ferjančič have contributed at least a half of the information presented in this report. The long-term collaboration with the Population Registry of the Republic of Slovenia, the Institute of Public Health of the Republic of Slovenia and the Statistical Office of the Republic of Slovenia is indispensable for our work. We thank all of them as well as to all others who have helped to present the results of our work in this report. Editors REFERENCE / References Ravnihar B, Gruden I. . Zdrav Vestn 1951; 20: 264-77. Geneva: World Health Organization, 1961-1966. . Geneva: World Health Organization, 1970-1974. Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1967-1980. Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1981-2004. Doll R, Payne P, Waterhouse J, eds. Berlin: Springer, 1966. Doll R, Muir C, Waterhouse J, eds. . Lyon: International Agency for Research on Cancer, 1970. Waterhouse J, Muir C, Correa C, Powell J, eds. Lyon: International Agency for Research on Cancer, 1976 (IARC Sci Publ 15). Waterhouse J, Muir C, Shanmugaratnam K, Powell J, eds. Lyon: International Agency for Research on Cancer, 1982 (IARC Sci Publ 42). Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. Lyon: International Agency for Research on Cancer, 1987 (IARC Sci Publ 88). Parkin DM, Muir C, Whelan S, Gao Y, Ferlay J, Powell J, eds. . International Agency for Research on Cancer, 1992 (IARC Sci Publ 120). Parkin DM, Whelan S, Ferlay J, Raymond L, Young J, eds. Lyon: International Agency for Research on Cancer, 1997 (IARC Sci Publ 143). Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, eds. Lyon: International Agency for Research on Cancer, 2002 (IARC Sci Publ 155). European Network of Cancer Registries. European incidence database V2.4, ICD- 10 dictionary (2003), Lyon 2001. Ferlay J, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. Lyon: IARC Press, 2004. Šteliarova-Foucher E, Berrino F, Coebergh JW et al. software for analysis and presentation of data on incidence and survival of children and adolescents in Europe. Lyon: ENCR, 2002. Statističen pregled in kratka analiza prijavljenih rakovnih obolenj iz področja LRS za leto 1950 Epidemiological and Vital Statistics Report. World Health Statistics Report Rak v Sloveniji (1965-77). Incidenca raka v Sloveniji (1978-2001). Cancer incidence in five continents. Vol 1. Cancer incidence in five continents. Vol 2 Cancer incidence in five continents. Vol 3. Cancer incidence in five continents. Vol 4. Cancer incidence in five continents. Vol 5. Cancer incidence in five continents Lyon. Vol 6 Cancer incidence in five continents. Vol 7. Cancer incidence in five continents. Vol 8. EUROCIM version 4.0. GLOBOCAN 2002. ACCISpass 1.01 Berrino F, Capocaccia R, Esteve J et al, eds. Lyon: International Agency for Research on Cancer, 1999. Berrino F, Capocaccia R, Gatta G et al, eds. Ann Oncol 2003: 14 (Suppl 5). Pompe-Kirn V, Primic Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1992. Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1995. Pompe-Kirn V, Zakotnik B, Zadnik V. Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2003. Savezni zavod za zdravstvenu zaštitu. Novi sad: Savezni zavod za zdravstvenu zaštitu, 1970. Inštitut za varovanje zdravja RS. Ljubljana: Inštitut za varovanje zdravja, 1995. Wor ld Hea l th Organ i sa t ion . Geneva: World Health Organisation, 2000. . Ur. l. RS št. 28/2000. Moller B, Fekjaer H, Hakulinen T et al. Stat Med 2003; 15: 2751-66. Jensen OM, Parkin M et al, eds. Lyon: International Agency for Research on Cancer, 1991. (IARC Sci Publ 95). . lovenije, 2005. Ederer F, Axtell LM, Cutler SJ. Monogr Natl Cancer Inst 1961; 6: 101-21. Hakulinen T. Biometrics 1982; 38: 933-42. Pohar M, Stare J. Computer Methods and Programs in Biomedicine 2006; 81: 272-8. Survival of cancer patients in Europe: the EUROCARE-2 study. Survival of cancer patients in Europe: the EUROCARE-3 study. Zemljevidi incidence raka v Sloveniji 1978-1987 (Atlas of Cancer Incidence in Slovenia 1978-1987). Preživetje bolnikov z rakom v Sloveniji 1963-1990 (Cancer Patients' Survival in Slovenia 1963-1990). Preživetje bolnikov z rakom v Sloveniji 1983-1997 (Cancer Patients' Survival in Slovenia 1983-1997). Medunarodna klasifikacija bolesti, povreda i uzroka smrti. 8. revizija. 10. revizija (International Statistical Classification of Diseaseses and Related health Problems). In te rnat iona l Calssification of Diseases for Oncology. Uredba o standardni klasifikaciji teritorialnih enot SKTE Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Cancer registration principles and methods. Statistični letopis republike Slovenije 2004 The relative survival rate: a statistical methodology. Relative survival analysis in R. Žakelj M, Ferligoj A, Škrk J. Pompe-Kirn V, Zakotnik B, Benulič T, Volk N, Škrk J. Ljubljana: Statistični urad Republike S Mednarodna klasifikacija bolezni in sorodnih zdravstvenih problemov za statistične namene. Cancer survival corrected for heterogeneity in patient withdrawal. – – – – –– – – – – – – – – – – – – – – – – – – – – – – – – Cancer Incidence in Slovenia 2004 15 Institute of Oncology Ljubljana, Cancer Registry of Slovenia – Incidenca Incidence Umrljivost Mortality Prevalenca Prevalence Tabela A. Breme raka Slovenija 2004- Table A. Cancer burden Slovenia 2004- Skupaj Moški Ženske Total Males Females 36385 2253 515310625 5075 60323 5472 2822 23938 Tabela B. Prevalenca glede na obdobje opazovanja Slovenija 31. 12. 2004- Table B. Prevalence by period of observation Slovenia, December 31, 2004- Obdobje Število bolnikov Število Odstotek Period Number of patients Number Percentage 1950 2004– 60320 2199 3,6 1965 2004– 58732 1284 2,2 1975 2004– 56723 875 1,5 1985 2004– 51804 316 0,6 1995 2004– 39819 71 0,2 Od tega izgubljenih Lost to follow-up Tabela C. Stabilnost podatkov število in odstotek novih primerov raka, prijavljenih po izdaji letnega poročila, po obdobju Slovenija, 1965 2003 - - – Table C. Data stability number and percentage of new cases reported after the publication of annual reports, by time period Slovenia, 1965 2003 - - – Obdobje Letno poročilo 2. 4. 2007 Število Odstotek Period Annual report April 2, 2007 Number Percentage 1965 68– 14696 14842 146 1,0 1969 72– 15719 16170 451 2,9 1973 76– 17711 18276 565 3,2 1977 80– 19176 19894 718 3,7 1981 84– 20701 21414 713 3,4 1985 88– 22715 23378 663 2,9 1989 92– 25973 26704 731 2,8 1993 96– 29141 30446 1305 4,5 1997 00– 33859 35295 1436 4,2 2001 03– 28411 29489 1078 3,8 Naknadno prijavljeni Subsequently registered 16 Incidenca raka v Sloveniji 2004 Onkološki inštitut Ljubljana, Register raka za Slovenijo Institute of Oncology Ljubljana, Cancer Registry of Slovenia Cancer Incidence in Slovenia 2004 17 Tabela D Opazovana in napovedana incidenca raka -. Slovenija, 1995–2007 Table D. Observed and predicted cancer incidence - Slovenia 995–2007, 1 Šifra Primarna MKB lokacija Spol ICD Primary code site C00 Vse lokacije – C96 All sites Usta in žrelo Mouth and pharynx Požiralnik Oesophagus Želodec Stomach Debelo črevo Colon Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction Jetra in intrahepatični vodi Liver and intrahepatic bile ducts Žolčnik in žolčevodi Gallbladder and billiary tract Trebušna slinavka Pancreas Grlo Larynx Sapnik, sapnici in pljuča Trachea, bronchus and lung C00 -C14 C19 -C20 C22 C23 -C24 C18 C16 C15 C25 C32 C33 -C34 Maligni melanom kože Malignant melanoma of skin Druge maligne neoplazme kože Skin, other malignomas Vezivno in mehko tkivo Connective and soft tissue Dojka Breast Maternični vrat Cervix uteri Maternično telo Corpus uteri Jajčnik Ovary Prostata Prostate Modo Testis Ledvica z ledvičnim mehom Kidney with renal pelvis C53 C54 C43 C44 C56 C61 C62 C64 -C65 C48 -C49 C50 Sečni mehurC67 Bladder Centralni in avtonomni živčni sistem Central and autonomic nervous system Ščitnica Thyroid gland C70 -C72 C73 Hodgkinova bolezenC81 -C95 C82 -C85 C90 Hodgkin's disease ne-Hodgkinovi limfomi non-Hodgkin's lymphoma Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms Levkemije Leukaemias Napoved za 2007 Incidenčna stopnja na 100.000 (95 % napovedni interval) Prediction for 2007 Incidence rate per 100,000 (95% predict interval). Število (95 % napovedni interval) Number (95% predict interval). Sex C91 M+Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž 578–618 527–564 8352 4247 4104 268 46 75 16 296 198 272 249 255 194 69 35 45 77 94 109 95 9 826 196 96 114 457 505 23 25 – 215 – 261 – 181 445 – 71 – 124 82 154 52 61 50 19 58 20 19 95 97 33 40 101 77 7 904 421,5 442,4 401,9 27,9 4,5 7,8 1,6 30,9 19,3 28,4 24,4 26,6 19,0 7,1 3,4 4,7 7,6 9,8 10,7 9,9 0,9 86,0 19,2 10,0 11,2 47,6 49,5 2,4 2,5 – 21,1 – 25,6 – 17,7 46,4 – 7,4 – 12,9 8,0 16,0 5,1 6,4 4,9 2,0 5,7 2,1 1,9 9,9 9,5 3,4 3,9 10,5 7,6 0,7 88,5 9826 5031 4795 255 57 76 17 290 184 352 300 310 222 86 41 50 74 123 126 104 12 846 268 141 152 647 732 29 30 – 200 – 286 – 178 655 – 94 – 145 85 176 64 70 63 25 81 24 22 110 126 37 46 102 82 9 1030 492,8 516,6 470,1 26,2 29,8 18,0 36,1 29,4 31,8 21,8 12,6 12,3 10,7 86,9 26,3 14,5 14,9 66,5 71,7 19,6 28,0 17,4 67,3 14,9 18,0 5,6 7,8 1,7 8,8 4,0 5,1 7,3 1,1 3,0 2,9 9,7 8,4 6,3 7,2 6,2 2,6 7,9 2,5 – – – – – 2,2 11,3 12,4 3,8 4,5 10,5 8,1 101,0 1,0 11474 5898 5576 242 288 172 438 352 372 244 102 146 141 105 865 342 192 201 893 1013 190 316 171 880 116 177 202 110 69 76 19 51 65 78 12 29 30 – – – – – 96 76 72 69 34 23 25 117 144 48 50 103 88 1182 12 11198–11750 5698–6097 5385–5767 195–288 244–333 138–206 384–493 303–401 322–423 203–286 114–178 109–173 785–945 295–389 157–226 166–237 816–969 933–1093 154–227 269–363 137–205 803–956 142–212 164–240 48–91 52–100 7–31 75–130 32–70 43–86 53–103 77–133 3–22 17–40 19–41 89–143 70–121 54–99 54–89 47–92 17–50 84–136 13–33 – – – – – 12–39 94–139 113–175 30–67 31–70 76–130 68–107 1092–1271 2–22 558–585571 598 545 25 29 17 44 34 38 24 10 15 14 11 88 33 19 20 91 99 19 31 17 89 12 18 21 11 7 8 2 5 7 8 1 3 3 – – – – – 9 7 7 7 3 2 2 12 14 5 5 10 9 116 1 107–124 20–29 5–9 5–10 1–3 25–34 13–20 39–50 30–39 33–43 20–28 8–13 3–7 4–9 5–10 12–18 11–17 8–14 0–2 80–96 29–38 16–23 16–23 83–98 91–107 2–4 2–4 0–2 15–22 26–35 13–20 81–97 9–15 14–22 7–12 17–24 5–10 5–9 5–9 2–5 8–13 1–3 1–4 10–14 11–17 3–7 3–7 8–13 7–10 – – – – – M Ž Povp. letne opazovane vrednosti 2000 2004– stopnja na 100.000 values 2000 2004– Incidance rate per 100,000 Number IncidenčnaŠtevilo Povp. letne opazovane vrednosti 1995–1999 stopnja na 100.000 Average ann. bservedo values 1995–1999 Incidance rate per 100,000 Number IncidenčnaŠtevilo Average ann. bservedo Other Pancreas Kidney Melanoma Bladder Stomach Head and neck* Colorectum* Skin, other Prostate Lung MOŠKI MALES- Ostalo Trebušna slinavka Ledvica Maligni melanom Mehur Želodec Glava in vrat* Debelo črevo in danka* Koža, drugo Prostata Pljuča 18,8 2,1 2,8 3,1 3,9 5,5 7,1 13,1 13,4 13,5 16,8 Other Pancreas Ovary Stomach Melanoma Cervix uteri Corpus uteri Lung Colorectum* Skin, other Breast ŽENSKE FEMALES- Ostalo Trebušna slinavka Jajčnik Želodec Maligni melanom Maternični vrat Maternično telo Pljuča Debelo črevo in danka* Koža, drugo Dojka 23,4 2,8 3,3 3,4 3,5 3,8 5,5 5,6 11,1 16,6 21,0 Slika 1. Figure 1. Najpogostejše rakave bolezni po spolu Slovenija 2004- The leading cancer sites by sex Slovenia 2004- * Pojasnilo - - - C Debelo črevo in danka C18–C20 Glava in vrat C00–C14, 30–C32 Explantion Colorectum: Head and neck: 18 Incidenca raka v Sloveniji 2004 Onkološki inštitut Ljubljana, Register raka za Slovenijo Slika 2. Figure 2. Odstotni delež vseh rakov po starostnih skupinah in spolu - Slovenija 2004 Percentage distribution of all cancer sites by age groups and sex - Slovenia 2004by Slika 3. Figure 3. Odstotni odklon grobe incidenčne stopnje raka po statističnih regijah od povprečne slovenske - Slovenija 2000 2004– Percentage deviation of crude cancer incidence rate in statistical regions from average - Slovenia 2000 2004– Cancer Incidence in Slovenia 2004 19 Institute of Oncology Ljubljana, Cancer Registry of Slovenia 4,6 8,2 9,3 12,6 17,7 6,2 2,1 8,5 5,3 1,1 3,4 11,6 2,3 9,2 16,5 7,3 2,4 9,9 9,8 13,5 3,8 7,6 3,7 6,9 -20 -15 -10 -5 0 5 10 15 20 Pomurska Podravska Koroška Savinjska Zasavska Spodnjeposavska JV Slovenija Osrednjeslovenska Gorenjska Notranjsko-kraška Goriška Obalno-kraška % Slika 4. Groba in kumulativna letna incidenč a stopnja vseh rakov po spolu - Slovenija 1950– 204 Crude and cuulative anual cancer incidence rate for al sites by sex - Slovenia 1950– 204 20 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo , Figure 4. Slika 5. Groba letna incidenč a stopnja izbranih rakov po spolu - Slovenija 1950– 204 Crude anual cancer incidence rate for selcted primary sites by sex - Slovenia 1950– 204 Cancer Incidence in Slovenia 204 21 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia MOŠ KI – MALES Ž ENSKE – FEMALES , , Figure 5. 2 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo D eb el o č re vo m o šk i - S lo ve ni ja , 2 00 0 20 04 (C 18 ), – C o lo n (C 18 ), m a le s - S lo ve ni a , 2 00 0– 20 04 Po vp re čn o le tn o št ev ilo p rim er ov Re la tiv na fre kv en ca (% ) G ro b a s to p nj a na 1 00 .0 00 SS S* na 1 00 .0 00 KS ** 35 2 7, 0 36 ,1 24 ,0 3, 0 18 5 6, 7 19 ,0 12 ,5 1, 3 Ra zm er je in ci d en ca /u m rlj iv o st 1, 9 *S SS - st a ro st no s ta nd a rd iz ira na s to p nj a ( st a nd a rd - sv et ov na p o p ul a ci ja ) ** KS - ku m ul a tiv na s to p nj a N a či n ug o to vi tv e (le tn o p ov p re čj e) M ik ro sk o p sk o p o trj en i p rim er i 33 4 U g o to vl je ni z d ru g im i p re is ka va m i 13 Re g is tri ra ni s a m o iz z d ra vn iš ki h p o ro či l o v zr o ku s m rt i 5 Po vp re čn o le tn o š te vi lo h is to lo šk o a li ci to lo šk o p ot rje ni h p rim er ov A d en o ka rc in o m 27 2 M uc in o zn i a d en o ka rc in o m 30 A d en o ka rc in o m v p o lip u/ a d en o m u 22 D ru g i k a rc in o m i 9 2 1- le tn o 3- le tn o Kr iv ul ja re la tiv ne g a p re ži ve tja p o s ta d iju Re la tiv no p re ži ve tje ( 95 % in te rv a l z a up a nj a ) 0510152025303540 Število St a ro st Po vp re čn a le tn a s ta ro st no s p ec ifi čn a in ci d en ca 01020304050607080 05010 0 15 0 20 0 25 0 30 0 U m rlj iv o st na s to p nj a U m rlj iv o st St a ro st Število Stopnja na 10.0 In ci d e nč na s to p nj a In ci d e nc a G ro b e in s ta ro st no s ta nd a rd iz ira ne in ci d en čn e in u m rlj iv o st ne s to p nj e 1989 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 In ci d e nc a - g ro b a s to p nj a U m rlj iv o st - g ro b a s to p nj a In ci d e nc a - SS S* U m rlj iv o st - SS S* Le to (% ) 40 20 0 198 1987 608010 0 1 2 3 4 5 Relativno preživetj (%) Č a s v le tih Po vp re čn a le tn a s ta ro st no s p ec ifi čn a u m rlj iv o st St a d ij (N ; 5 -le tn o p re živ et je ): O m e je n (1 90 ; 9 6, 5 % ) Ra zš irj e n (1 02 8; 6 9, 7 % ) Ra zs e ja n (4 46 ; 5 ,9 % ) N e zn a n (4 1; š t. p rim e ro v je p re m a jh no ) 0 Sl ik e 6. Fi g ur e s 6. 1986 In ci d en ca U m rlj iv o st Br em e ra ka 5- le tn o 71 ,7 (6 9, 4– 74 ,1 ) 59 ,6 (5 6, 7– 62 ,5 ) 54 ,9 (5 1, 4– 58 ,5 ) O st a lo 05010 0 15 0 20 0 25 0 30 0 Stopnja na 10.0 05 10152025303540 1985 Stopnja na 10.0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 5- 60- 65- 70- 75- 80+ 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 5- 60- 65- 70- 75- 80+ Cancer Incidence in Slovenia 204 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia 23 40 20 0608010 0 1 2 3 4 5 Relative survial (%) Ti m e in y e a rs St a g e (N ; 5 -y ea r s ur vi va l): Lo ca liz e d (1 73 ; 9 3. 1% ) Re g io na l (8 80 ; 6 7. 4% ) U nk no w n (5 9; n o . o f c a se s is to o lo w ) 0 1989 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 D eb el o č re vo (C 18 ), že ns ke - Sl ov en ija , 2 00 0– 20 04 C o lo n (C 18 ), fe m a le s - S lo ve ni a , 2 00 0– 20 04 A ve ra g e a nn ua l nu m b er o f c a se s Re la tiv e fre q ue nc y (% ) C ru d e ra te p er 1 00 .0 00 A SR * p er 1 00 .0 00 C R* * (% ) 29 9 6. 2 29 .4 14 .1 1. 7 15 5 7. 1 15 .2 6. 1 0. 6 In ci d en ce /m o rt a lit y ra tio 1. 9 Ba si s o f d ia g no si s (a ve ra g e a nn ua l n um b er ) M ic ro sc o p ic a lly c o nf irm ed c a se s 27 9 C o nf irm ed b y o th er in ve st ig a tio ns 16 Re g is te re d fr o m d ea th c er tif ic a te s o nl y 5 A ve ra g e a nn ua l n um b er o f h is to lo g ic a lly o r c yt ol og ic a lly c om fir m ed c a se s A d en o ca rc in o m a 21 7 M uc in o us a d en o ca rc in o m a 29 A d en o ca rc in o m a in p o ly p /a d en o m a 18 O th er c a rc in o m a 10 C a nc er b ur d en 1- ye a r 3- ye a r Re la tiv e su rv iv a l b y st a g e Re la tiv e su rv iv a l ( 95 % c o nf id en ce in te rv a l) A ve ra g e a nn ua l a g e sp ec ifi c m o rt a lit y Number A ve ra g e a nn ua l a g e sp ec ifi c in ci d en ce M o rta lit y ra te M o rta lit y ra te A g e Number Rate per 10,0 In ci d e nc e ra te In ci d e nc e C ru d e a nd a g e st a nd a rd iz ed in ci d en ce a nd m o rt a lit y ra te s In ci d e nc e - cr ud e ra te Ye a r In ci d e nc e - A SR * M o rta lit y - c ru d e ra te M o rta lit y - A SR * 40506070 15 0 20 0 0102030 05010 0 0102030405060 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 5- 60- 65- 70- 75- 80+ 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 5- 60- 65- 70- 75- 80+ A g e *A SR - a g e s ta nd a rd ize d ra te ( w o rld s ta nd a rd ) 3 198 * C R - c um ul a tiv e ra te * 1985 1986 1987 Sl ik e 7. Fi g ur e s 7. In ci d en ce M o rt a lit y 5- ye a r D ist a nt (3 28 ; 7 .3 % ) 72 .8 (7 0. 3- 75 .3 ) 59 .3 (5 6. 3- 62 .3 ) 55 .6 (5 2. 0- 59 .2 ) 05101520253035 Rate per 10,0 Rate per 10,0 02040608010 0 12 0 14 0 O th er 24 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo 40 20 0608010 0 1 2 3 4 5 Relativno preživetj (%) Č a s v le tih 0 010203040506070 0 St a ro st Incidenca In ci d e nč na s to p nj a In ci d e nc a 5010 0 15 0 20 0 25 0 Sstopnja na 10.0 In ci d e nc a - g ro b a s to p nj a U m rlj iv o st - g ro b a s to p nj a In ci d e nc a - A SR * U m rlj iv o st - A SR * 1989 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 Le to 198 1987 1986 Re kt o si g m o id na z ve za in d a nk a (C 19 –C 20 ), m o šk i - S lo ve ni ja , 2 00 0- 20 04 Re ct o sig m o id ju nc tio n a nd re ct um ( C 19 –C 20 ), m a le s - S lo ve ni a , 2 00 0- 20 04 Po vp re čn o le tn o št ev ilo p rim er ov Re la tiv na fre kv en ca (% ) G ro b a s to p nj a na 1 00 .0 00 SS S* na 1 00 .0 00 KS ** 31 0 6, 2 31 ,8 21 ,3 2, 6 16 9 6, 1 17 ,4 11 ,4 1, 3 Ra zm er je in ci d en ca /u m rlj iv o st 1, 8 *S SS - st a ro st no s ta nd a rd iz ira na s to p nj a ( st a nd a rd - sv et ov na p o p ul a ci ja ) ** KS - ku m ul a tiv na s to p nj a N a či n ug o to vi tv e (le tn o p ov p re čj e) M ik ro sk o p sk o p o trj en i p rim er i 29 9 U g o to vl je ni z d ru g im i p re is ka va m i 9 Re g is tri ra ni s a m o iz z d ra vn iš ki h p o ro či l o v zr o ku s m rt i 2 Po vp re čn o le tn o š te vi lo h is to lo šk o a li ci to lo šk o p ot rje ni h p rim er ov A d en o ka rc in o m 24 9 M uc in o zn i a d en o ka rc in o m 21 A d en o ka rc in o m v p o lip u/ a d en o m u 19 D ru g i k a rc in o m i 8 1 1- le tn o 3- le tn o Kr iv ul ja re la tiv ne g a p re ži ve tja p o s ta d iju Re la tiv no p re ži ve tje ( 95 % ) in te rv a l z a up a nj a Po vp re čn a le tn a s ta ro st no s p ec ifi čn a in ci d en ca G ro b e in s ta ro st no s ta nd a rd iz ira ne in ci d en čn e in u m rlj iv o st ne s to p nj e (% ) Po vp re čn a le tn a s ta ro st no s p ec ifi čn a u m rlj iv o st St a d ij (N ; 5 -le tn o p re živ et je ): O m e je n (2 76 ; 8 3, 7 % ) Ra zš irj e n (8 52 ; 5 9, 1 % ) Ra zs e ja n (3 34 ; 7 ,6 % ) N e zn a n (6 5; š t. p rim e ro v je p re m a jh no ) Sl ik e 8. Fi g ur e s 8. In ci d en ca U m rlj iv o st 5- le tn o 74 ,2 (7 1, 8– 76 ,6 ) 57 ,3 (5 4, 2– 60 ,3 ) 51 ,2 (4 7, 5– 55 ,0 ) Br em e ra ka 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 5- 60- 65- 70- 75- 80+ U m rlj iv o st na s to p nj a U m rlj iv o st 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 5- 60- 65- Umrljivost St a ro st 70- 0510152025303540 0510152025303540 1985 O st a lo Stopnja na 10.0 80+ Stopnja na 10.0 75- 05010 0 15 0 20 0 25 0 Cancer Incidence in Slovenia 204 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia 25 Re kt o si g m o id na z ve za in d a nk a (C 19 –C 20 ), že ns ke - Sl ov en ija , 2 00 0- 20 04 Re ct o sig m o id ju nc tio n a nd re ct um ( C 19 –C 20 ), fe m a le s - S lo ve ni a , 2 00 0- 20 04 A ve ra g e a nn ua l nu m b er o f c a se s Re la tiv e fre q ue nc y (% ) C ru d e ra te p er 1 00 .0 00 A SR * p er 1 00 .0 00 C R* * (% ) 22 2 4. 6 21 .8 10 .5 1. 3 13 5 6. 2 13 .2 5. 6 0. 6 In ci d en ce /m o rt a lit y ra tio 1. 6 Ba si s o f d ia g no si s (a ve ra g e a nn ua l n um b er ) M ic ro sc o p ic a lly c o nf irm ed c a se s 20 9 C o nf irm ed b y o th er in ve st ig a tio ns 10 Re g is te re d fr o m d ea th c er tif ic a te s o nl y 4 A ve ra g e a nn ua l n um b er o f h is to lo g ic a lly o r c yt ol og ic a lly c om fir m ed c a se s A d en o ca rc in o m a 17 1 A d en o ca rc in o m a in p o ly p /a d en o m a 19 M uc in o us a d en o ca rc in o m a 12 C a rc in o m a N O S 6 1- ye a r 3- ye a r Re la tiv e su rv iv a l b y st a g e Re la tiv e su rv iv a l ( 95 % c o nf id en ce in te rv a l) A ve ra g e a nn ua l a g e sp ec ifi c m o rt a lit y Number A ve ra g e a nn ua l a g e sp ec ifi c in ci d en ce M o rta lit y ra te M o rta lit y ra te C ru d e a nd a g e st a nd a rd iz ed in ci d en ce a nd m o rt a lit y ra te s A g e 0 Sl ik e 9. Fi g ur e s 9. In ci d en ce M o rt a lit y 5- ye a r 74 .4 (7 1. 6- 77 .3 ) 56 .7 (5 3. 2- 60 .2 ) 49 .3 (4 5. 0- 53 .5 ) *A SR - A g e s ta nd a rd ize d ra te ( w o rld ) * C R - C um ul a tiv e ra te * In ci d e nc e - cr ud e ra te Ye a r In ci d e nc e - A SR * M o rta lit y - c ru d e ra te M o rta lit y - A SR * 1986 1987 198 198 190 191 192 193 194 195 196 197 198 19 20 201 202 203 204 05101520253035404550 02040608010 0 12 0 A g e Incidence Rate per 10,0 In ci d e nc e ra te In ci d e nc e 051015202530354045504 0 20 0608010 0 1 2 3 4 5 Relative survial (%) Ti m e in y e a rs 0 St a g e (N ; 5 -y ea r s ur vi va l): Lo ca liz e d (2 02 ; 8 8. 5% ) Re g io na l (6 03 ; 5 5. 2% ) U nk no w n (5 6; n o . o f c a se s is to o lo w ) D ist a nt (2 16 ; 5 .5 % ) 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 5- 60- 65- 70- 75- 80+ 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 5- 60- 65- 70- 75- 80+ C a nc er b un d er 1985 0510152025 Rate per 10,0 O th er Rate per 0,0 02040608010 0 12 0 In ci d e nč na s to p nj a In ci d e nc a D o jk a (C 50 ), že ns ke - Sl ov en ija , 2 00 0- 20 04 Br e a st ( C 50 ), fe m a le s - S lo ve ni a , 2 00 0- 20 04 Po vp re čn o le tn o št ev ilo p rim er ov Re la tiv na fre kv en ca (% ) G ro b a s to p nj a na 1 00 .0 00 SS S* na 1 00 .0 00 KS ** 10 30 21 ,5 10 0, 9 60 ,5 6, 9 38 3 17 ,6 37 ,6 19 ,1 2, 1 Ra zm er je in ci d en ca /u m rlj iv o st 2, 7 *S SS - st a ro st no s ta nd a rd iz ira na s to p nj a ( st a nd a rd - sv et ov na p o p ul a ci ja ) ** KS - ku m ul a tiv na s to p nj a N a či n ug o to vi tv e (le tn o p ov p re čj e) M ik ro sk o p sk o p o trj en i p rim er i 99 0 U g o to vl je ni z d ru g im i p re is ka va m i 28 Re g is tri ra ni s a m o iz z d ra vn iš ki h p o ro či l o v zr o ku s m rt i 12 Po vp re čn o le tn o št ev ilo h ist ol oš ko a li ci to lo šk o po trj en ih p rim er ov / A ve ra ge a nn ua l n um be r o f h ist ol og ic al ly o r c yt ol og ic al ly c om fir m ed c as es D uk ta ln i a d en o ka rc in o m 67 0 D ru g i k a rc in o m i 19 8 Lo b ul a rn i k a rc in o m 78 M uc in o zn i i n tu b ul a rn i a d en o ka rc in o m 26 9 1- le tn o 3- le tn o Kr iv ul ja re la tiv ne g a p re ži ve tja p o s ta d iju Re la tiv no p re ži ve tje ( 95 % ) in te rv a l z a up a nj a Po vp re čn a le tn a s ta ro st no s p ec ifi čn a in ci d en ca G ro b e in s ta ro st no s ta nd a rd iz ira ne in ci d en čn e in u m rlj iv o st ne s to p nj e (% ) Po vp re čn a le tn a s ta ro st no s p ec ifi čn a u m rlj iv o st St a d ij (N ; 5 -le tn o p re živ et je ): O m e je n (2 54 2; 9 4 % ) Ra zš irj e n (2 05 1; 7 9, 7 % ) Ra zs e ja n (4 39 ; 1 7, 9 % ) N e zn a n (5 0; š t. p rim e ro v je p re m a jh no ) Sl ik e 10 . Fi g ur e s 10 . In ci d en ca U m rlj iv o st 5- le tn o 95 ,1 (9 4, 3– 95 ,8 ) 87 ,4 (8 6, 3– 88 ,6 ) 81 ,1 (7 9, 5– 82 ,8 ) 3 M ed ul a rn i k a rc in o m 7 Kr ib rif o rm ni k a rc in o m D uc ta l a d en o ca rc in o m a O th er c a rc in o m a C rib rif o rm c a rc in o m a In ci d e nc a - g ro b a s to p nj a U m rlj iv o st - g ro b a s to p nj a In ci d e nc a - A SR * U m rlj iv o st - A SR * Le to 1986 1987 198 198 190 191 192 193 194 195 196 197 198 19 20 201 202 203 204 0 2 0 4 0 6 0 8 0 10 0 12 0 14 0 05 0 10 0 15 0 2 0 0 2 5 0 3 0 0 St a ro st Incidenca Stopnja na 10.0 U m rlj iv o st na s to p nj a U m rlj iv o st Umrljivost St a ro st 010203040506070809040 20 0608010 0 1 2 3 4 5 Relativno preživetj (%) Č a s v le tih 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 5- 60- 65- 70- 75- 80+ 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 5- 60- 65- 70- 75- 80+ Br em e ra ka Lo b ul a r c a rc in o m a M uc in o us a nd tu b ul a r a d en o ca rc in o m a M ed ul la ry c a rc in o m a O th er O st a lo Stopnja na 10.0 02040608010 0 12 0 1985 Stopnja na 10.0 05010 0 15 0 20 0 25 0 26 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo Cancer Incidence in Slovenia 204 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia 27 M a te rn ič ni v ra t ( C 53 ), že ns ke - Sl ov en ija , 2 00 0- 20 04 C e rv ix u te ri (C 53 ), fe m a le s - S lo ve ni a , 2 00 0- 20 04 A ve ra g e a nn ua l nu m b er o f c a se s Re la tiv e fre q ue nc y (% ) C ru d e ra te p er 1 00 .0 00 A SR * p er 1 00 .0 00 C R* * (% ) 20 0 4. 2 19 .6 14 .2 1. 4 52 2. 4 5. 1 3. 0 0. 3 In ci d en ce /m o rt a lit y ra tio 3. 8 Ba si s o f d ia g no si s (a ve ra g e a nn ua l n um b er ) M ic ro sc o p ic a lly c o nf irm ed c a se s 19 8 C o nf irm ed b y o th er in ve st ig a tio ns 1 Re g is te re d fr o m d ea th c er tif ic a te s o nl y 1 Sq ua m o us c a rc in o m a 16 0 A d en o ca rc in o m a 22 A d en o sq ua m o us c a rc in o m a 12 O th er c a rc in o m a 3 1- ye a r 3- ye a r Re la tiv e su rv iv a l b y st a g e Re la tiv e su rv iv a l ( 95 % c o nf id en ce in te rv a l) A ve ra g e a nn ua l a g e sp ec ifi c m o rt a lit y A ve ra g e a nn ua l a g e sp ec ifi c in ci d en ce C ru d e a nd a g e st a nd a rd iz ed in ci d en ce a nd m o rt a lit y ra te s 1 Sl ik e 11 . Fi g ur e s 11 . In ci d en ce M o rt a lit y 5- ye a r 89 .4 (8 7. 4- 91 .4 ) 79 .3 (7 6. 5- 82 .1 ) 77 .5 (7 4. 3- 80 .7 ) *A SR - A g e s ta nd a rd ize d ra te ( w o rld ) * C R - C um ul a tiv e ra te * C a nc er b ur d en I nc id e nc e - cr ud e ra te Ye a r In ci d e nc e - A SR * M o rta lit y - c ru d e ra te M o rta lit y - A SR * Rate per 10,0 0510152025 1985 1986 1987 198 198 190 191 192 193 194 195 196 197 198 19 20 201 202 203 204 A g e Incidence Rate per 10,0 In ci d e nc e ra te In ci d e nc e 051015202530 0510152 025303540 Number M o rta lit y ra te M o rta lit y ra te A g e Rate per 10,0 012345678910 0510152 025 40 20 0608010 0 1 2 3 4 5 Relative survial (%) Ti m e in y e a rs 0 St a g e (N ; 5 -y ea r s ur vi va l): Lo ca liz e d (6 13 ; 9 6. 2% ) Re g io na l (3 36 ; 4 8. 5% ) U nk no w n (1 0; n o . o f c a se s is to o lo w ) D ist a nt (3 5; 1 9. 1% ) Sk va m o zn i k a rc in o m A d en o ka rc in o m A d en o sk va m o zn i k a rc in o m D ru g i k a rc in o m i O st a lo O th er 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 5- 60- 65- 70- 75- 80+ 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 5- 60- 65- 70- 75- 80+ Po vp re čn o le tn o š te vi lo h is to lo šk o a li ci to lo šk o p ot rje ni h p rim er ov / A ve ra g e a nn ua l n um b er o f h is to lo g ic a lly o r c yt ol og ic a lly c om fir m ed c a se s MOŠŠ KI –– Slika 12. Relativno 5-letno prež ivetj bolnikov s 95 % intervalom zaupanja z izbranimi raki po spolu, zbolelih v letih 195– 19 in 20– 204 Figure 12. 5-year elative survial with 95% confidence interval for selcted cancer sites by sex MALES 28 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo in priods 195– 19 nd 20– 204 42 4 10 2 21 4 54 42 57 46 57 60 65 60 61 7 84 84 95 50 3 5 8 1 24 25 45 50 51 5 5 59 59 63 63 75 7 89 89 95 5 Prež ivetj / Survial (%) 2 (C62) (C73) (C81) (C43) (C61) (C91.1–C91.9) (C32) (C82–C85) (C91.0) (C18) (C67) (C00–09) (C16) (C10–C14) (C33–C34) (C15) (C25) (C22) (C00–C96) (C64–C65) Prež ivetj je več kot 50 % (43,8 % vsh ugtvljenih rakov 20-204) Prež ivetj je več kot 10–50 % (27,5 % vsh ugtovljenih rakov 20-204) Prež ivetj je manj kot 10 % (5,4 % vsh ugtvljenih rakov 20-204) rectosig. junction (C19–C20) Slika 12. – Figure 12. Nadljevanje – Contiued Ž ENSKE – FEMALES 60 2 3 20 49 53 45 48 69 52 59 62 64 69 72 75 80 80 92 84 64 5 6 10 14 23 29 43 46 48 49 56 60 60 60 63 63 6 7 81 83 84 90 91 10 17 Cancer Incidence in Slovenia 204 29 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia 20– 204 (N=2393) 195– 19 (N=19823) Prež ivetj / Survial (%) Les than 10% survial (3,2% of al cancer diagnosed in 20-204) 10%-50% survial (19,5 of al cancer diagnosed in 20-204) More than 50% survial (50,1% of al cancer diagnosed in 20-204) (C73) (C81) (C43) (C54) (C50) (C53) (C00–C09) (C32) (C64–C65) (C91.1–C91.9) (C91.0) (C82–C85) (C18) rectosig. junction (C19–C20) (C56) (C10–C14) (C67) (C16) (C15) (C33–C34) (C00–C96) (C25) (C22) 0-4 89142 4585 43287 5-9 93604 48205 4539 10-14 106140 548 51652 15-19 12694 64954 6201 20-24 14396 74243 70153 25-29 152065 78524 73541 30-34 143714 7386 6987 35-39 152715 76934 7581 40-4 154596 78506 7609 45-49 158076 809 707 50-54 152745 7849 73896 5-59 120 5986 56234 60-64 107631 5130 56301 65-69 94832 42907 51925 70-74 85716 34683 5103 75-79 6373 21458 4215 80+ 5875 1535 4340 Vse starosti Al ges Tabela 1. Prebivalstvo po starosti in spolu - Slovenija, 30. 6. 204* Table 1. Population by age and by sex - Slovenia, June 30, 204* Starost Skupaj Moš ki Ž enske Age Total ales Females *Vir: Statistič ni urad Republike Slovenije Source: Statistical Ofice of the Republic of Slovenia 30 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo 19704 97092 10912 Pomurska 12879 59475 63404 Podravska 31986 1574 163412 Korš ka 73816 36759 37057 Savinjska 257105 126396 13079 Zasvska 4560 201 23459 Spodnjeposavska 7023 35140 3583 JV Slovenija 138245 6837 69872 Osrednjeslovenska 49563 240197 2546 Gorenjska 198275 96817 10458 Notranjsko-kraš ka 50937 2587 2560 Goriš ka 19532 58920 6012 Obalno-kraš ka 104983 51753 5320 Slovenija Skupaj Slveni Totl Tabela 2. Prebivalstvo po statistič nih regijah in spolu - Slovenija, 30. 6. 204* Table 2. Population by statistical regions and by sex - Slovenia, June 30, 204* *Vir: Statistič ni urad Republike Slovenije Source: Statistical Ofice of the Republic of Slovenia Statistič na regija Ž enske Sttistical region Skupaj Moš ki Total ales Females Cancer Incidence in Slovenia 204 31 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia 19704 97092 10912 Tabela 3.Š tevilo novih primerov rak, š tevilo in odstotek mikroskopsko potrjenih primerov, š tevilo in odstotek prierov, ugotvljenih z drugimi preiskavmi in š tevilo in odstotek registrianih samo iz dravniš kih porč il o vzroku srti, po lkacij in spolu – Slovenija 204 Table 3. Total number of new cancer cases, number and percentage of microscopicaly confirmed cases, number and percentge of cses confired by other investigations, and number and percentge of cases registerd from death certificates only, y site and by sex – Sloveni 204 Š ifra Spol Š teviloMikroskopskoUgotvljeni Registriani MKB*Primarna lokacija novih ptrjeni z drugimi samo iz drv– primerov rimri preiskavi niš kih porč il o vzrku smrti Š tevilo %* Š tevilo %* Š tevilo %* Number MicroscopicalyConfirmedRegisterd from of nw nfirmed by thr dath certifi– ICD Sex cases cass investigations ctes only code*Primary site Number %* Number %* Numbr %* C0Vse lokacije M+Ž Al sitesC96 Ž Ustnica M Lip Ž Baz jezika M Bse of tongue Ž Jezik, drugi deli M Tongue, other & unspecified parts Ž Dlesn M Gum Ž Ustno dno M Flor of mouth Ž Nebo M Palte Ž Usta, drugi deli M Mouth, other & unspecified parts Ž Parotidna ž leza M Parotid gland Ž Druge in eopredeljne velike ž lez slinavke M Othr & unspcified major salivary glands Ž Tonzila M Tonsil Ž Orofarinks M ropharynx Ž Nazofarinks M Nasopharynx Ž Piriformni sinus M Pyrifor sinus Ž Hipofarinks M Hypoharynx Ž Druga in slabo predeljna mesta na ustnici, v ustni votlini in frinksu M Other and il–defined sites in the lip, oral cavity pharyx Ž 10625 5472 513 26 1 15 4 14 5 10 2 31 5 13 3 16 6 4 5 0 3 40 7 37 4 5 3 38 6 26 0 0 0 9837 5042 4795 25 1 15 4 14 5 10 2 31 5 13 3 16 6 4 5 0 3 40 7 36 4 5 3 38 6 26 0 0 0 92,6 92,1 93,1 96,2 – 10,0 – – – – – 0,0 – – – 10,0 – – – – – 10,0 – 97,3 – – – 10,0 – 10,0 – – – C14 C12 C09 C10 C13 C08 C05 C06 C1 C0 C03 C04 C01 C02 C07 29 650 351 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 138 79 59 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 32 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo 6,1 6,4 5,8 3,8 0, 0, 0, 0, 0, 0, – – – – – – – – – – – – – – – – – – – – – – 0, 1,3 1,4 1, 0, – 0, – – – – – – – – 0, – – – – – 0, – 2,7 – – – 0, – 0, – – – 0, Tabela 3. – Table 3. Nadljevanje – Contiued Š ifra Spol Š teviloMikroskopskoUgotvljeni Registriani MKB*Primarna lokacija novih ptrjeni z drugimi samo iz drv– primerov rimri preiskavi niš kih porč il o vzrku smrti Š tevilo %* Š tevilo %* Š tevilo %* Number MicroscopicalyConfirmedRegisterd from of nw nfirmed by thr dath certifi– ICD Sex cases cass investigations ctes only code*Primary site Number %* Number %* Numbr %* C15 C16 Pož iralnik M Oesophagus Ž Ž elodec M Stomach Ž C17 C18 C19 C3 C26 C31 C32 C30 C25 C24 C23 C20 C21 C2 C34 C37 Tanko č revo M Smal intestine Ž Debelo č revo M Coln Ž Rektosigmoidna zveza M Rectosigoid junction Ž Pancreas Ž Druga in slabo predeljna mesta v prebvih rganih M Other and il–defined igestive organs Ž Nosna votlina in srednje uho M Nasl cavity and midle ar Ž Obnosni sinusi M Acesory sinuses Ž Grlo M Larynx Ž Sapnik M Trachea Ž Trebuš na slinavka M Ž olč nik M Galblader Ž Drugi in eopredeljni deli biliarnega trakta M Biliry trct, other nd unspecified parts Ž Rektum M Rectu Ž Anus in anlni kanl M nus and anl canl Ž Jetra in itrahepatič ni vodi M ŽLiver and intrahepatic bile ducts Sapnica in pljuč a Bronchus and lung Timus Thyus M Ž M Ž 70 10 302 175 13 7 371 38 59 59 143 2 5 3 5 9 7 9 15 6 3 16 12 47 36 32 289 175 1 14 87 43 917 28 1 2 64 9 280 159 12 7 350 318 58 5 6 29 2 14 64 0 1 3 5 9 7 9 15 5 3 76 280 169 1 14 45 25 82 270 1 2 91,4 – 92,7 90,9 – – 94,3 94,1 98,3 93,2 96,9 – 61,7 61, 43,8 4,8 – – – – – – 10,0 10,0 – – 65, 96, – – 51,7 58,1 89,6 93,8 – – 4 0 10 12 1 0 16 18 1 3 6 6 0 0 39 13 6 16 13 18 37 74 1 1 0 0 0 0 0 0 1 0 72 17 0 0 12 2 1 4 0 0 5 2 0 1 3 0 0 0 3 5 0 2 1 0 3 5 1 3 0 0 0 0 0 0 0 0 23 1 0 0 2,9 – 4,0 2,3 – – 1,3 0,6 0, 1,7 1,0 0, – – 3,4 1,6 – 4,3 2,8 0, 2,6 3,5 – – – – – – 0, 0, – – 2,5 0,3 – – Cancer Incidence in Slovenia 204 3 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia 5,7 3, 6,9 – 4,3 5,3 1,7 5,1 – – 2,1 3,4 – – 4,8 30,2 – 34,0 36,1 56,3 31,9 51,7 – – – – – – 0, 0, – – 7,9 5,9 – – Tabela 3. – Table 3. Nadljevanje – Contiued Š ifra Spol Š teviloMikroskopskoUgotvljeni Registriani MKB*Primarna lokacija novih ptrjeni z drugimi samo iz drv– primerov rimri preiskavi niš kih porč il o vzrku smrti Š tevilo %* Š tevilo %* Š tevilo %* Number MicroscopicalyConfirmedRegisterd from of nw nfirmed by thr dath certifi– ICD Sex cases cass investigations ctes only code*Primary site Number %* Number %* Number %* Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts Maligni melanom kož e linant elnoa of skin Druge maligne neoplazme kož e Skin, other alinomas Mezoteliom esothelioa Kaposijev sarkom Kosi' sarcoa Periferni ž ivci in avtonmno ž ivč evje Peripheral nerves and autonmic nrvous ystm Peritonej in retroperitonej Rtrpritoum and peritoneum Drugo vezivno in mehko tkivo Other conective and soft isue Dojka Breast Ž ensko zunanje spolvilo Vulva Nož nica Vagi Maternič ni vrat Cervix uteri Maternič no telo Corpus uteri Maternica, neopredeljno Uterus, unspecified M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž C41 C43 C4 C45 C46 C47 C48 C49 C50 C51 C52 C53 C54 C5 C38 C40 C39 Srce, mediastinum, plevra Heart, edistinu, pleur Druga in slabo predeljna mesta v dihlih in prsnih organih Other and il–defined sites in the rspiratory systm n intrathoraci organs Kosti, sklepni hrustanec udov Bne and articular crtilage f limbs M Ž M Ž M Ž Jajč nik Ovry M Ž C56 34 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo – – 10,0 10,0 9,2 9,3 10,0 – – – – – – 10,0 10,0 90,9 – 97,3 – 96,4 – 9,0 9,6 – – – – – – – 92,3 – – – – – 0, 0, 0, 0, 0, 0, 0, 0, 0,8 1,8 0, 0, – – – – – – – – – – – – – – – – – – 1,2 – – – – – 3 5 167 180 731 85 2 1 1 0 1 3 12 16 21 2 5 1084 56 5 195 285 6 5 1 0 0 9 5 169 – – – – – 3 5 167 180 725 849 2 1 1 0 1 3 12 16 2 20 4 105 54 5 193 284 6 4 0 0 0 9 5 156 – – – – – 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 9 1 0 0 0 0 0 0 0 0 0 0 2 – – – – – 0 0 0 0 6 6 0 0 0 0 0 0 0 0 0 2 1 20 1 0 2 1 0 1 1 0 0 0 0 1 – – – – – – – 0, 0, 0,8 0,7 0, – 1,8 1,0 0,4 – – – – – – –– – – – 9,1 1,8 – – – 0, 0, 6,5 – – – – – – – – –– Tabela 3. – Table 3. Nadljevanje – Contiued Š ifra Spol Š teviloMikroskopskoUgotvljeni Registriani MKB*Primarna lokacija novih ptrjeni z drugimi samo iz drv– primerov rimri preiskavi niš kih porč il o vzrku smrti Number MicroscopicalyConfirmedRegisterd from of nw nfirmed by thr dath certifi– ICD Sex cases cass investigations ctes only C73 C74 C75 Drugi n eopredljeni ž enski spolni organi Other and unspecified parts of emale gnitl organs Posteljica Placnt Penis Penis Prostat M Ž M Ž M Ž M Ž C57 C58 C60 C61 Prostte Modo MC62Testis Ž Drugi in eopredeljni moš ki spolni organi MC63 Other and uspecified male gnitl organs Ž Ledvica rzen meha M154 Ž C64 Kiney, except renal pelvis Ledvič ni meh MC65 Renal pelvis Ž Seč vod MC6 Uretr Ž Seč ni mehur M Ž C67 Blader Drugi in eopredeljni seč ni organi MC68 Other and unsecified urinary orns Ž Oko in oč esni adneksi MC69 Eye and adnex Ž Menige M Ž C70 eni es Mož gani MC71Brain Ž Hrbtni mozeg, mož ganski ž ivci in drugi deli CŽ S MC72 Spinal cord, cranial nerves and other parts of CNS Ž Š č itnica Thyroid glnd Nadledvič na ž leza Arenal glnd M Ž M Ž M Ž Druge ndokrine ž lez in sordne strukture Other ndocrine glands and related structures – Cancer Incidence in Slovenia 204 35 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia Š tevil %* Š tevil %* Š tvilo %* code*Primary site Number %* Number %* Number %* – 5 1 10 740 10 2 102 15 14 8 2 213 73 1 1 14 13 2 3 72 58 2 3 29 106 4 0 0 0 – – – 4 1 10 68 10 2 130 8 15 14 8 2 201 71 1 1 12 12 2 3 60 40 2 3 29 106 1 0 0 0 – – – – – – 93,0 – 10,0 – 84, 86,3 10,0 – – – 94, 97,3 – – – – – – 83, 69,0 – – 10,0 10,0 – – – – – – – 0 0 0 43 0 0 23 14 0 0 0 0 8 1 0 0 2 1 0 0 12 18 0 0 0 0 3 0 0 0 – – 1 0 0 9 – 0 0 1 0 0 0 0 0 4 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 – – – – – – 1,2 – – 0,6 0, 0, – – 1,9 1,4 – – – – 0, 0, – – – – – – – – 5,8 0, – 14,9 13,7 – – 3,8 1,4 – – – – 16,7 31,0 – – – – – – – – – 0, – – – – – – – – – – – – – – –– – – – – – –– – 0, – – – 0, 0, 0, 0, Tabela 3. – Table 3. Nadljevanje – Contiued Š ifra Spol Š teviloMikroskopskoUgotvljeni Registriani MKB*Primarna lokacija novih ptrjeni z drugimi samo iz drv– primerov rimri preiskavi niš kih porč il o vzrku smrti Number MicroscopicalyConfirmedRegisterd from of nw nfirmed by thr dath certifi– ICD Sex cases cass investigations ctes only C91.– 91.9 C76 C7 C78 C79 C80 C81 C82 C83 C84 C85 C8 C90 C91.0 C92 C93 M Ž M Ž 6 14 20 15 58 57 23 19 52 31 26 20 26 38 68 68 12 9 8 17 0 0 38 45 13 10 36 25 34 28 5 4 4 7 19 13 31 25 15 12 36 18 26 20 26 38 68 68 12 9 8 17 0 0 38 42 13 10 35 25 34 28 5 4 1 3 1 2 23 25 6 7 13 5 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 4 0 0 4 7 2 0 3 8 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 1 0 0 0 0 0 – – 0, 0, 6,9 12,3 8,7 0, 5,8 25,8 0, 0, 0, 0, 0, 0, – – – 0, – – 0, 4, – – 2,8 0, 0, 0, – – Druga in slabo predeljna mesta Other nd il–define sites Metastaz in eopredeljna maligna neoplzma bezgavk Metastasi and unspecified malignant noplsm of lymh nods Metastaze dihal in prebavil etstses of respiratory nd igestive organs Metastaze, drugje etastases of ther sites Maligna neoplazma brez opredeljnega mest Malignant eoplasm without specifiction f site Hodgkinova bolezn okin's disese Folikularni e–Hodgkinov limfom Foliculr non– odgkin's lymphoa Difuzni e–Hodgkinov limfom ifuse non– odgkin's lyphoa Limfomi celic T in kož ni limfom celic T Peripheral nd cutaneous T–cel lyphomas Druge in eopredeljne vrste ne–Hodgkinvega limfoma Other and unspecified types of non–Hogkin's lymphoma Maligne imunoproliferativne bolezni lignant i unoprolifertive diseases Difuzni plazmocitom in maligne neoplaze plazcitov Multiple myeloma nd malignant plasma cl nplss Limfatič na levkemija, kutna Lyphoblstic lukaei, acute Limfatič na levkemija, druga Lyphoid lukai, other Mieloič na levkemija yeloid leukeia Moncitna levkemija nytic lukai M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž 36 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo Š tevilo %* Š tevilo %* Š tevilo %* code*Primary site Number %* Number %* Number %* – – 95,0 86,7 53,4 43,9 65,2 63,2 69,2 58,1 10,0 10,0 10,0 10,0 10,0 10,0 – 10,0 – – 10,0 93, – – 97,2 10,0 10,0 10,0 – – – – – – 5,0 13, 39,7 43,9 26,1 36,8 25,0 16,1 0, 0, 0, 0, 0, 0, – – 0, – – 0, 2, – – 0, 0, 0, 0, – – – Tabela 3. – Table 3. Nadljevanje – Contiued Š ifra Spol Š teviloMikroskopskoUgotvljeni Registriani MKB*Primarna lokacija novih ptrjeni z drugimi samo iz drv– primerov rimri preiskavi niš kih porč il o vzrku smrti Number MicroscopicalyConfirmedRegisterd from of nw nfirmed by thr dath certifi– ICD Sex cases cass investigations ctes only *MKB – Mednarodna klasifikacija bolezni, desta revizija, 195 ICD – International Clasification of Diseases, Tenth Revision, 195 *Odstotki niso rač unani, č e j š tevilo novih primerov manjš e od 15 Percentages are not calculated when umber of new cases is les than 15 C96 D03 D05 D06 D09.0 M Ž 94 108 0, 0, 0, 0, 0, 0, 0, Druge in eopredeljne maligne neoplazme limfatič nega, krvotvornega ali srodnega tkiv Other and unspecified malignant noplsms of lymphoi, hemtopoietic and related tisue Zgoraj neupoš tevani Nt includ abv Melanom, in situ elanoa, in situ Dojka, in situ Brest, in situ Maternič ni vrat, in situ CIN I( ) Cervix uteri, in situ (CIN I) Seni mehur, in situč Blader, in situ Menige, benigna neoplazma Benign eoplasm of meniges Mož gani, benigna neoplazma Benign eopasm of brain Jajč nik, neopl. negotvega znač ja Ovary, neopl. of uncertain behavior Mož gani, neopredeljno Brain, uncertain or unkown D3.0 3.2 – D32.0 D43.0 43.2 – D39.1 5,9 1,1 0, C94 C95 M Ž M Ž 34 37 23 10 2 87 38 17 36 4 2 41 6 6 1 0 1 5 10,0 10,0 10,0 – – 10,0 – 10,0 10,0 10,0 94,1 8,9 – – – 10,0 – – – – – – – – – – – – – – – – – – 0, 0, 0, – – 0, – 0, 0, 0, 0, 0, – – – 0, – – – – – – Druge opredeljne lvkemije Other leukaemias of specified cels Levkemija z neopredeljnim celič ni tipom Leukaemia, unspecified cel type M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž Cancer Incidence in Slovenia 204 37 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia Š tevil %* Š tevil %* Š tvilo %* code*Primary site Number %* Number %* Number %* – 34 37 23 10 2 87 94 108 38 16 32 4 2 41 2 0 1 0 1 5 – –– 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 6 0 0 0 0 – – 0 0 0 0 0 0 0 0 0 1 4 0 0 0 0 0 0 0 0 0 – – Tabela 4a. Š tevilo novih primerov rak po lkacij (MKB– 10), spolu in starosti – Slovenija 204 Table 4a. Number of new cancer cases by site (ICD– 10), by sex and by age – Slovenia 204 Š ifraPrimarna Vse Starosti MKBlokcij Spolstarosti Age ICDPrimary Sex Al codesite ages0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 5– 60– 65– 70– 75– 80+ C0Vse lokacije – C96Al sites M+Ž M Ž C0UstnicaLip C01Baz jezikas of tongue C02 Jezik, drui deli Tongue, othr & uspcified parts C03DlesnGum C04Ustno dnoFlor f muth C05NeboPalte C06 Usta, drugi deli Mouth, othr & unspecified parts C07Parotidna ž lezarti glnd C08 Druge in eopredeljne velik ž lz slinavk Othr & unspecified major salivary glans C09TonzilaTsil C10Orofarinksrphrynx C1Nazofarinkssphrynx C12Piriformni sinusyrifr sis C13Hipofarinksyphrynx C14 Druga in slabo prede– ljen mest na ustnici, v usti votlii i friksu Other and il–defined sites in t lip, oral cavity ad harynx C15Pož iralnikOesophagus C16Ž elodecStmah C17Smal intestine C18Debelo č revoColn C19Rektosigmoidna zvezactsi i juction C20Rektumct C21Anus in anlni kanls d al cal C2 Jetra in itrahepatič ni vodi Livr d intr tic bile ducts C23Ž olč nikGalblader C24 Drugi in eopredeljni deli bilarnga trakta Biliary trct, other nd unspecified parts C25Trebuš na slinavkaPancres 38 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo 106252815305781129193316589289041290153016791421437 5472143114424057512625149490756910963704524 5138541615417418190344344153462071671913 Tnko č rvo M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž 2600000001106242253 100000000001001216 1500000000303211401 4 0 11 0 0 1400000000103161200 500000001000000211 1000000000012112300 2 00000011 3100000011338552210 500000001000101020 1300000000133104001 300000000021000000 1600000000142302211 600000010000022100 400000000010110010 5 1 1 0100110 000000000000000000 3 11 1 4000000010178647420 700000000000302020 37000000013171010310 4 0001 011 500000000002111000 3 10 0 1 38000000002415544220 6 0000111 1 2600000000127342520 000000000000000000 000000000000000000 700000000025710813816 1 001 1 1 3 302000002113141713376056138 175 02240 01622834 1300000000112303012 700000000000011311 371000020134818376374754937 8 0 0451391 56576 59000000102185810978 59000000001163541117 2890000011321420233467564820 175000000032613201925283128 100000000000000010 4 1 41224 8700000001031231717101212 43200000000240349910 1200000000000103512 47 3 544678 3600000000112229676 2 0 05343610 160000000145141582321014 43 014 410 6266 Incidenca rka v Slovenij 204 Tabela 4a. – Table 4a. Nadljevanje – Contiued Š ifraPrimarna Vse Starosti MKBlokcij Spolstarosti Age ICDPrimary Sex Al codesite ages0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 5– 60– 65– 70– 75– 80+ Druga in slabo predljena mest v prevnih orgaihC26Othr and il–defied digestive organs C30 Nasl cavity and midle r C31Obnosni sinusiAcesry sises C32GrloLarynx C3SapnikTrchea C34Sapnica in pljuč aBrohus d lng C37TimusThys C38Srce, mediastinum, plevraHart, isti , lur Druga in slabo prede– ljen mest v dihalih C39i prsnih organiOther ad il–defined sites in t respiratory systm ad intrathrci organs C40 Kosti, sklepni hrustanec udov Bne ad articlr cartilge of limbs Kosti, sklepni hrustanec, drugje C41Bon and articular cartilge of ther nd unspecifid parts C43 Maligni melanom kož e li at lna of skin Druge maligne C4neoplze kož Ski, thr malignomas C45Mezoteliosthlima C46Kaposijev sarkomsi' srca C47 Periferni ž ivci in avtomno ž ivč evje Peripheral ervs and autonmic nrvous ystem C48Retro– in peritonej tr– ad rit um Drugo vezivno in C49mehk tkivOtr conective and sft isu C50DojkaBrest C51Ž ensko zunanje spolviloVulva C52Nož nicaVagi C53Maternič ni vratCrvix uteri C54Maternič no teloCorpus uteri C5Maternica, neopredeljnoUtrus, uspcifi C56Jajč nikOvry Nosna votlina in srednje uho Cancer Incidence in Slovenia 204 39 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia 2 00000000000000101 5 00000000000000113 3 00000000100010010 5 00000000110100200 9 00000000103121100 7 00000000101002102 9 0000001011219117201062 15 0 0522 1 30 6 00100000000201110 3 0 1 1 0 00 917 00001013165215101361241901563 28 0 009134372734484 100000000000001000 2 00000000000001001 5 00001110000100010 100000000000010000 0 00000000000000000 0 00000000000000000 9 00011000202001011 5 01000100001010010 3 00100000100001000 5 00010010001100100 167 001122561818211720182387 180 00013101291202014171513132 73100011061213265156103161201313 85 003 230484710 572 2 00000001013365102 1 00000000200212211 M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž 100000001000000000 0 00000000000000000 100000000000000100 3 1 1 1 0 12 10001310001021110 16 00000000001424131 2100001110021271311 2 00011031212101315 5 00000001011001010 1084 0000021232721212010213131529312 56 000010010452564820 5 00000001010000012 195 00001913242322917161271210 285 000000027143234648393727 6 00000000011012001 169 00000245101618202517191518 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – Tabela 4a. – Table 4a. Nadljevanje – Contiued Š ifraPrimarna Vse Starosti MKBlokcij Spolstarosti Age ICDPrimary Sex Al codesite ages0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 5– 60– 65– 70– 75– 80+ Drugi in eopredeljni ž enski splni rgai C57Othr and unspecified parts of emle geital orgns C58Pstljicalacent C60Penisis C61Prostatrstte C62ModTestis C63 Drugi in eopredeljni moš ki splni rgani Other and uspecified mal geital organs C64Ledvica rzen mehaKiney, excpt rnl pelvis C65Ledvič ni mehRnal pelvis C6Seč vodUrtr C67Seč ni mehurBladr Drugi in eopredeljni seč ni organi C68Other and unspecified urinry orgas C69Oko in č esni adneksiEye ad adex C70Menigei s C71Mož ganiBrain Hrbtni mozeg, mož ganski ž ivci i drui deli CŽ S C72Spinal cor, cranial nerves ad other prts of CNS C73Š č itnicaThyroid glnd C74Nadledvič na ž lezaArnal gl d C75 Druge ndokrine ž lez in sor e struktur Other ndocrine glands and rlate structures Druga in slabo opredelj mestaC76 Othr and il–dfined sites C7 Metastaz in eoprede– ljn mliga eoplaz bezgavk Mtstsi and unspecified malignant eoplasm of lyph ods Metastaze dihal C78Metastses of respiratory and igstiv rgns C79Metastaze, drujetstss of thr sites Maligna neoplazma brez opredelj g estC80Malignant eoplasm without spcifi tion of site C81Hodgkinova boleznki's diseas Folikularni e–Hodgkinov limfC82Folicular non–Hodgkin's lymphoma in prbvil 40 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo Incidenca rka v Slovenij 204 5 0 10 10 0 740 0 10 0 2 0 154 1 102 1 15 0 14 0 8 0 2 213 0 73 0 10 10 14 2 3 0 2 0 3 0 72 3 58 0 M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 2 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 15 0 1 0 0 0 0 0 0 0 0 0 0 0 2 1 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 1 0 0 19 0 2 2 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 18 1 1 2 0 0 0 1 0 0 0 1 0 0 0 3 0 0 0 0 0 1 0 5 2 0 0 0 0 1 0 0 0 0 0 5 0 0 0 0 6 9 0 10 6 1 0 0 6 1 0 0 0 2 0 0 4 4 50 17 19 0 0 1 19 0 0 23 14 1 2 3 0 31 2 1 0 2 5 0 1 10 9 1 0 0 176 0 1 26 9 5 4 1 0 34 8 0 0 2 1 0 0 9 9 1 0 3 17 0 0 2 17 5 3 2 0 47 17 0 1 3 0 0 0 7 1 1 0 2 105 0 0 20 16 0 2 0 1 32 1 0 0 1 3 1 1 7 8 1 0 1 89 0 0 9 16 0 2 0 25 27 0 0 1 2 0 0 3 3 2 0000001001 00000 3 0000000000 02000 29 0011123121 50201 106 00263739613 1387385 4 1000000000 00110 0 0000000000 00000 0 0000000000 00000 0 0000000000 00000 6 0010000001 10101 14 1000000000 01237 20 0000000001 13522 15 0000000002 20332 58 0000000000 5716149 57 0000000001 17101024 23 0000000003 34344 19 1 0 1 25 52 0000000102 68158 310000001201 45436 26 1004522202 12011 20 0005243011 00102 26 0000102124 32312 38 0000100043 0 0 2 23 4 0 17 9 2 1 1 0 18 2 0 0 0 1 0 7 4 0 0 4 13 0 0 0 0 1 0 3 1 3 2 1 3 6 4 1 1 3 5 1 0 1 1 0 8 1 0 1 3 0 0 1 0 0 0 6 6 0 1 5 1 0 0 0 0 0 3 2 4 2 1 0 5 1 2 0 2 652642 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – Tabela 4a. – Table 4a. Nadljevanje – Contiued Š ifraPrimarna Vse Starosti MKBlokcij Spolstarosti Age ICDPrimary Sex Al codesite ages0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 5– 60– 65– 70– 75– 80+ Difuzni e–Hodgkinov limfoC83Difuse non–Hodgkin's lymphma C84 Lifoi celic T in kož ni limf li T Peripheral nd cutaneous T–cl lymphoms Druge in eoredljen vrste ne–Hodgkinvga limfoaC85Othr an uspecifed types of no– Hodgkin's lymphoma C8 Maligne imunoprolife– rtiv bolezi Malignant imunopro– lifertive diseases Difuzni plazmocitom in malige neplaze plzmocitovC90Multiple myeloma nd malignant plas cel neoplsms C91.0 Limfatič na levkemija, akutn Lymphoblastic leukaemi, ute C91. – Limftič na levkemija, druga . Lyphoid lukai, other C92Mieloič na levkemijaylid lukai C93Moncitna levkemijaytic lukai C94 Druge opredeljne levkmij Other leukaemias of spcifid cls Levkemija z neoprede– ljni celič im tiomC95Leukamia, unspecified cl type Druge in eopredeljne mali lazm liftič nega, krvotvornega C96in sord tkivaOther an unspecified maligt eolasms of lyphoid, hamtopietic and relate tisue Zgoraj neupoš tevani Nt icld above D03Melanom, in situl a, i sit D05Dojka, in situBrest, i sit D06Maternič ni vrat, in situ (CIN I)Crvix uteri, in situ (CIN I) D09.0Seč ni mehur, in situBladr, in sit Menige, benigna noplazmaD32.0Beign eoplasm of mi s D3.0– Mož gani, benigna neplzma.2Bign eopsm of brain Jajč nik, neol. negotvga znač ja D39.1Ovary, neopl. of uncertai behavior D43.0 – Mož gani, neopredeljno .2 Brain, ucrtain or unkwn Cancer Incidence in Slovenia 204 41 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia 68201142 68000002 12001000 9 010000 8000000 17000000 0000000 0000000 38000000 45000000 13220210 10320100 36 000000 25000000 34 102110 280 000 5000000 4 1000000 0000000 1000000 5000000 34 000000 37000011 M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž 2 1 0 2 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 4 3 2 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 2 1 3 1 1 0 0 0 0 0 1 2 1 0 1 0 2 1 0 0 0 0 0 3 0 3 3 1 0 0 2 0 0 2 1 0 0 0 1 2 0 0 0 0 0 0 2 2 2 4 0 0 1 0 0 0 5 2 0 0 2 0 2 2 1 0 0 0 0 0 4 5 3 0 1 4 1 0 0 6 1 1 0 2 2 2 1 0 0 0 0 0 3 2 6 12 2 1 0 0 0 0 4 1 2 0 4 3 6 5 0 1 0 0 0 0 3 3 8 8 2 0 1 2 0 0 6 10 0 1 4 2 6 3 0 1 0 0 1 0 4 4 10 1 1 3 1 1 0 0 5 12 1 1 7 4 1 2 2 1 0 0 0 0 6 6 6 9 2 0 1 6 0 0 6 7 1 1 9 7 3 6 0 1 0 0 0 7 5 9 1 0 0 0 5 0 0 3 9 0 1 7 6 3 6 1 0 0 0 0 5 4 7 2300010010213336111 10 10 21 00210 0 870 0000028142112139413 94 000169189176169132123528196431 108000000003516914218110 3800000000103369376 1700000001142311310 36 00010003434151365 200000001000010000 4100010434565225130 6 00010010001000210 0 0 10 1022 0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – Tabela 4b. Š tevilo novih primerov rak po lkacij (MKB– 8), spolu in starosti – Slovenija 204 Table 4b. Number of new cancer cases by primary site (ICD– 8), sex, and age – Slovenia 204by by Š ifraPrimarna Vse Starosti MKBlokcij Spolstarosti Age ICDPrimary Sex Al codesite ages0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 5– 60– 65– 70– 75– 80+ 10570 Al sites M Ž Ustnica Lip Jezik Tongue Slinavke Slivry glands Dlesni Gum Ustno dno Flor f muth Usta, drugo Mouth, other parts Orofarinks rphrynx Epifarinks Eihrynx Hipofarinks yphrynx Ž relo, neoznač eno Pharyx, t spcified Pož iralnik Oesophagus Ž elodec Stmah Tanko č revo Sml intstine Debelo č revo Coln Rektum ct Jetra Livr Ž olč nik, ž olč ni vodi Galblader, bile ucts Trebuš na slinavka Pancres Retro–peritonej tr-rit um Prebavila, drugo Digstie orans, ther Nos, obnosne votline, drugo se, siuss, tc. Grlo Larynx Trachea, bronchus, lung Spnik, spia, pljč a Pleura, mediastinum, etc. Bone Soft isues Skin, malignant melanoma Skin, other malignancies Breast lvr, isti , drugo Kož a, lii l Mehka tkiva Ksti Kož a, drugi linoi Dojk M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž 548 512 26 1 29 9 5 1 10 2 31 5 29 10 81 15 5 3 64 6 0 0 70 1 314 98 17 8 375 39 349 250 65 26 48 79 17 43 13 19 0 4 13 14 9 15 296 924 24 10 13 10 23 23 168 180 734 862 5 1085 2 14 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8 3 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 15 1 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 1 0 0 0 0 0 30 14 16 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 1 1 0 0 0 56 42 14 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 2 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 2 0 2 1 2 3 1 1 0 0 80 40 40 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 1 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 2 10 0 3 0 2 128 5 73 0 0 0 0 0 0 0 0 1 0 0 1 1 0 0 0 0 0 0 0 0 0 1 2 0 0 1 0 2 1 0 0 0 0 0 1 0 0 0 0 0 1 0 1 1 1 0 0 1 1 3 5 12 6 8 0 12 19 17 74 1 0 0 1 0 1 0 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 3 0 0 3 4 3 3 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 3 1 0 0 0 0 1 6 9 14 11 1 32 31 123 190 1 0 4 0 0 0 0 0 3 0 2 0 4 1 0 0 3 0 0 0 2 0 4 5 2 0 4 5 4 3 0 0 1 0 4 1 0 0 0 0 2 2 1 0 9 16 0 2 3 0 0 2 18 11 13 21 0 72 583 250 3 0 0 0 0 1 1 1 0 3 0 7 2 8 0 0 0 6 0 0 0 5 0 14 2 2 0 8 13 15 7 3 1 1 4 5 4 0 0 0 0 0 1 12 5 13 52 1 0 0 0 2 1 18 20 26 30 1 121 924 49 430 6 1 6 1 0 3 2 0 8 0 5 1 15 1 2 1 2 0 0 0 7 1 19 8 2 0 18 19 28 19 1 3 2 0 14 2 1 0 0 3 1 19 2 34 15 2 0 2 2 1 2 21 20 51 48 1 120 901 48 413 2 0 3 1 1 1 1 0 5 1 4 1 16 3 1 0 8 0 0 0 10 0 14 3 0 37 17 28 23 2 0 3 10 15 4 0 4 0 0 1 1 1 2 37 103 4 2 0 1 2 1 17 14 56 55 0 102 1286 754 532 4 0 7 1 1 0 1 0 5 0 0 2 16 0 1 1 8 1 0 0 8 1 38 17 1 2 64 36 42 28 12 2 2 7 8 10 3 3 0 0 4 0 17 1 27 136 5 1 0 1 8 0 20 17 104 72 0 133 1526 90 617 2 1 2 1 0 1 2 0 2 1 6 2 8 4 1 0 6 1 0 0 13 3 62 0 4 1 74 54 7 31 1 3 12 8 23 1 5 0 0 1 2 20 1 35 126 5 1 2 0 1 1 19 15 116 100 1 133 169 958 71 2 2 6 2 0 1 3 0 2 0 2 1 7 1 0 0 7 1 0 0 8 2 56 30 0 3 7 57 65 42 6 7 1 9 23 6 1 2 0 0 1 3 10 1 4 19 1 1 0 1 3 3 23 13 120 123 0 153 140 698 712 5 1 0 1 2 2 0 1 1 2 1 0 5 3 0 0 4 2 0 0 1 1 61 39 1 1 49 57 56 4 9 4 8 23 10 26 1 3 0 1 1 2 6 3 50 16 1 1 1 1 1 2 8 13 113 157 1 93 1428 521 907 3 6 1 1 0 0 0 1 0 0 2 0 0 2 0 1 0 1 0 0 6 3 39 48 2 1 38 7 28 49 10 4 8 18 14 6 0 1 0 3 0 2 2 0 46 63 2 1 1 0 1 5 7 22 113 233 0 112 140 14 142 143 14 145 146 147 148 149 150 15 152 153 154 15 156 157 158 159 160 16 162 163 170 17 172 173 174 42 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo M+Ž M Ž 140Vse lokacije – 209 Tabela 4b. – Table 4b. Nadljevanje – Contiued Š ifraPrimarna Vse Starosti MKBlokcij Spolstarosti Age ICDPrimary Sex Al codesite ages0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 5– 60– 65– 70– 75– 80+ 180 18 182 183 184 185 186 187 18 189 190 19 192 193 194 195 196 197 198 19 20 + 20 201 203 204.0 204.1– 204.9 205 206 207 208 209 Maternica, vrat Utrus, ervix Horiepiteliom Chrioithli a Maternica, telo, drugo Utrus, orpus, etc. Jajč nik, jajcevod, rugo Ovry, Flopian tube, ther Nož nica, vulva, drugo Vagi , l, etc. Prostat rstte Modo Testis Penis, obmodek, drugo is, epidiymis, etc. Mehur Blader Ledvica, seč vod, rugo Kiney, urtr, etc. Oko Eye Mož gani Brain Ž ivč evje, drugo Nrvous ystem, ther 15 17 Metastaze v bezgavkah Lymph nod mtstses Metastaze v dihalih, prebavilih Rspirtive, digestive tract mtastass Š č itnica Thyroid Endokrine ž lez, druge cri glans, othr Slabo predeljne lokacije Il–defin sit Metastaze, drugje tstss, othr Malignomi, neopredeljni li ancis, unscified M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž Ne–Hodgkinovi limfomi on–Hodgkin's lyphoa Hdgkinv limfom oki's disease Plazmacitom Pls yta Levkemija, limftič na, akutna Lekemia, lymphatic, acut Levkemija, limfatič na, drugo Lekaemia, lymphatic, othr Levkemija, mieloič na Lukai, ylic Levkemija, moncitna Leukaeia, oncytic Lvkmije, druge Leukaeias, othr Policitemija, prav Polycytheia, vera Mielofibroza ylfirsi – 0 – 0 – 0 – 0 – 0 0 – 0 – 0 – 0 0 1 1 2 0 3 0 2 1 1 0 0 0 0 0 0 0 0 0 0 0 2 0 1 0 0 0 2 3 0 0 1 0 0 0 0 0 0 0 0 0 – 0 – 0 – 0 – 0 – 0 0 – 0 – 0 – 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 2 2 0 0 0 0 0 0 0 0 0 0 0 0 – 0 – 0 – 0 – 0 – 0 0 – 0 – 0 – 0 0 0 0 1 0 1 2 0 0 0 0 0 1 2 0 0 1 0 0 0 2 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 – 0 – 0 – 0 – 0 – 0 0 – 1 – 0 – 0 0 0 0 0 0 1 0 0 1 0 0 0 0 1 6 0 0 0 0 0 0 1 0 4 5 0 0 2 1 0 0 1 0 0 0 0 0 0 0 0 0 – 1 – 0 – 0 – 0 – 1 1 – – 0 – 0 0 1 0 0 0 2 1 0 0 0 0 0 0 1 3 0 0 0 0 0 0 3 0 5 2 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 – 9 – 0 – 0 – 2 – 0 0 – 2 – 0 – 0 0 0 0 0 0 2 0 0 0 0 0 0 0 2 7 0 0 0 0 0 0 2 1 2 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 – – 13 – 1 – 0 – 4 – 0 0 – 19 – 0 – 0 1 2 2 0 0 1 0 1 2 0 0 0 0 3 3 0 0 0 0 0 1 4 1 2 3 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 – 24 – – 0 – – 2 – – 5 – – 2 0 – 18 – 0 – 1 0 1 2 1 0 4 0 0 0 0 0 0 0 1 9 0 0 0 0 1 1 2 4 3 2 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 1 0 – 23 – 0 – 7 – 10 – 0 0 – 1 – 0 – 0 1 6 2 0 0 5 0 0 0 0 0 0 0 2 6 0 0 0 0 0 0 3 3 0 1 1 2 1 0 1 0 1 0 1 1 0 0 0 0 0 0 – 12 – 0 – 50 – 18 – 6 176 – 0 – 0 – 34 8 3 13 2 1 10 2 0 2 1 3 0 13 8 0 7 1 1 0 4 8 5 6 5 2 0 5 10 0 1 4 1 4 3 2 1 2 1 2 0 1 1 47 17 29 21 12 19 2 – 7 – 0 – 39 – 19 – 5 – 0 – 3 – 3 0 7 1 1 2 5 3 2 3 1 0 1 3 1 4 13 13 0 1 5 12 1 1 7 4 1 2 2 1 0 0 1 0 0 1 105 – 0 – 2 – 32 1 20 19 1 3 7 9 1 1 – 12 – 0 – 37 – 15 – 10 3 2 3 17 5 0 8 1 0 0 4 2 5 3 7 7 1 0 6 7 1 1 7 7 2 5 1 1 3 0 1 0 0 0 – 89 – 0 – 1 – 25 27 9 18 1 2 3 0 0 10 – 0 – 28 – 18 – 23 7 2 2 10 3 1 6 0 1 1 5 8 6 10 8 1 2 3 9 0 1 7 6 3 6 1 0 0 5 0 1 1 0 – 195 – 1 – 291 – 17 – 64 740 – 10 – 10 – 213 73 180 19 15 13 74 6 7 10 14 20 15 78 4 29 10 4 2 6 24 19 52 31 82 70 26 20 36 45 13 10 34 23 26 25 13 7 5 7 5 3 3 5 Cancer Incidence in Slovenia 204 43 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia 29 0 3 18 5 23 – 4 – 2 – 18 2 20 10 0 0 7 4 1 0 0 3 1 4 3 4 13 0 0 1 1 3 6 4 4 7 1 1 5 2 0 0 2 0 1 2 3 1 0 0 0 0 0 0 – – – – – – – – – 17 0 3 21 2 50 – 1 – 1 – 19 3 19 9 1 0 6 0 1 0 3 2 5 2 5 13 1 0 0 1 0 5 1 10 4 2 0 6 1 1 0 2 1 2 1 0 0 0 1 0 1 1 0 – – – – – 16 0 47 25 5 19 – 0 – 1 – 31 2 28 16 2 5 10 0 1 0 1 2 10 2 5 10 0 0 1 3 1 6 4 5 12 1 0 3 1 2 0 4 3 4 4 2 2 0 0 0 1 1 0 – – – – – 2 – 0 – 15 – 16 – 5 6 – 9 – 0 – 6 1 1 6 1 2 4 1 0 0 1 2 0 2 1 3 0 0 1 3 0 2 1 6 5 2 1 2 1 0 0 0 1 1 0 1 0 0 0 1 0 0 1 – Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo Tabela 4b. – Table 4b. Nadljevanje – Contiued Š ifraPrimarna Vse Starosti MKBlokcij Spolstarosti Age ICDPrimary Sex Al codesite ages0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 5– 60– 65– 70– 75– 80+ Zgoraj neupoš tevani Not include above 219 +34 25.0 + 2.2 23.2 23 235 237.6 238.1 Maternič ni vrat, in situ (CIN II) Crvix uteri, in sit (I I) Mož gani, benigni tumor Brain, beig tumor Maligni melano, in situ li at l ma, in situ Dojka, in situ Brest, i sit Jajč nik, neopl. negotvega znač ja Ovary, nopl. of uncertain behvir Sč ni mehur, in situ Bladr, in sit Mož gani, neopredeljno Brain, uspcifi – 94 26 41 23 10 2 87 – 41 108 38 6 6 – 0 0 0 0 0 0 0 0 0 0 0 0 – 0 0 0 0 0 0 0 – 0 0 0 0 0 – 0 0 0 0 1 0 0 – 0 0 0 0 0 – 1 0 1 1 0 0 0 – 1 0 0 1 0 – 69 0 0 0 0 0 0 – 0 0 0 0 0 – 189 1 0 0 0 0 0 – 4 0 0 0 0 – 176 0 0 1 1 0 0 – 3 0 0 1 0 – 169 3 4 0 2 0 2 – 4 0 0 0 0 19 14 18 – 132 1 4 2 1 0 8 – 5 3 1 0 0 – 12 5 5 1 1 0 14 – 6 5 0 0 1 – 35 2 5 3 0 1 21 – 5 16 3 1 0 – 28 4 1 3 0 0 12 – 2 9 3 0 0 13 – 2 6 3 2 0 – 2 6 0 0 – 6 2 1 6 1 1 9 – 5 2 9 0 1 – 3 2 6 1 1 0 1 – 3 1 7 1 2 – 1 0 5 1 0 0 3 – 0 10 6 0 2 4 4 3 1 0 0 4 1 3 2 0 – –M Ž M Ž M Ž M Ž M Ž M Ž M Ž 4 Incidenca rka v Slovenij 204 š š – Cancer Incidence in Slovenia 204 45 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia Ta b el a 5 . G ro b a in s ta ro st no s p ec ifi čn a in ci d en čn a s to p nj a n a 1 00 .0 00 p re b iv a lc ev te r k um ul a tiv na s to p nj a (K S) , p o lo ka ci ji in s p ol u - S lo ve ni ja 2 00 4 Ta b le 5 . C ru d e a nd a g e s p e ci fic c a nc e r i nc id e nc e ra te p e r 1 00 ,0 00 a nd c um ul a tiv e ra te ( C R) b y sit e a nd b y se x - S lo ve ni a 2 00 4 Ši fra Pr im a rn a V se S t a r o s t i KS M KB lo ka ci ja Sp ol st a ro st i A g e C R IC D Pr im a ry Se x A ll co d e sit e a g e s 0– 5– 10 – 15 – 20 – 25 – 30 – 35 – 40 – 45 – 50 – 55 – 60 – 65 – 70 – 75 – 80 + 0 – 7 4 C 00 V se lo ka ci je – C 96 A ll sit e s M +Ž M Ž C 00 Us tn ic a Li p C 01 Ba za je zi ka Ba se o f t on g ue C 02 Je zi k, d ru g i d el i To ng ue , o th er & un sp ec ifi ed p a rt s C 03 D le se n G um C 04 Us tn o d no Fl oo r o f m ou th C 05 N eb o Pa la te C 06 Us ta , d ru g i d el i M ou th , o th er & un sp ec ifi ed p a rt s C 07 Pa ro tid na ž le za Pa ro tid g la nd C 08 D ru g e in n eo p re d el je ne ve lik e žl ez e sl in a vk e O th er & u ns p ec ifi ed m a jo r s a liv a ry g la nd s C 09 To nz ila To ns il C 10 O ro fa rin ks O ro p ha ry nx C 11 N a zo fa rin ks N a so p ha ry nx 14 72 ,8 M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž 35 ,7 43 ,5 29 ,8 0, 2 0, 0 0, 1 0, 0 0, 1 0, 0 0, 1 0, 0 0, 2 0, 0 0, 1 0, 0 0, 1 0, 1 0 ,0 0, 0 0, 0 0, 0 0, 3 0, 0 0, 3 0, 0 0, 0 0, 0 22 31 ,7 32 80 ,8 16 98 ,4 23 ,3 2, 4 0 0 0 2, 4 0 2, 4 4, 7 4, 7 0 0 4, 7 0 4, 7 0 0 2, 4 9, 3 4, 7 4, 7 2, 4 0 0 24 44 ,9 34 17 ,0 21 01 ,7 19 ,6 13 ,8 6, 5 0 0 2, 3 0 2, 3 0 0 6, 5 0 6, 5 0 0 0 0 0 0 0 0 0 0 2, 3 53 2, 0 56 0, 0 50 5, 2 2, 7 1, 1 1, 5 0, 4 1, 4 0, 5 1, 0 0, 2 3, 2 0, 5 1, 3 0, 3 1, 6 0, 6 0, 4 0, 5 0, 0 0, 3 4, 1 0, 7 3, 8 0, 4 0, 5 0, 3 24 ,7 30 ,5 18 ,5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8, 5 6, 2 11 ,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 14 ,1 20 ,2 7, 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 23 ,6 21 ,6 25 ,8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 39 ,5 56 ,6 21 ,4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1, 4 0 0 0 0 0 0 0 0 53 ,3 50 ,9 55 ,8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 89 ,8 74 ,5 10 5, 9 0 0 0 0 0 0 0 0 1, 4 0 0 0 0 1, 4 0 0 0 0 1, 4 0 0 0 0 0 12 6, 4 97 ,5 15 5, 7 1, 3 0 0 0 0 1, 3 0 0 1, 3 1, 3 0 0 0 0 0 1, 3 0 0 0 0 1, 3 0 0 0 20 4, 4 16 0, 5 24 9, 7 1, 3 0 3, 8 0 1, 3 0 0 0 3, 8 0 1, 3 0 1, 3 0 0 0 0 0 1, 3 0 3, 8 0 0 0 37 0, 1 30 9, 9 43 3, 3 0 0 0 0 0 0 1, 2 0 3, 7 0 3, 7 2, 6 4, 9 0 1, 2 0 0 1, 3 8, 6 0 1, 2 0 0 0 60 7, 5 62 6, 5 58 7, 3 7, 6 1, 4 3, 8 1, 4 3, 8 0 2, 5 0 10 ,1 0 3, 8 1, 4 2, 5 0 0 1, 4 0 1, 4 10 ,1 0 8, 9 1, 4 2, 5 1, 4 80 5, 6 87 5, 2 73 6, 2 3, 6 0 3, 6 1, 8 1, 8 0 1, 8 0 8, 9 1, 8 1, 8 0 5, 4 0 1, 8 0 0 0 10 ,7 5, 3 17 ,9 0 1, 8 0 11 98 ,5 94 8, 5 7, 8 0 1, 9 1, 8 11 ,7 0 1, 9 0 9, 7 0 0 0 0 3, 6 1, 9 0 0 0 7, 8 0 21 ,4 0 1, 9 1, 8 16 13 ,4 21 20 ,9 11 94 ,0 4, 7 1, 9 2, 3 1, 9 2, 3 0 4, 7 0 4, 7 1, 9 9, 3 0 4, 7 3, 9 0 1, 9 0 0 16 ,3 3, 9 0 1, 9 2, 3 0 19 58 ,8 27 76 ,6 14 03 ,0 5, 8 3, 9 11 ,5 0 5, 8 3, 9 8, 6 0 5, 8 0 0 0 5, 8 2, 0 0 2, 0 0 0 11 ,5 0 8, 6 2, 0 0 0 46 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo Ta b el a 5 . – Ta b le 5 . N a d a lje va nj e – C on tin ue d Ši fra Pr im a rn a V se S t a r o s t i KS M KB lo ka ci ja Sp ol st a ro st i A g e C R IC D Pr im a ry Se x A ll co d e sit e a g e s C 12 Pi rif or m ni s in us Py rif or m s in us C 13 H ip of a rin ks H yp op ha ry nx D ru g a in s la b o o p re d el je na m es ta n a u st ni ci , C 14 v us tn i v ot lin i i n fa rin ks u O th er a nd il l-d ef in ed s ite s in th e li p , o ra l c a vi ty a nd p ha ry nx C 15 Po ži ra ln ik O es op ha g us C 16 Že lo d ec St om a ch C 17 Sm a ll in te st in e C 18 D eb el o č re vo C ol on C 19 Re kt os ig m oi d na z ve za Re ct os ig m oi d ju nc tio n C 20 Re kt um Re ct um C 21 A nu s in a na ln i k a na l A nu s a nd a na l c a na l C 22 Je tra in in tra he p a tič ni v od i Liv er a nd in tra he p a tic b ile d uc ts C 23 Žo lč ni k G a llb la d d er D ru g i i n ne op re d el je ni d el i b ili a rn eg a tr a kt a C 24 Bi llia ry tr a ct , o th er a nd un sp ec ifi ed p a rt s C 25 Tr eb uš na s lin a vk a Pa nc re a s D ru g a in s la b o op re d el je na m es ta C 26 v p re b a vn ih o rg a ni h O th er a nd il l-d ef in ed d ig es tiv e o rg a ns 21 ,6 22 ,8 25 ,7 10 ,1 25 ,4 17 ,6 28 4, 3 22 8, 4 Ta nk o č re vo M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž 15 ,2 17 ,8 3, 9 0, 6 2, 7 0, 0 0, 0 0, 0 7, 2 1, 0 30 ,9 17 ,2 1, 3 0, 7 38 ,0 33 ,1 6, 0 5, 8 29 ,6 17 ,2 0, 1 1, 4 8, 9 4, 2 1, 2 4, 6 3, 7 3, 1 11 ,9 14 0, 2 0, 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4, 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 5 0 0 0 0 0 0 0 1, 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1, 4 2, 9 0 0 1, 4 0 1, 4 0 1, 4 0 0 1, 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1, 3 2, 6 0 0 3, 9 5, 3 0 0 3, 9 4, 0 0 0 1, 3 0 0 0 0 0 1, 3 0 0 0 2, 5 0 1, 3 0 0 0 2, 5 0 3, 8 5, 3 1, 3 0 5, 1 6, 6 2, 5 1, 3 2, 5 2, 6 0 0 0 0 0 0 1, 3 0 5, 1 1, 3 0 0 4, 9 0 2, 5 0 0 0 6, 2 0 17 ,3 13 ,0 1, 2 0 9, 9 16 ,9 1, 2 1, 3 17 ,3 7, 8 0 0 3, 7 2, 6 0 3, 9 1, 2 1, 3 6, 2 5, 2 0 0 19 ,0 0 8, 9 0 0 0 8, 9 1, 4 9, 5 2, 5 0 8, 1 0 0 5, 4 0 0 2, 5 0 5, 4 0 0 8, 9 0 5, 4 0 0 0 17 ,9 0 23 ,2 17 ,8 5, 4 0 66 ,1 30 ,2 8, 9 5, 3 41 ,1 35 ,6 0 0 5, 4 0 1, 8 8, 9 3, 6 8, 9 26 ,8 7, 1 0 0 7, 8 1, 8 7, 8 0 0 0 15 ,6 1, 8 72 ,1 28 ,4 0 1, 8 12 2, 7 63 ,9 15 ,6 8, 9 66 ,2 33 ,7 0 7, 1 33 ,1 5, 3 0 7, 1 3, 9 5, 3 15 ,6 17 ,8 0 0 9, 3 1, 9 4, 7 0 0 0 30 ,3 5, 8 13 9, 8 38 ,5 7, 0 1, 9 17 2, 5 10 5, 9 23 ,3 7, 7 15 6, 2 48 ,1 0 1, 9 39 ,6 7, 7 7, 0 7, 7 21 ,0 7, 7 53 ,6 42 ,4 0 0 5, 8 2, 0 14 ,4 0 0 0 23 ,1 2, 0 15 8, 6 54 ,9 0 5, 9 21 6, 2 10 9, 7 25 ,9 21 ,6 16 1, 5 54 ,9 0 3, 9 28 ,8 17 ,6 14 ,4 11 ,8 17 ,3 5, 9 63 ,4 50 ,9 2, 9 2, 0 9, 3 4, 7 9, 3 0 0 0 51 ,3 2, 4 78 ,2 4, 7 2, 4 13 5, 0 32 ,6 26 ,1 22 3, 7 73 ,4 4, 7 4, 7 55 ,9 21 ,3 4, 7 40 ,3 32 ,6 14 ,2 46 ,6 61 ,6 0 2, 4 0 2, 3 0 0 0 0 39 ,1 6, 9 24 7, 8 99 ,0 13 ,0 2, 3 24 1, 3 17 5, 0 52 ,2 39 ,1 13 0, 4 64 ,5 0 9, 2 78 ,3 23 13 ,0 18 ,4 39 ,1 23 ,0 91 ,3 10 5, 9 6, 5 6, 9 0, 3 0, 0 0, 2 0, 0 0, 0 0, 0 0, 5 0, 1 2, 2 0, 9 0, 1 0 3, 1 1, 8 0, 4 0, 3 2, 4 1, 0 0, 0 0, 1 0, 6 0, 2 0, 1 0, 2 0, 3 0, 1 0, 9 0, 7 0, 0 0, 0 0– 5– 10 – 15 – 20 – 25 – 30 – 35 – 40 – 45 – 50 – 55 – 60 – 65 – 70 – 75 – 80 + 0 – 7 4 Cancer Incidence in Slovenia 204 47 Ta b el a 5 . – Ta b le 5 . N a d a lje va nj e – C on tin ue d Ši fra Pr im a rn a V se S t a r o s t i KS M KB lo ka ci ja Sp ol st a ro st i A g e C R IC D Pr im a ry Se x A ll co d e sit e a g e s N os na v ot lin a in sr ed nj e uh o C 30 N a sa l c a vi ty a nd m id d le e a r C 31 O b no sn i s in us i A cc es so ry s in us es C 32 G rlo La ry nx C 33 Sa p ni k Tra ch ea C 34 Sa p ni ca in p lju ča Br on ch us a nd lu ng C 37 Ti m us Th ym us C 38 Sr ce , m ed ia st in um , p le vr a H ea rt , m ed ia st in um , p le ur a C 39 D ru g a in s la b o o p re d el je na m es ta v d ih a lih in p rs ni h or g a ni h O th er a nd il l-d ef in ed s ite s in th e re sp ira to ry s ys te m a nd in tra th or a ci c or g a ns Ko st i, sk le p ni h ru st a ne c ud ov C 40 Bo ne a nd a rt ic ul a r ca rt ila g e o f l im b s C 41 Ko st i, sk le p ni h ru st a ne c, d ru g je Bo ne a nd a rt ic ul a r c a rt ila g e of o th er a nd u ns p ec ifi ed p a rt s C 43 M a lig ni m el a no m k ož e M a lig na nt m el a no m a o f s ki n C 44 D ru g e m a lig ne ne op la zm e ko že Sk in , o th er m a lig no m a s C 45 M ez o te lio m M es ot he lio m a C 46 Ka p os ije v sa rk om Ka p os i's s a rc om a M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž 14 5, 8 18 0, 4 0, 3 0, 5 0, 9 0, 7 10 ,1 1, 5 0, 6 0, 3 93 ,8 28 ,2 0, 1 0, 2 0, 5 0, 1 0, 0 0, 0 0, 9 0, 5 0, 3 0, 5 17 ,1 17 ,6 74 ,8 83 ,8 2, 3 1, 1 0, 1 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1, 8 0 0 0 0 0 0 0 0 0 0 0 1, 8 0 1, 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1, 5 0 0 1, 6 1, 5 1, 6 1, 5 0 0 0 0 0 0 0 0 0 0 0 0 0 1, 3 0 0 0 1, 3 0 0 0 1, 3 0 0 0 2, 7 4, 3 1, 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1, 3 0 0 0 0 1, 4 0 0 2, 5 13 ,6 0 4, 1 0 0 0 0 0 0 0 0 1, 4 0 0 1, 4 1, 4 0 0 0 1, 4 0 0 0 0 0 0 1, 4 6, 8 17 ,2 8, 1 8, 6 0 0 0 0 0 0 0 0 0 0 0 0 3, 9 0 0 0 0 0 0 0 0 0 0 0 7, 8 11 ,9 15 ,6 14 ,5 1, 3 0 1, 3 0 1, 3 1, 3 1, 3 1, 3 1, 3 0 0 0 20 ,4 11 ,8 0 0 0 0 0 0 2, 5 0 1, 3 0 22 ,9 14 ,5 16 ,6 27 ,6 0 2, 6 0 0 0 1, 3 0 0 14 ,8 6, 5 0 1, 3 64 ,2 14 ,3 0 0 0 0 0 0 0 0 0 0 22 ,2 25 ,9 32 ,1 38 ,9 1, 2 0 0 0 0 0 3, 8 1, 4 24 ,1 2, 7 0 0 46 ,0 0 0 0 0 0 0 2, 5 1, 4 0 1, 4 26 ,6 27 ,1 64 ,7 65 ,0 3, 8 0 0 0 0 1, 8 1, 8 0 19 ,6 3, 6 3, 6 0 65 ,8 0 0 1, 8 0 0 0 0 0 0 1, 8 30 ,4 24 ,9 10 0, 0 96 ,0 5, 4 3, 6 0 0 1, 9 0 3, 9 0 33 ,1 1, 8 0 0 26 5, 0 48 ,0 0 0 0 1, 8 0 0 0 1, 8 0 0 39 ,0 30 ,2 20 0, 7 12 6, 1 11 ,7 1, 8 0 0 0 0 2, 3 3, 9 46 ,6 1, 9 2, 3 0 28 9, 0 61 ,6 2, 3 1, 9 0 0 0 0 2, 3 0 2, 3 0 42 ,0 28 ,9 27 0, 4 19 2, 6 11 ,7 3, 9 0 0 0 3, 9 2, 9 2, 0 28 ,8 2, 0 2, 9 0 54 7, 8 86 ,2 0 0 0 0 0 0 0 0 0 2, 0 66 ,3 25 ,5 34 6, 0 23 9, 1 2, 9 3, 9 0 0 4, 7 0 0 0 28 ,0 7, 1 4, 7 2, 4 53 5, 9 11 3, 7 0 0 4, 7 0 0 0 4, 7 2, 4 0 0 37 ,3 30 ,8 52 6, 6 37 1, 9 0 2, 4 0 0 0 0 0 4, 6 13 ,0 0 0 0 41 0, 8 10 5, 9 0 2, 3 0 0 0 0 6, 5 0 0 0 45 ,6 50 ,6 73 6, 9 53 4, 1 13 ,0 2, 3 0 0 0, 0 0, 0 0, 1 0, 0 0, 8 0, 1 0, 1 0, 0 7, 6 1, 7 0, 0 0, 0 0, 0 0, 0 0, 0 0, 0 0, 1 0, 0 0, 0 0, 0 1, 4 1, 1 5, 3 4, 1 0, 2 0, 1 0, 0 0, 0 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia 0– 5– 10 – 15 – 20 – 25 – 30 – 35 – 40 – 45 – 50 – 55 – 60 – 65 – 70 – 75 – 80 + 0 – 7 4 48 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo Ta b el a 5 . – Ta b le 5 . N a d a lje va nj e – C on tin ue d Ši fra Pr im a rn a V se S t a r o s t i KS M KB lo ka ci ja Sp ol st a ro st i A g e C R IC D Pr im a ry Se x A ll co d e sit e a g e s Pe rif er ni ž iv ci in C 47 Pe rip he ra l n er ve s a nd a ut on om ic n er vo us s ys te m C 48 Re tro - i n p er ito ne j Re tro - a nd p er ito ne um D ru g o v ez iv no in m eh ko tk iv o C 49 O th er c on ne ct iv e a nd so ft ti ss ue C 50 D o jk a Br ea st C 51 Že ns ko z un a nj e sp ol ov ilo Vu lv a C 52 N ož ni ca Va g in a C 53 M a te rn ič ni v ra t C er vi x ut er i C 54 M a te rn ič no te lo C or p us u te ri C 55 M a te rn ic a , n eo p re d el je no Ut er us , u ns p ec ifi ed C 56 Ja jč ni k O va ry D ru g i i n ne op re d el je ni že ns ki s p o ln i o rg a ni C 57 O th er a nd u ns p ec ifi ed p a rt s of fe m a le g en ita l o rg a ns C 58 Po st el jic a Pl a ce nt a C 60 Pe ni s Pe ni s C 61 Pr o st a ta Pr os ta te C 62 M od o Te st is C 63 D ru g i i n ne op re d el je ni m oš ki s p ol ni o rg a ni O th er a nd u ns p ec ifi ed m a le g en ita l o rg a ns a vt on om no ž iv če vj e M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž 16 2, 4 29 7, 8 12 ,2 0, 1 0, 3 1, 2 1, 6 2, 1 2, 2 0, 5 10 6, 3 5, 5 0, 5 19 ,1 27 ,9 0, 6 16 ,6 0, 5 0, 1 1, 0 75 ,7 10 ,2 0, 2 0 2, 3 2, 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1, 6 0 0 0 1, 6 0 0 0 0 0 0 0 0 0 0 0 0 1, 5 0 0 0 1, 3 0 1, 3 1, 4 0 0 1, 4 0 1, 4 0 0 0 0 0 0 1, 3 20 ,2 0 0 0 3, 8 0 1, 3 0 0 2, 7 0 0 0 0 2, 7 0 0 0 0 28 ,0 0 0 1, 4 1, 4 0 1, 4 4, 3 0 17 ,2 0 0 18 ,6 0 0 5, 7 0 1, 4 0 0 25 ,7 0 0 0 0 0 0 1, 3 1, 3 42 ,2 1, 3 1, 3 31 ,7 2, 6 0 6, 6 0 0 0 0 23 ,4 1, 3 0 0 0 0 0 2, 6 0 94 ,6 0 0 30 ,2 9, 2 0 13 ,1 0 0 0 0 14 ,0 0 0 0 0 0 2, 5 1, 3 1, 2 15 7, 0 5, 2 1, 3 28 ,5 18 ,2 1, 3 20 ,8 0 0 0 7, 4 11 ,1 0 0 0 1, 3 1, 4 1, 3 2, 7 1, 3 6, 8 0 39 ,2 43 ,3 1, 4 24 ,4 0 0 2, 5 29 ,2 5, 1 0 0 0 0 7, 1 3, 6 1, 8 0 18 1, 4 3, 6 0 30 ,2 58 ,7 0 35 ,6 1, 8 0 1, 8 89 ,3 1, 8 0 0 0 3, 9 3, 6 13 ,6 0 0 23 6, 2 8, 9 0 28 ,4 81 ,7 1, 8 44 ,4 0 0 1, 9 23 1, 8 0 0 0 0 2, 3 7, 7 2, 3 1, 9 2, 3 25 6, 1 11 ,6 0 23 ,1 92 ,4 3, 9 32 ,7 1, 9 0 0 41 0, 2 0 2, 3 2, 9 0 2, 9 2, 0 8, 6 5, 9 0 7, 8 0 13 ,7 76 ,4 0 37 ,2 2, 0 0 8, 6 49 3, 0 0 0 0 0 4, 7 7, 1 4, 7 2, 4 4, 7 22 0, 3 19 ,0 2, 4 28 ,4 87 ,6 0 35 ,5 2, 4 0 9, 3 48 9, 3 0 0 0 0 0 2, 3 6, 5 11 ,5 0 25 7, 8 46 ,0 4, 6 23 ,0 62 ,2 2, 3 41 ,4 2, 3 0 6, 5 58 0, 4 0 0 0, 0 0, 0 0, 1 0, 1 0, 2 0, 1 0, 0 7, 2 – – – – – – – – – – – – – – – – – – – 0, 2 0, 0 1, 3 1, 9 0, 0 1, 1 0, 0 0, 0 0, 1 6, 3 0, 7 0, 0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – 0– 5– 10 – 15 – 20 – 25 – 30 – 35 – 40 – 45 – 50 – 55 – 60 – 65 – 70 – 75 – 80 + 0 – 7 4 Cancer Incidence in Slovenia 204 49 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia Ta b el a 5 . – Ta b le 5 . N a d a lje va nj e – C on tin ue d Ši fra Pr im a rn a V se S t a r o s t i KS M KB lo ka ci ja Sp ol st a ro st i A g e C R IC D Pr im a ry Se x A ll co d e sit e a g e s C 64 Le d vi ca ra ze n m eh a Ki d ne y, e xc ep t r en a l p el vi s C 65 Le d vi čn i m eh Re na l p el vi s C 66 Se če vo d U re te r C 67 Se čn i m eh ur Bl a d d er D ru g i i n ne op re d el je ni se čn i o rg a ni C 68 O th er a nd u ns p ec ifi ed ur in a ry o rg a ns C 69 O ko in o če sn i a d ne ks i Ey e a nd a d ne xa C 70 M en in g e M en in g es C 71 M ož g a ni Br a in H rb tn i m oz eg , m ož g a ns ki ži vc i i n d ru g i d el i C ŽS C 72 Sp in a l c or d , c ra ni a l n er ve s a nd o th er p a rt s of C N S C 73 Šč itn ic a Th yr oi d g la nd C 74 N a d le d vi čn a ž le za A d re na l g la nd C 75 D ru g e en d ok rin e žl ez e in s or od ne s tru kt ur e O th er e nd oc rin e g la nd s a nd re la te d s tru ct ur es D ru g a in s la b o op re d el je na m es ta C 76 O th er a nd il l-d ef in ed s ite s C 77 M et a st a za in n eo p re d el je na m a lig na n eo p la zm a b ez g a vk M et a st a sis a nd u ns p ec ifi ed m a lig na nt n eo p la sm of ly m p h no d es M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž 15 ,8 10 ,0 1, 5 1, 4 0, 8 0, 2 21 ,8 7, 2 0, 1 0, 1 1, 4 1, 3 0, 2 0, 3 7, 4 5, 7 0, 2 0, 3 3, 0 10 ,4 0, 4 0, 0 0, 0 0, 0 0, 6 1, 4 2, 0 1, 5 2, 2 2, 3 0 0 0 0 0 0 0 0 4, 4 0 0 0 6, 5 0 0 0 0 0 2, 2 0 0 0 0 2, 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 1 2, 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1, 8 0 0 0 1, 8 3, 9 0 0 1, 8 3, 9 0 0 0 0 1, 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1, 5 0 0 0 1, 5 9, 7 0 0 0 0 0 0 0 0 1, 3 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 7 1, 4 0 0 1, 3 4, 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 5 0 0 0 2, 5 9, 5 0 0 0 0 0 0 0 0 2, 7 2, 9 0 0 0 0 0 1, 4 0 0 0 0 0 1, 4 1, 4 0 1, 4 0 4, 1 4, 3 0 0 0 0 0 0 0 0 1, 3 2, 6 0 0 0 0 1, 3 0 0 0 1, 3 0 0 0 3, 9 0 0 0 1, 3 11 ,9 0 0 0 0 0 0 0 0 6, 4 2, 6 0 0 0 0 0 1, 3 0 0 0 0 0 0 6, 4 0 0 0 2, 5 7, 9 0 0 0 0 0 0 0 0 12 ,3 7, 8 1, 2 0 0 0 7, 4 1, 3 0 0 0 2, 6 0 0 4, 9 5, 2 1, 2 0 1, 2 16 ,9 0 0 0 0 1, 2 0 1, 2 2, 6 21 ,6 12 ,2 2, 5 1, 4 1, 3 0 22 ,8 2, 7 0 0 0 0 1, 3 0 8, 9 5, 4 0 0 5, 1 17 ,6 0 0 0 0 1, 3 0 3, 8 1, 4 30 ,4 14 ,2 1, 8 0 1, 8 1, 8 33 ,9 5, 3 0 0 1, 8 0 0 0 10 ,7 10 ,7 0 1, 8 8, 9 23 ,1 1, 8 0 0 0 0 0 5, 4 3, 6 44 ,8 24 ,9 1, 9 3, 6 5, 8 0 60 ,4 3, 6 1, 9 0 3, 9 8, 9 0 1, 8 19 ,5 16 ,0 0 0 9, 7 14 ,2 0 0 0 0 1, 9 0 1, 9 3, 6 60 ,6 17 ,3 11 ,7 7, 7 2, 3 0 79 ,2 15 ,4 0 0 4, 7 1, 9 0 0 21 ,0 17 ,3 0 3, 9 0 13 ,5 0 0 0 0 0 1, 9 7, 0 0 63 ,4 33 ,3 14 ,4 5, 9 5, 8 0 13 5, 5 33 ,3 0 2, 0 8, 6 0 0 0 20 ,2 21 ,6 0 0 5, 8 5, 9 2, 9 0 0 0 2, 9 3, 9 14 ,4 5, 9 14 9, 1 93 ,2 37 ,9 0 4, 7 0 2, 4 26 ,1 0 0 4, 7 7, 1 4, 7 2, 4 32 ,6 19 ,0 0 0 0 19 ,0 4, 7 0 0 0 0 7, 1 9, 3 7, 1 58 ,7 36 ,8 0 4, 6 0 0 16 3, 0 62 ,2 0 0 6, 5 4, 6 0 0 19 ,6 6, 9 0 0 6, 5 11 ,5 0 0 0 0 6, 5 16 ,1 13 ,0 4, 6 1, 2 0, 6 0, 2 0, 1 0, 1 0, 0 1, 7 0, 3 0, 0 0, 0 0, 1 0, 1 0, 0 0, 0 0, 6 0, 4 0, 0 0, 0 0, 2 0, 7 0, 0 0, 0 0, 0 0, 0 0, 0 0, 0 0, 2 0, 1 0– 5– 10 – 15 – 20 – 25 – 30 – 35 – 40 – 45 – 50 – 55 – 60 – 65 – 70 – 75 – 80 + 0 – 7 4 50 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo Ta b el a 5 . – Ta b le 5 . N a d a lje va nj e – C on tin ue d Ši fra Pr im a rn a V se S t a r o s t i KS M KB lo ka ci ja Sp ol st a ro st i A g e C R IC D Pr im a ry Se x A ll co d e sit e a g e s M et a st a ze d ih a l i n p re b a vi l M et a st a se s o f r e sp ira to ry C 78 a nd d ig es tiv e o rg a ns C 79 M et a st a ze , d ru g je M et a st a se s of o th er s ite s M a lig na n eo p la zm a b re z op re d el je ne g a m es ta C 80 M a lig na nt n e o p la sm w ith o ut s p e ci fic a tio n o f s ite C 81 H od g ki no va b ol ez en H od g ki n' s d ise a se Fo lik ul a rn i n e- H od g ki no v lim fo m C 82 Fo llic ul a r n on -H od g ki n' s ly m p ho m a C 83 D ifu zn i n e- H od g ki no v lim fo m D iff us e n on -H od g ki n' s ly m p ho m a Li m fo m i c el ic T in k ož ni lim fo m c el ic T C 84 Pe rip he ra l a nd c ut a ne ou s T- ce ll ly m p ho m a s C 85 D ru g e in n eo pr ed el je ne v rs te ne -H od g ki no ve g a li m fo m a O th er a nd u ns p ec ifi ed ty p es of n on -H od g ki n' s ly m p ho m a M a lig ne im un op ro lif er a tiv ne b ol ez ni C 88 M a lig na nt im m un op ro lif er a tiv e d ise a se s C 90 D ifu zn i p la zm oc ito m in m a lig ne ne op la zm e p la zm oc ito v M ul tip le m ye lo m a a nd m a lig na nt p la sm a c el l ne op la sm s C 91 .0 Lim fa tič na le vk em ija , a ku tn a Ly m ph ob la sti c le uk ae m ia , a cu te C 91 .1 - Lim fa tič na le vk em ija , d ru ga C 91 .9 Ly m p ho id le uk a em ia , o th er M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž 5, 9 5, 6 2, 4 1, 9 5, 3 3, 0 2, 7 2, 0 2, 7 3, 7 7, 0 6, 7 1, 2 0, 9 0, 8 1, 7 0 0 3, 9 4, 4 1, 3 1, 0 3, 7 2, 5 0 0 0 0 0 0 2, 2 0 0 0 4, 4 0 0 0 0 0 0 0 0 0 4, 4 6, 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 2 0 0 0 0 0 0 4, 1 4, 4 0 0 0 0 0 0 0 0 0 0 0 0 1, 8 0 1, 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6, 2 8, 1 0 0 1, 5 0 0 0 0 0 0 0 0 0 3, 1 1, 6 0 0 0 0 0 0 0 0 6, 7 2, 9 1, 3 1, 4 5, 4 0 0 0 0 0 0 0 0 0 1, 3 0 0 0 0 0 0 0 0 0 2, 5 5, 4 0 0 2, 5 2, 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1, 4 2, 7 4, 3 2, 7 0 2, 7 1, 4 0 2, 9 0 0 0 0 0 0 0 0 0 0 0 0 0 1, 3 1, 3 2, 6 2, 6 0 1, 3 0 5, 2 4, 0 2, 6 1, 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1, 3 2, 5 5, 3 3, 8 1, 3 1, 3 0 0 0 0 0 1, 3 2, 6 1, 3 0 1, 3 0 0 1, 3 3, 7 0 2, 5 1, 3 2, 5 1, 3 4, 9 3, 9 3, 7 3, 9 1, 2 0 0 2, 6 0 0 2, 5 1, 3 0 0 0 1, 3 3, 8 2, 7 1, 3 4, 1 7, 6 5, 4 1, 3 1, 4 3, 8 6, 8 2, 5 5, 4 0 0 1, 3 0 0 0 6, 3 2, 7 0 0 2, 5 0 7, 1 3, 6 1, 8 0 8, 9 1, 8 3, 6 0 3, 6 10 ,7 8, 9 5, 3 0 1, 8 7, 1 1, 8 0 0 10 ,7 1, 8 1, 8 0 3, 6 3, 6 9, 7 1, 8 5, 8 1, 8 11 ,7 7, 1 1, 9 0 5, 8 8, 9 11 ,7 21 ,3 3, 9 1, 8 0 0 0 0 7, 8 1, 8 3, 9 0 7, 8 5, 3 16 ,3 13 ,5 9, 3 7, 7 18 ,6 9, 6 4, 7 0 4, 7 3, 9 18 ,6 15 ,4 4, 7 0 2, 3 3, 9 0 0 14 ,0 19 ,3 0 1, 9 9, 3 3, 9 46 ,1 19 ,6 8, 6 5, 9 31 ,7 7, 8 0 2, 0 8, 6 11 ,8 28 ,8 21 ,6 2, 9 5, 9 2, 9 2, 0 0 0 14 ,4 23 ,5 2, 9 2, 0 20 ,2 7, 8 65 ,2 23 ,7 18 ,6 4, 7 23 ,3 7, 1 4, 7 4, 7 9, 5 28 ,0 21 ,3 9, 3 4, 7 14 ,2 28 ,0 16 ,6 4, 7 2, 4 41 ,9 16 ,60 0 0 0 58 ,7 55 ,2 52 ,2 13 ,8 58 ,7 25 ,3 19 ,6 20 ,7 45 ,6 13 ,8 26 ,1 11 ,5 6, 5 4, 6 13 ,0 4, 6 11 ,5 2, 30 0 0 0 0 0 0, 4 0, 2 0, 2 0, 1 0, 4 0, 2 0, 2 0, 1 0, 2 0, 3 0, 5 0, 4 0, 1 0, 1 0, 1 0, 1 0, 3 0, 3 0, 1 0, 1 0, 2 0, 1 0, 0 0, 0 0– 5– 10 – 15 – 20 – 25 – 30 – 35 – 40 – 45 – 50 – 55 – 60 – 65 – 70 – 75 – 80 + 0 – 7 4 Cancer Incidence in Slovenia 204 51 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia Ta b el a 5 . – Ta b le 5 . N a d a lje va nj e – C on tin ue d Ši fra Pr im a rn a V se S t a r o s t i KS M KB lo ka ci ja Sp ol st a ro st i A g e C R IC D Pr im a ry Se x A ll co d e sit e a g e s C 92 M ie lo ič na le vk em ija M ye lo id le uk a em ia C 93 M on oc itn a le vk em ija M on oc yt ic le uk a em ia C 94 D ru ge o pr ed el je ne le vk em ije O th er le uk a em ia s of s p ec ifi ed c el ls C 95 Le vk em ija z n eo p re d el je ni m ce lič ni m ti p om Le uk a em ia , u ns p ec ifi ed c el l t yp e D ru g e in n eo p re d el je ne m a lig ne n eo p la zm e lim fa tič ne g a , k rv o tv o rn eg a a li so ro d ne g a tk iv a C 96 O th er a nd u ns pe ci fie d m al ig na nt ne op la sm s of ly m p ho id , ha em a to p oi et ic a nd re la te d ti ss ue Zg or a j n eu p oš te va ni N ot in cl ud ed a b ov e D 03 M el a no m , i n si tu M el a no m a , i n sit u D 05 D oj ka , i n si tu Br ea st , i n sit u D 06 M at er ni čn i v ra t, in s itu (C IN II I) C er vi x ut er i, in s itu ( C IN II I) D 09 .0 Se čn i m eh ur , i n si tu Bl a d d er , i n sit u D 32 .0 M en in ge , b en ig na n eo pl az m a Be ni g n ne op la sm o f m en in g es D 33 .0 -M ož ga ni , b en ig na n eo pl az m a D 33 .2 Be ni g n ne op la sm o f b ra in D 39 .1 Ja jč ni k, n eo p l. ne g o to ve g a z na ča ja O va ry , n eo p l. of u nc er ta in b eh a vi or D 43 .0 -M ož g a ni , n eo p re d el je no D 43 .2 Br a in , u nc er ta in o r u nk no w n M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž 0, 5 0, 4 0, 1 0 0, 1 0, 5 3, 5 3, 6 2, 4 1, 0 0, 2 8, 5 – 92 ,6 11 ,1 3, 7 1, 7 3, 5 0, 4 0, 2 4, 0 0, 6 0, 6 3, 5 2, 7 0 0 0 0 0 0 0 0 0 0 0 0 – 0 0 0 0 0 0 0 0 0 0 2, 2 0 0 0 0 0 0 0 0 0 0 0 0 0 – 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 0 0 0 0 0 1, 9 0 0 – 0 0 0 0 0 0 0 0 0 0 3, 7 0 0 0 0 0 0 0 0 0 1, 5 0 0 0 – 1, 6 0 0 0 1, 6 0 0 1, 6 1, 5 0 1, 5 0 0 0 0 0 0 0 0 1, 4 0 0 0 0 – 98 ,4 0 0 0 0 0 0 0 0 01, 3 0 0 0 0 0 0 0 0 1, 4 0 0 0 0 – 25 7, 0 0 0 0 0 1, 3 0 5, 4 0 00 0 0 0 0 0 0 0 0 1, 4 1, 4 1, 4 0 0 – 25 1, 9 0 0 0 0 0 0 4, 3 1, 4 0 1, 4 1, 4 0 0 0 0 0 0 2, 6 1, 3 0 2, 6 0 2, 6 – 22 3, 0 0 0 1, 3 4, 0 2, 6 1, 3 5, 3 0 0 1, 3 1, 3 0 0 0 0 0 0 3, 8 0 2, 5 1, 3 0 10 ,5 – 47 ,4 3, 8 1, 3 1, 3 5, 3 0 0 6, 6 0 0 2, 5 1, 3 0 0 0 0 0 0 2, 5 2, 6 1, 2 1, 3 0 18 ,2 – 14 5, 3 6, 2 0 4, 9 3, 9 1, 2 0 7, 8 0 1, 3 2, 5 0 2, 5 1, 4 0 0 0 0 0 5, 4 3, 8 0 1, 3 28 ,4 – 17 3, 5 20 ,3 4, 1 2, 5 5, 4 0 0 6, 8 1, 3 0 2, 5 2, 7 0 0 0 0 0 0 5, 4 3, 6 5, 4 0 0 21 ,3 – 49 ,8 16 ,1 5, 3 5, 4 1, 8 0 0 3, 6 0 0 3, 6 1, 8 0 1, 8 0 0 0 0 5, 8 5, 3 5, 8 3, 6 0 23 ,1 – 33 ,7 27 ,3 10 ,7 1, 9 8, 9 0 1, 8 3, 6 0 0 11 ,7 8, 9 0 1, 9 0 0 2, 3 0 9, 3 7, 7 14 ,0 1, 9 2, 3 17 ,3 – 11 ,6 51 ,3 17 ,3 2, 3 1, 9 0 0 9, 6 0 1, 9 14 ,0 5, 8 5, 8 2, 0 0 0 0 0 17 ,3 11 ,8 2, 9 0 0 7, 8 – 7, 8 51 ,9 5, 9 8, 6 5, 9 0 0 2, 0 5, 8 0 2, 9 3, 9 32 ,6 11 ,8 51 ,3 16 ,6 14 ,24, 7 4, 7 2, 4 2, 4 7, 1 4, 7 7, 1 4, 7 4, 70 0 0 0 0 0 – 0 0 14 ,0 14 ,2 6, 5 11 ,5 26 ,1 16 ,1 6, 5 6, 9 2, 3 65 ,2 13 ,8 11 ,5 4, 60 0 0 0 0 0 – 0 0 0 0 0 19 ,6 13 ,8 0, 0 0, 0 0, 0 0, 0 0, 0 0, 0 0, 2 0, 2 0, 2 0, 1 0, 0 0, 6 – 6, 5 0, 9 0, 2 0, 1 0, 2 0, 0 0, 0 0, 3 0, 1 0, 0 0, 3 0, 1 – – – – – – – – – – – – – – – – – – – 0– 5– 10 – 15 – 20 – 25 – 30 – 35 – 40 – 45 – 50 – 55 – 60 – 65 – 70 – 75 – 80 + 0 – 7 4 Tabela 6a. Š tevilo novih primerov rak po statistič nih regijah po najpogostejš ih lokacijah in spolu - Slovenija 204 Table 6a. Number of new cancer cases by health regions by most frequent sites and by sex - Slovenia 204 Statistič na Spol Skupaj Lokacija (š ifre MKB-10) Druga regij C0-C96C16C18C19C20C34C4C50C53C54C61 Other D06* Statistical region *Neupoš tevano v skupnem š tevilu: D06 - Maternič ni vrat, in situ (CIN I) ot include in Al sites: 06-Ce rvix uteri, in situ (CIN I) Rectum C34Sapnica in pljuč a Brohus d lng Opis š ifer MKB Description of the ICD code C16Ž elodec Stmah C18Debelo č revo Coln C19Rektosigmoidna zveza ctsi i juction C20 kt C4Druge maligne neoplazme kož e Skin, othr li omas C50Dojka Brest C53Maternič ni vrat Crvix uteri C54Maternič no telo Corpus uteri C61Prostat rstte D06 Maternič ni vrat, in situ (CIN I) Crvix uteri, in situ (CIN I) Jugovzhodna Slovenija Osrednjeslovenska Notranjsko-kraš ka Spodnjeposavska Slovenija, skupaj Obalno-kraš ka Slovenia, total Gorenjska Podravska Pomurska Savinjska Zasvska Goriš ka Korš ka 52 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo M5472302371592899177315– – 7402058– Ž 513175385917528851084195285– 16994 M327121611849520– – 6415– Ž 30924291886561617– 9349 M7596152832135521– – 109309– Ž 710360131387152265– 271 M18715133838290– – 972– Ž 162413247383107– 430 M60365083896450– – 87246– Ž 624243 92336761383039– 216168 M1408102930140– – 125– Ž 1299156102637– 462 M18411721919140– – 1983– Ž 15716186103514– 543 M389303 520703 1– – 4615– Ž 308823481941621418– 146 M1495710419672826 1– – 29504– Ž 149543871852912902965365– 50267 M5720241291051051– – 81209– Ž 58153161628131251728– 179103 M15641 31032130– – 2459– Ž 10423043142645– 4318 M30182122656420– – 2818– Ž 3171323412141711016– 10737 M352020513596 1– – 32137– Ž 2688161415596714– 7870 Sex Al sites Site (ID-10 codes) Tabela 6b.Starostno standardiziran* incidenč na stopnja rka po statistič nih regijah, po najpogostejš ih lokacijah in spolu - Slovenija 204 Age standardised* cancer incidence rate by statistical regions by most frequent sites and by sex - Statistič na Spol Skupaj Lokacija (š ifre MKB-10) Druga regij C0-C96C16C18C19C20C34C4C50C53C54C61 Other D06* Statistical region SexAl sites Site (ICD-10 codes) *Standard - prebivalstvo Slovenije po poisu 202 Standard - poulation of Slovenia cording to census 202 Opis š ifer MKB Description of the ICD code C16Ž elodec Stmah C18Debelo č revo Coln C19Rektosigmoidna zveza ctsi i juction C20Rektum ct C34Sapnica in pljuč a Brohus d lng C4Druge maligne neoplazme kož e Skin, othr li omas C50Dojka Brest C53Maternič ni vrat Crvix uteri C54Maternič no telo Corpus uteri C61Prostat rstte D06 Maternič ni vrat, in situ (CIN I) Crvix uteri, in situ (CIN I) * Neupoš tevano v skupnem š tevilu:D06 - Maternič ni vrat, in situ (CIN I) ot include in Al sites: 06 - Cervix uteri, in situ (CIN I) Slovenija, skupaj Slovenia, total Goriš ka Spodnjeposavska Obalno-kraš ka Osrednjeslovenska Gorenjska Notranjsko-kraš ka Korš ka Savinjska Zasvska Jugovzhodna Slovenija Pomurska Podravska Cancer Incidence in Slovenia 204 53 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia Slovi 204 M534,929,336,25,728,289,570,90,5– – 72,020,5– Ž 489,116,532,05, 16, 27,280,2103,818, 27,2– 16,392,7 M532,719,126,31,829,679,482,00, – – 105,818,7– Ž 487,612,836,22,913,226,7123,786,324, 24,5– 137,078,0 M457,536,431, 4,919,681,531,00,6– – 64,9187,4– Ž 410,719,234,66,317, 21,84,087, 15,231,8– 132,468,0 M502,440,134,88,221,310,878,90, – – 24,9192,4– Ž 452,61,836, 5, 1,119,5106,191,527,220,4– 123,079,6 M481,329,139,66,330,375,735,70, – – 69,5194,9– Ž 482,518,625,66,917,828,059,4106,123,030,3– 16,8127,0 M581,049,837,29,041,418,548,41,9– – 41,023,7– Ž 480,819,732,07,613,424,731,692,512,327,9– 218,912,4 M508,029,047,35, 52,552, 38,60, – – 52,0230,8– Ž 416,718,741,32,821,815,925, 90, 13,938,6– 148,124,9 M578,043,849,67,629,5104,749,21,4– – 67,524,5– Ž 49,01,534,06,01,827,859,490,920,227,4– 160, 6,5 M594,330,541,37,526,590,6105,20,4– – 90,220,2– Ž 569,316,53,16,819, 34,510,313,120,324,7– 190,103,5 M572,919,823,70,928,4104,5104,10,9– – 79,321,3– Ž 547,114,830,75,715,827,4109,3123,516,927,5– 175,102,4 M564,513, 41, 1,036,214,843,40, – – 87,0217, – Ž 382,66,88,20, 14,11,04,598,616,317,5– 165,772,0 M456,81,030,82,640, 85,061,80, – – 42,183,6– Ž 470,318,331,75,616,732,457,108,916,023,2– 159,763,2 M592,932,03,27,821,810,8109,61,8– – 52,523,5– Ž 465,713,927,61,77,126,101,615,012,124,5– 136,3130,3 Table 6b. 54 Incidenca rka v Slovenij 204 Histolš ka vrsta Skupaj Lokacija (š ifre MKB-10) Histolgic type Al sites Site (ICD-10 codes) C0– C96C0C01C02C03C04C05C06 C07C08C09 H HH HCH HCHHCHCHHC Vse vrste / 891492334217218111360160208121470 Smal cel carcinoma 14568– – – – – – – – – – – – – – – – – – – – Non– smal cel carcinoma 354– – – – – – – – – – – – – – – – – – – – Squaous cel carcinoa12914032216– 18– 10– 35– 12– 19– – – – – 47– Basl cel carcinoma 19140– – – – – – – – – – – – – – – – – – – – Transitonal cel carcinoma 295– – – – – – – – – – – – – – – – – – – – – Adenocarcinoma 458236– – – – – – 1– – – 2– 2– 41– – – – Other specifed carcinomas 15719– – – – – – – – 1– 2– 1– 1– 11– – Carcinoma, unspecifed 1421532– 12– 1– 1– – – – – – – – – – – – Malignat hymoa 21– – – – – – – – – – – – – – – – – – – – alignat parganglioma/ – – – – – – – – – – – – – – – – – – – – – – pheochromocytom Malignat elanoa 3712– – – – – – – – – – – – – – – – – – – – Fibrosarcoma 6– – – – – – – – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 121– – – – – – – – – – – – – – – – – – – – Liposarcoma 16– – – – – – – – – – – – – – – – – – – – – Leiomyosarcoma 26– – – – – – – – – – – – – – – – – – – – – Rhabdoyosarcoa 4– – – – – – – – – – – – – – – – – – – – – Synovial sarcoma 6– – – – – – – – – – – – – – – – – – – – – Angiosarcoa 4– – – – – – – – – – – – – – – – – – – – – Kaposi arcoma 1– – – – – – – – – – – – – – – – – – – – – Osteosarcoa 51– – – – – – – – – – – – – – – – – – – – Chondrosarcoma 11– – – – – – – – – – – – – – – – – – – – Ewing sarcoa/PNET 21– – – – – – – – – – – – – – – – – – – – Other specifed sarcomas 31– – – – – – – – – – – – – – – – – – – – Sarcoma, unspecifed 41– – – – – – – – – – – – – – – – – – – – Malignat complex mixed and 503– – – – – – – – – – – – – – 3– 1– – – stroml turs Malignat fibroepithelial tumors 1– – – – – – – – – – – – – – – – – – – – – alignat mesothelioa 276– – – – – – – – – – – – – – – – – – – – Malignat gonadl stromal 2– – – – – – – – – – – – – – – – – – – – – tumors Dysgerminoma nd seminoma56– – – – – – – – – – – – – – – – – – – – – Other alignat ger cel tuors43– – – – – – – – – – – – – – – – – – – – – Malignat rophoblastic tumors1– – – – – – – – – – – – – – – – – – – – – alignat gliomas 102– – – – – – – – – – – – – – – – – – – – – Malignat neuroepithelial tumors41– – – – – – – – – – – – – – – – – – – – alignat menigioma 4– – – – – – – – – – – – – – – – – – – – – Malignat nerve sheath tumors 4– – – – – – – – – – – – – – – – – – – – – Non Hodgkin lymphoma 2135– – – – – – – – – – – – – – – – – – – – Hodgkin lymphoa 433– – – – – – – – – – – – – – – – – – – – Plasma cel tuors 5228– – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 2531– – – – – – – – – – – – – – – – – – – – Leukeia except chronic 6441– – – – – – – – – – – – – – – – – – – – lymphoid Other lymphoreticular – – – – – – – – – – – – – – – – – – – – – – neoplass Chronic myeloproliferative 631– – – – – – – – – – – – – – – – – – – – diseases Myelodysplastic syndromes 1024– – – – – – – – – – – – – – – – – – – – Other specifed malignat umors1– – – – – – – – – – – – – – – – – – – – – Malignat uor, unspecifed 101– – – – – – – – – – – – – – – – – – – – Al types Tabela 7. Š tevilo histolš ko (H) in citolš ko (C) potrjenih novih primerov rak po histolš ki vrsti in lokaciji - Slvenija 204 Table 7. Number of histolgicly (H) and cytolgicaly (C) confirmed new cancer cases by histolgical type and y site - Slvenia 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo Tabela 7. – Table 7. Nadljevanje – Contiued Histolš ka vrsta Skupaj Lokacija (š ifre MKB-10) Histolgic type Al sites Site (ICD-10 codes) Cancer Incidence in Slovenia 204 5 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia C0– C96C10C1C12C13C14C15C16 C17C18C19 H HHHCH H HCHCHHCH Vse vrste / 89149234– 714– 242– – 712432719– 65313– Smal cel carcinoma 14568– – – – – – – – – – 1– 1– – – – – – – Non– smal cel carcinoma 354 – – – – – – – – – – – – – – – – – – – – Squaous cel carcinoa1291404 – 7– 4– 232– – 5323– – – – – – – Basl cel carcinoma 19140– – – – – – – – – – – – – – – – – – – – Transitonal cel carcinoma 295– – – – – – – – – – – – – – – – – – – – – Adenocarcinoma 458236– – – – – – – – – – 13– 39416– 6403109– Other specifed carcinomas 15719– – – 1– – – – – – 1– – – – – 4– – – Carcinoma, unspecifed 142153– – – – – – 1– – – 3– 162– – 18– 4– Malignat hymoa 21– – – – – – – – – – – – – – – – – – – – alignat parganglioma / – – – – – – – – – – – – – – – – – – – – – – pheochromocytom Malignat elanoa 3712– – – – – – – – – – – – – – – – – – – – Fibrosarcoma 6– – – – – – – – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 121– – – – – – – – – – – – – – – – – – – – Liposarcoma 16– – – – – – – – – – – – – – – – – – – – – Leiomyosarcoma 26– – – – – – – – – – – – – 1– – – 2– – – Rhabdoyosarcoa 4– – – – – – – – – – – – – – – – – – – – – Synovial sarcoma 6– – – – – – – – – – – – – – – – – – – – – Angiosarcoa 4– – – – – – – – – – – – – – – – – – – – – Kaposi arcoma 1– – – – – – – – – – – – – – – – – – – – – Osteosarcoa 51– – – – – – – – – – – – – – – – – – – – Chondrosarcoma 11– – – – – – – – – – – – – – – – – – – – Ewing sarcoa/PNET 21– – – – – – – – – – – – – – – – – – – – Other specifed sarcomas 31– – – – – – – – – – – – – – – – – – – – Sarcoma, unspecifed 41– – – – – – – – – – – – – – – – – – – – Malignat complex mixed and 503– – – – – – – – – – – – 113– – – – – stroml turs Malignat fibroepithelial tumors 1– – – – – – – – – – – – – – – – – – – – – alignat mesothelioa 276– – – – – – – – – – – – – – – – – – – – Malignat gonadl stromal 2– – – – – – – – – – – – – – – – – – – – – tumors Dysgerminoma nd seminoma56– – – – – – – – – – – – – – – – – – – – – Other alignat ger cel tuors43– – – – – – – – – – – – – – – – – – – – – Malignat rophoblastic tumors1– – – – – – – – – – – – – – – – – – – – – alignat gliomas 102– – – – – – – – – – – – – – – – – – – – – Malignat neuroepithelial tumors41– – – – – – – – – – – – – – – – – – – – alignat menigioma 4– – – – – – – – – – – – – – – – – – – – – Malignat nerve sheath tumor 4– – – – – – – – – – – – – – – – – – – – – Non Hodgkin lymphoma 2135– – – – – – – – – – – – – – – – – – – – Hodgkin lymphoa 433– – – – – – – – – – – – – – – – – – – – Plasma cel tuors 5228– – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 2531– – – – – – – – – – – – – – – – – – – – Leukeia except chronic 6441– – – – – – – – – – – – – – – – – – – – lymphoid Other lymphoreticular – – – – – – – – – – – – – – – – – – – – – – neoplass Chronic myeloproliferative 631– – – – – – – – – – – – – – – – – – – – diseases Myelodysplastic syndromes 1024– – – – – – – – – – – – – – – – – – – – Other specifed malignat umors1– – – – – – – – – – – – – – – – – – – – – Malignat uor, unspecifed101– – – – – – – – – – – – 1– – – 1– – – Al types Tabela 7. – Table 7. Nadljevanje – Contiued Histolš ka vrsta Skupaj Lokacija (š ifre MKB-10) Histolgic type Al sites Site (ICD-10 codes) 56 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo Vse vrste / Smal cel carcinoma 14568– – – – – – – – – – – – – – – – – – – – Non– smal cel carcinoma 354– – – – – – – – – – – – – – – – – – – – Squaous cel carcinoa 129140– – 8– – – – – – – – – – – 5– 7– 1– Basl cel carcinoma 19140– – – – – – – – – – – – – – – – – – – – Transitonal cel carcinoma 295– – – 1– – – – – – – – – – – – – – – – – Adenocarcinoma 4582364114– 521326331– 107171– – – 4– – – Other specifed carcinomas 157191– – – – – 3– 1– 3– – – – – 3– 1– Carcinoma, unspecifed 1421535– 1– – 3112248– – – – 1– 3– Malignat hymoa 21– – – – – – – – – – – – – – – – – – – – alignat parganglioma/ – – – – – – – – – – – – – – – – – – – – – – pheochromocytom Malignat elanoa 37121– 1– – – – – – – – – – – 1– 1– – – Fibrosarcoma 6– – – – – – – – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 121– – – – – – – – – – – – – – – – – – – – Liposarcoma 16– – – – – – – – – – – – – – – – – – – – – Leiomyosarcoma 26– – – – – – – – – – – – – – – – – – – – – Rhabdoyosarcoa 4– – – – – – – – – – – – – – – – – – – – – Synovial srcoma 6– – – – – – – – – – – – – – – – – – – – – Angiosarcoa 4– – – – – – – – – – – – – – – – – – – – – Kaposi arcoma 1– – – – – – – – – – – – – – – – – – – – – Osteosarcoa 51– – – – – – – – – – – – – – – – – – – – Chondrosarcoma 11– – – – – – – – – – – – – – 1– – – – – Ewing sarcoa/PNET 21– – – – – – – – – – – – – – – – – – – – Other specifed sarcomas 31– – – – – – – – – – – – – – – – – – – – Sarcoma, unspecifed 41– – – – – – – – – – – – – – – – – – – – Malignat complex mixed and503– – – – 11– – – – – – – – – – – – – – stroml turs Malignat fibroepithelial tumors 1– – – – – – – – – – – – – – – – – – – – – alignat mesothelioa 276– – – – – – – – – – – – – – – – – – – – Malignat gonadl stromal 2– – – – – – – – – – – – – – – – – – – – – tumors Dysgerminoma nd seminoma56– – – – – – – – – – – – – – – – – – – – – Other alignat ger cel tuors43– – – – – – – – – – – – – – – – – – – – – Malignat rophoblastic tumors 1– – – – – – – – – – – – – – – – – – – – – alignat gliomas 102– – – – – – – – – – – – – – – – – – – – – Malignat neuroepithelial tumors41– – – – – – – – – – – – – – 1– – – – – alignat menigioma 4– – – – – – – – – – – – – – – – – – – – – Malignat nerve sheath tumors 4– – – – – – – – – – – – – – – – – – – – – Non Hodgkin lymphoma 2135– – – – – – – – – – – – – – – – – – – – Hodgkin lymphoa 433– – – – – – – – – – – – – – – – – – – – Plasma cel tuors 5228– – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 2531– – – – – – – – – – – – – – – – – – – – Leukeia except chronic 6441– – – – – – – – – – – – – – – – – – – – lymphoid Other lymphoreticular – – – – – – – – – – – – – – – – – – – – – – neoplass Chronic myeloproliferative 631– – – – – – – – – – – – – – – – – – – – diseases Myelodysplastic syndromes 1024– – – – – – – – – – – – – – – – – – – – Other specifed malignat umors1– – – – – – – – – – – – – – – – – – – – – Malignat uor, unspecifed101– – – – – – 1– – – 1– – – – – – – – – Al types 8914923481150531731434215251080160140 C0– C96C20C21C2 C23C24C25C26C30C31 C32 H HHCHCH HCHHCHCHCH Tabela 7. – Table 7. Nadljevanje – Contiued Histolš ka vrsta Skupaj Lokacija (š ifre MKB-10) Histolgic type Al sites Site (ICD-10 codes) Cancer Incidence in Slovenia 204 57 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia C0– C96C3C34C37C38C39C40C41 C43C4 C45 H HH HCH HCHHCHHCH Vse vrste / Smal cel carcinoma 145681– 1386– – – – – – – – – – – – – – – – Non– smal cel carcinoma 354– 23542– – – – – – – – – – – – – – – – Squaous cel carcinoa1291403– 2471– – – – – – – – – – – – 2916– – Basl cel carcinoma 19140– – – – – – – – – – – – – – – – 18640– – Transitonal cel carcinoma 295– – – – – – – – – – – – – – – – – – – – – Adenocarcinoma 458236– 123107– – – – – – – – – – – – 14– – – Other specifed carcinomas 157191– 729– – – – – – – – – – – – 2– – – Carcinoma, unspecifed 142153– – 1214– – – – – – – – – – – – 34– – Malignat hymoa 21– – – – 21– – – – – – – – – – – – – – alignat parganglioma/ – – – – – – – – – – – – – – – – – – – – – – pheochromocytom Malignat elanoa 3712– – – – – – – – – – – – – – 3461– – – – Fibrosarcoma 6– – – – – – – – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 121– – – – – – – – – – – – – – – – 7– – – Liposarcoma 16– – – – – – – – – – – – – – – – – – – – – Leiomyosarcoma 26– – – – – – – – – – – 1– – – – – – – – – Rhabdoyosarcoa 4– – – – – – – – – – – – – – – – – – – – – Synovial sarcoma 6– – – – – – – – – – – – – – – – – – – – – Angiosarcoa 4– – – – – – – 1– – – 1– 1– – – – – – – Kaposi arcoma 1– – – – – – – – – – – – – – – – – – – – – Osteosarcoa 51– – – – – – – – – – 213– – – – – – – Chondrosarcoma 11– – – – – – – – – – 613– – – – – – – Ewing sarcoa/PNET 21– – 1– – – – – – – – 1– – – – – – – – Other specifed sarcomas 31– – – – – – – – – – – – – – – – – – – – Sarcoma, unspecifed 41– – – – – – – – – – 1– – – – – 1– – – Malignat complex mixed and 503– – – – – – – – – – – – – – – – – – – – stroml turs Malignat fibroepithelial tumors 1– – – – – – – – – – – – – – – – – – – – – alignat mesothelioa 276– – – – – – – – – – – – – – – – – – 276 Malignat gonadl stromal 2– – – – – – – – – – – – – – – – – – – – – tumors Dysgerminoma nd seminoma56– – – – – – – 1– – – – – – – – – – – – – Other alignat ger cel tuors43– – – – – – – 1– – – – – – – – – – – – – Malignat rophoblastic tumors 1– – – – – – – – – – – – – – – – – – – – – alignat gliomas 102– – – – – – – – – – – – – – – – – – – – – Malignat neuroepithelial tumors41– – – – – – – – – – – – – – – – – – – – alignat menigioma 4– – – – – – – – – – – – – – – – – – – – – Malignat nerve sheath tumors 4– – – – – – – – – – – – – – – – – – – – – Non Hodgkin lymphoma 2135– – – – – – – – – – – – – – – – – – – – Hodgkin lymphoa 433– – – – – – – – – – – – – – – – – – – – Plasma cel tuors 5228– – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 2531– – – – – – – – – – – – – – – – – – – – Leukeia except chronic 6441– – – – – – – – – – – – – – – – – – – – lymphoid Other lymphoreticular – – – – – – – – – – – – – – – – – – – – – – neoplass Chronic myeloproliferative 631– – – – – – – – – – – – – – – – – – – – diseases Myelodysplastic syndromes 1024– – – – – – – – – – – – – – – – – – – – Other specifed malignat umors 1– – – – – – – – – – – – – 1– – – – – – – Malignat uor, unspecifed 101– – 15– – – 1– – – – – – – – 11– – Al types 8914923537383542131– – 138– 346115361276 Tabela 7. – Table 7. Nadljevanje – Contiued Histolš ka vrsta Skupaj Lokacija (š ifre MKB-10) Histolgic type Al sites Site (ICD-10 codes) 58 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo C0– C96C46C47C48C49C50C51C52 C53C54C5 H HH HCH HCHHCH HCH Vse vrste / Smal cel carcinoma 14568– – – – – – – – – – – – – – 1– – – – – Non– smal cel carcinoma 354– – – – – – – – – – – – – – – – – – – – Squaous cel carcinoa129140– – – – – – – – – – 4– 4– 16– 1– – – Basl cel carcinoma 19140– – – – – – – – – – 5– – – – – – – – – Transitonal cel carcinoma 295– – – – – – – – – – – – – – – – – – – – – Adenocarcinoma 458236– – – – 7– – – 94201– – – 15– 230– – – Other specifed carcinomas 15719– – – – – – – – 311– – – 9– 30– – – Carcinoma, unspecifed 142153– – – – – – – – 6782– – – 1– 2– – – Malignat hymoa 21– – – – – – – – – – – – – – – – – – – – alignat parganglioma/ – – – – – – – – – – – – – – – – – – – – – – pheochromocytom Malignat elanoa 3712– – – – – – – – – – – – – – – – – – – – Fibrosarcoma 6– – – – – 1– 3– 1– 1– – – – – – – – – Fibrohistiocytic sarcoma 121– – – – – – 51– – – – – – – – – – – – Liposarcoma 16– – – – – 9– 7– – – – – – – – – – – – – Leiomyosarcoma 26– – – – – 2– 13– – – – – – – – – 2– 1– Rhabdoyosarcoa 4– – – – – 1– – – – – – – – – – – – – 1– Synovial sarcoma 6– – – – – 1– 4– – – – – 1– – – – – – – Angiosarcoa 4– – – – – – – 1– – – – – – – – – – – – – Kaposi arcoma 1– 1– – – – – – – – – – – – – – – – – – – Osteosarcoa 51– – – – – – – – – – – – – – – – – – – – Chondrosarcoma 11– – – – – – 1– – – – – – – – – – – – – Ewing sarcoa/PNET 21– – – – – – 1– – – – – – – – – – – – – Other specifed sarcomas 31– – – – – 13– – – – – – – – – – – – – Sarcoma, unspecifed 41– – – – – 11– – – – – – – – – – – 1– Malignat complex mixed and 503– – – – 2– 1– – – – – – – 1– 19– 3– stroml turs Malignat fibroepithelial tumors 1– – – – – – – – – 1– – – – – – – – – – – alignat mesothelioa 276– – – – – – – – – – – – – – – – – – – – Malignat gonadl stromal 2– – – – – – – – – – – – – – – – – – – – – tumors Dysgerminoma nd seminoma 56– – – – – 2– – – – – – – – – – – – – – – Other alignat ger cel tuors43– – – – – – – – – – – – – – – – – – – – – Malignat rophoblastic tumors 1– – – – – – – – – – – – – – – – – – – – – alignat gliomas 102– – – – – – – – – – – – – – – – – – – – – Malignat neuroepithelial tumors41– – – 11– – – – – – – – – – – – – – – alignat menigioma 4– – – – – – – – – – – – – – – – – – – – – Malignat nerve sheath tumors 4– – – 3– – – – – – – – – – – – – – – – – Non Hodgkin lymphoma 2135– – – – – – – – – – – – – – – – – – – – Hodgkin lymphoa 433– – – – – – – – – – – – – – – – – – – – Plasma cel tuors 5228– – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 2531– – – – – – – – – – – – – – – – – – – – Leukeia except chronic 6441– – – – – – – – – – – – – – – – – – – – lymphoid Other lymphoreticular – – – – – – – – – – – – – – – – – – – – – – neoplass Chronic myeloproliferative 631– – – – – – – – – – – – – – – – – – – – diseases Myelodysplastic syndromes 1024– – – – – – – – – – – – – – – – – – – – Other specifed malignat umors 1– – – – – – – – – – – – – – – – – – – – – Malignat uor, unspecifed101– – – – – – – – – – – – – – – – – – – – Al types 891492310312624019609540501930284060 Tabela 7. – Table 7. Nadljevanje – Contiued Histolš ka vrsta Skupaj Lokacija (š ifre MKB-10) Histolgic type Al sites Site (ICD-10 codes) Cancer Incidence in Slovenia 204 59 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia C0– C96C56C57C58C60C61C62C63 C64C65C6 H HH HCH HCHHCHHCHC Vse vrste / Smal cel carcinoma 14568– – – – – – – – – – – – – – – – – – – – Non– smal cel carcinoma 354– – – – – – – – – – – – – – – – – – – – Squaous cel carcinoa129140– – 2– – – 8– – – – – 1– – – 1– – – Basl cel carcinoma 19140– – – – – – – – – – – – – – – – – – – – Transitonal cel carcinoma 295– – – – – – – – – – – – – – – – – 28– 10– Adenocarcinoma 4582361392– – – – – 6346– – – – 207– – – – Other specifed carcinomas 157194– – – – – – – – – – – – – 2– – – – – Carcinoma, unspecifed 142153– 5– – – – 2– 398– – – – 1– – – – – Malignat hymoa 21– – – – – – – – – – – – – – – – – – – – alignat parganglioma/ – – – – – – – – – – – – – – – – – – – – – – pheochromocytom Malignat elanoa 3712– – – – – – – – – – – – 1– – – – – – – Fibrosarcoma 6– – – – – – – – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 121– – – – – – – – – – – – – – – – – – – – Liposarcoma 16– – – – – – – – – – – – – – – – – – – – – Leiomyosarcoma 26– – – – – – – – – – – – – – – – – – – – – Rhabdoyosarcoa 4– – – – – – – – – 1– – – – – – – – – – – Synovial sarcoma 6– – – – – – – – – – – – – – – – – – – – – Angiosarcoa 4– – – – – – – – – – – – – – – – – – – – – Kaposi arcoma 1– – – – – – – – – – – – – – – – – – – – – Osteosarcoa 51– – – – – – – – – – – – – – – – – – – – Chondrosarcoma 11– – – – – – – – – – – – – – – – – – – – Ewing sarcoa/PNET 21– – – – – – – – – – – – – – – – – – – – Other specifed sarcomas 31– – – – – – – – – – – – – – – – – – – – Sarcoma, unspecifed 41– – – – – – – – – – – – – – – – – – – – Malignat complex mixed and 5032– – – – – – – – – – – – – 11– – – – stroml turs Malignat fibroepithelial tumors 1– – – – – – – – – – – – – – – – – – – – – alignat mesothelioa 276– – – – – – – – – – – – – – – – – – – – Malignat gonadl stromal 2– 2– – – – – – – – – – – – – – – – – – – tumors Dysgerminoma nd seminoma 56– 2– – – – – – – – – 51– – – – – – – – – Other alignat ger cel tuors 43– 1– – – – – – – – – 40– – – – – – – – – Malignat rophoblastic tumors 1– – – – – 1– – – – – 9– – – 1– – – – – alignat gliomas 102– – – – – – – – – – – – – – – – – – – – – Malignat neuroepithelial tumors41– – – – – – – – – – – – – – – – – – – – alignat menigioma 4– – – – – – – – – – – – – – – – – – – – – Malignat nerve sheath tumors 4– – – – – – – – – – – – – – – – – – – – – Non Hodgkin lymphoma 2135– – – – – – – – – – – – – – – – – – – – Hodgkin lymphoa 433– – – – – – – – – – – – – – – – – – – – Plasma cel tuors 5228– – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 2531– – – – – – – – – – – – – – – – – – – – Leukeia except chronic 6441– – – – – – – – – – – – – – – – – – – – lymphoid Other lymphoreticular – – – – – – – – – – – – – – – – – – – – – – neoplass Chronic myeloproliferative 631– – – – – – – – – – – – – – – – – – – – diseases Myelodysplastic syndromes 1024– – – – – – – – – – – – – – – – – – – – Other specifed malignat umors 1– – – – – – – – – – – – – – – – – – – – – Malignat uor, unspecifed101– – – – – – – – – – – – – – 21– – – – Al types 891492314214401010067414100202099290100 Tabela 7. – Table 7. Nadljevanje – Contiued Histolš ka vrsta Skupaj Lokacija (š ifre MKB-10) Histolgic type Al sites Site (ICD-10 codes) 60 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo Vse vrste / Smal cel carcinoma 145681– – – – – – – – – – – – – – – – – – – Non– smal cel carcinoma 354– – – – – – – – – – – – – – – – – – – – Squaous cel carcinoa1291405– 1– 5– – – – – – – – – – – – – – – Basl cel carcinoma 19140– – – – – – – – – – – – – – – – – – – – Transitonal cel carcinoma 295– 25– 1– – – – – – – – – – – – – – – – – Adenocarcinoma 4582369– – – – – – – – – – – 1231– – – – 5– Other specifed carcinomas 15719– – – – – – – – – – – – 37– – – – 1– Carcinoma, unspecifed 142153– 1– – – – – – – – – – – – – 1– – – – Malignat hymoa 21– – – – – – – – – – – – – – – – – – – – alignat parganglioma/ – – – – – – – – – – – – – – – – – – – – – – pheochromocytom Malignat elanoa 3712– – – – 17– – – – – – – – – – – – – – – Fibrosarcoma 6– – – – – – – – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 121– – – – – – – – – – – – – – – – – – – – Liposarcoma 16– – – – – – – – – – – – – – – – – – – – – Leiomyosarcoma 26– 1– – – – – 1– – – – – – – – – – – 2– Rhabdoyosarcoa 4– – – – – 1– – – – – – – – – – – – – – – Synovial sarcoma 6– – – – – – – – – – – – – – – – – – – – – Angiosarcoa 4– – – – – – – – – – – – – – – – – – – – – Kaposi arcoma 1– – – – – – – – – – – – – – – – – – – – – Osteosarcoa 51– – – – – – – – – – – – – – – – – – – – Chondrosarcoma 11– – – – – – – – – – – – – – – – – – – – Ewing sarcoa/PNET 21– – – – – – – – – – – – – – – – – – – – Other specifed sarcomas 31– – – – – – – – – – – – – – – – – – – – Sarcoma, unspecifed 41– – – – – – – – – – – – – – – – – – – – Malignat complex mixed and 503– – – – – – – – – – – – – – – – – – 1– stroml turs Malignat fibroepithelial tumors 1– – – – – – – – – – – – – – – – – – – – – alignat mesothelioa 276– – – – – – – – – – – – – – – – – – – – Malignat gonadl stromal 2– – – – – – – – – – – – – – – – – – – – – tumors Dysgerminoma nd seminoma 56– – – – – – – – – – – – – – – – – – – – – Other alignat ger cel tuors 43– – – – – – – – – – – – – – – – – – – 1– Malignat rophoblastic tumors 1– – – – – – – – – – – – – – – – – – – – – alignat gliomas 102– – – – – – – – – 98– 4– – – – – – – – – Malignat neuroepithelial tumors41– – – – 1– – – 1– – – – – – – – – – – alignat menigioma 4– – – – – – – 4– – – – – – – – – – – – – Malignat nerve sheath tumors 4– – – – – – – – – – – 1– – – – – – – – – Non Hodgkin lymphoma 2135– – – – – – – – – – – – – – – – – – – – Hodgkin lymphoa 433– – – – – – – – – – – – – – – – – – – – Plasma cel tuors 5228– – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 2531– – – – – – – – – – – – – – – – – – – – Leukeia except chronic 6441– – – – – – – – – – – – – – – – – – – – lymphoid Other lymphoreticular – – – – – – – – – – – – – – – – – – – – – – neoplass Chronic myeloproliferative 631– – – – – – – – – – – – – – – – – – – – diseases Myelodysplastic syndromes 1024– – – – – – – – – – – – – – – – – – – – Other specifed malignat umors1– – – – – – – – – – – – – – – – – – – – – Malignat uor, unspecifed 101– – – – – – – – 1– – – 1– – – – – – 1 Al types 8914923271120240501005012780100101 C0– C96C67C68C69C70C71C72C73 C74C75C76 H HHHCH HCH H HHCHC Tabela 7. – Table 7. Nadljevanje – Contiued Histolš ka vrsta Skupaj Lokacija (š ifre MKB-10) Histolgic type Al sites Site (ICD-10 codes) Cancer Incidence in Slovenia 204 61 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia Vse vrste / Smal cel carcinoma 14568– – 2– – – – 2– – – – – – – – – – – – Non– smal cel carcinoma 354– – – – – – – – – – – – – – – – – – – – Squaous cel carcinoa1291401251– 3– – 2– – – – – – – – – – – – Basl cel carcinoma 19140– – – – – – – – – – – – – – – – – – – – Transitonal cel carcinoma 295– – – – – – – – – – – – – – – – – – – – – Adenocarcinoma 4582365313211511918– – – – – – – – – – – – Other specifed carcinomas 157191– 2– 2– 1– – – – – – – – – – – – – Carcinoma, unspecifed 142153152132173– – – – – – – – – – – – Malignat hymoa 21– – – – – – – – – – – – – – – – – – – – alignat parganglioma/ – – – – – – – – – – – – – – – – – – – – – – pheochromocytom Malignat elanoa 3712– – – – 2– 11– – – – – – – – – – – – Fibrosarcoma 6– – – – – – – – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 121– – – – – – – – – – – – – – – – – – – – Liposarcoma 16– – – – – – – – – – – – – – – – – – – – – Leiomyosarcoma 26– – – – – – – – – – – – – – – – – – – – – Rhabdoyosarcoa 4– – – – – – – – – – – – – – – – – – – – – Synovial sarcoma 6– – – – – – – – – – – – – – – – – – – – – Angiosarcoa 4– – – – – – – – – – – – – – – – – – – – – Kaposi arcoma 1– – – – – – – – – – – – – – – – – – – – – Osteosarcoa 51– – – – – – – – – – – – – – – – – – – – Chondrosarcoma 11– – – – – – – – – – – – – – – – – – – – Ewing sarcoa/PNET 21– – – – – – – – – – – – – – – – – – – – Other specifed sarcomas 31– – – – – – – – – – – – – – – – – – – – Sarcoma, unspecifed 41– – – – – – – – – – – – – – – – – – – – Malignat complex mixed and 503– – 1– – – – – – – – – – – – – – – – – stroml turs Malignat fibroepithelial tumors 1– – – – – – – – – – – – – – – – – – – – – alignat mesothelioa 276– – – – – – – – – – – – – – – – – – – – Malignat gonadl stromal 2– – – – – – – – – – – – – – – – – – – – – tumors Dysgerminoma nd seminoma56– – – – – – – – – – – – – – – – – – – – – Other alignat ger cel tuors 43– – – – – – – – – – – – – – – – – – – – – Malignat rophoblastic tumors 1– – – – – – – – – – – – – – – – – – – – – alignat gliomas 102– – – – – – – – – – – – – – – – – – – – – Malignat neuroepithelial tumors 41– – – – – – – – – – – – – – – – – – – – alignat menigioma 4– – – – – – – – – – – – – – – – – – – – – Malignat nerve sheath tumors 4– – – – – – – – – – – – – – – – – – – – – Non Hodgkin lymphoma 2135– – – – – – – – – – 61316201921510– – Hodgkin lymphoa 433– – – – – – – – 433– – – – – – – – – – Plasma cel tuors 5228– – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 2531– – – – – – – – – – – – – – – – – – – – Leukeia except chronic 6441– – – – – – – – – – – – – – – – – – – – lymphoid Other lymphoreticular – – – – – – – – – – – – – – – – – – – – – – neoplass Chronic myeloproliferative 631– – – – – – – – – – – – – – – – – – – – diseases Myelodysplastic syndromes 1024– – – – – – – – – – – – – – – – – – – – Other specifed malignat umors1– – – – – – – – – – – – – – – – – – – – – Malignat uor, unspecifed 101– – – 1– 1– – – – – – – – – – – – – – Al types 89149231913213524328264336131620192151000 C0– C96C7C78C79C80C81C82C83 C84C85 C8 H HH HH HHHCHHCH Tabela 7. – Table 7. Nadljevanje – Contiued Histolš ka vrsta Skupaj Lokacija (š ifre MKB-10) Histolgic type Al sites Site (ICD-10 codes) 62 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo C0– C96C90C91C92C93C94C95C96 H HH HCH HCHHC Vse vrste / Smal cel carcinoma 14568– – – – – – – – – – – – – – Non– smal cel carcinoma 354– – – – – – – – – – – – – – Squaous cel carcinoa129140– – – – – – – – – – – – – – Basl cel carcinoma 19140– – – – – – – – – – – – – – Transitonal cel carcinoma 295– – – – – – – – – – – – – – – Adenocarcinoma 458236– – – – – – – – – – – – – – Other specifed carcinomas 15719– – – – – – – – – – – – – – Carcinoma, unspecifed 142153– – – – – – – – – – – – – – Malignat hymoa 21– – – – – – – – – – – – – – alignat parganglioma/ – – – – – – – – – – – – – – – – pheochromocytom Malignat elanoa 3712– – – – – – – – – – – – – – Fibrosarcoma 6– – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 121– – – – – – – – – – – – – – Liposarcoma 16– – – – – – – – – – – – – – – Leiomyosarcoma 26– – – – – – – – – – – – – – – Rhabdoyosarcoa 4– – – – – – – – – – – – – – – Synovial sarcoma 6– – – – – – – – – – – – – – – Angiosarcoa 4– – – – – – – – – – – – – – – Kaposi arcoma 1– – – – – – – – – – – – – – – Osteosarcoa 51– – – – – – – – – – – – – – Chondrosarcoma 11– – – – – – – – – – – – – – Ewing sarcoa/PNET 21– – – – – – – – – – – – – – Other specifed sarcomas 31– – – – – – – – – – – – – – Sarcoma, unspecifed 41– – – – – – – – – – – – – – Malignat complex mixed and 503– – – – – – – – – – – – – – stroml turs Malignat fibroepithelial tumors 1– – – – – – – – – – – – – – – alignat mesothelioa 276– – – – – – – – – – – – – – Malignat gonadl stromal 2– – – – – – – – – – – – – – – tumors Dysgerminoma nd seminoma56– – – – – – – – – – – – – – – Other alignat ger cel tuors43– – – – – – – – – – – – – – – Malignat rophoblastic tumors 1– – – – – – – – – – – – – – – alignat gliomas 102– – – – – – – – – – – – – – – Malignat neuroepithelial tumors41– – – – – – – – – – – – – – alignat menigioma 4– – – – – – – – – – – – – – – Malignat nerve sheath tumors 4– – – – – – – – – – – – – – – Non Hodgkin lymphoma 2135– – – – – – – – – – – – – – Hodgkin lymphoa 433– – – – – – – – – – – – – – Plasma cel tuors 52285228– – – – – – – – – – – – Chronic lymphoid leukemia 2531– – 2531– – – – – – – – – – Leukeia except chronic 6441– – 2343626451– – 6– – lymphoid Other lymphoreticular – – – – – – – – – – – – – – – – neoplass Chronic myeloproliferative 631– – – – – – – – – – – – 631 diseases Myelodysplastic syndromes 1024– – – – – – – – – – – – 1024 Other specifed malignat umors1– – – – – – – – – – – – – – – Malignat uor, unspecifed101– – – – – – – – – – – – – – Al types 8914923522848353626451006165 Tabela 8. Š tevilo primerov ne-Hodgkinovih limfoov* po lkacij, spolu in starosti - Slovenija 204 Table 8. Total number of non-Hodgkin’ s malignant lymphomas* by site, by sex and by age - Slovenia 204 *Vključ eni so samo citolš ko in histolš ko potrjeni primeri Al cases include have ben verified citolgicaly and histolgicaly Cancer Incidence in Slovenia 204 63 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia Š ifra Vse Starosti MKB–8Lokacija Spol starosti Age ICD–8Site Sex Al code ages0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 5– 60– 65– 70– 75– 80+ M+Ž Vse lokacije M Al sites Ž 142 145 146 150 15 152 153 154 160 162 163 170 17 173 174 189 190 19 192 193 20 246 14 132 1 3 0 1 4 4 0 1 12 23 4 1 2 1 0 1 1 2 1 5 0 1 1 0 0 1 1 7 0 1 2 0 1 0 2 6 0 1 0 3 82 70 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 Slinavke Slivry glands Usta, drugo Mouth, other parts Orofarinks rophrynx Pož iralnik Oesophagus Ž elodec Stmach Tanko č revo Sml intestine Debelo č revo Coln Rektum ct Nos, obnosne votline, drugo se, siuss, tc. Plevra, mediastinum, drugo Pleura, ediastinu, etc. Sapnik, sapnica, pljuč a Trche, brohus, lng Kosti Bne Mehka tkiva Soft isues Kož a, drugi malignomi Skin, other linancies Dojka Brest Ledvica, seč vod, rugo Kiney, urtr, etc. Oko Eye Mož gani Brain Ž ivč evje, drugo Nrvous ystem, ther Š č itnica Thyroid Bezgavke Lymph nodes M Ž 6 5 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 3 0 4 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 7 4 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 4 1 1 7 4 0 0 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 4 3 1 6 5 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 3 3 16 8 8 0 0 0 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 6 5 15 6 9 0 1 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 7 2 1 1 0 1 0 1 0 0 0 0 1 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 10 4 29 1 18 0 0 0 0 1 0 0 0 1 1 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 0 2 5 12 25 13 12 0 0 0 0 1 1 0 0 2 0 1 0 0 0 0 0 0 0 1 3 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 3 0 0 0 0 6 5 M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž M Ž 29 10 19 1 1 0 0 2 0 0 0 0 6 0 0 0 0 0 0 0 2 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 7 36 15 21 13 13 0 0 0 0 0 0 0 1 1 2 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 1 0 1 0 0 29 1 18 0 0 0 0 0 2 0 0 1 5 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 10 8 Tabela 9.Š tevilo novih primerov rak po bolniš nicah ugotvite diagnoze tr š tevilo in odstotek* primerov, napotenih na Onkolš ki inš tiut Ljubljan (OI) - Slovenija 204 Table 9. Number of new cancer cases diagnosed by reporting hospitals, and number and percentage* of cases refred to the Instiute of Oncolgy Ljuljan (IO) - Sloveni 204 Bolniš nice Š tevilo novih Napoteni a OI primerov Š tevilo %* Hospitals Number of new Refred to the IO cases Number %* Onkolš ki inš tiut Ljubljan Instiute of Oncolgy Ljuljna Klinič ni center Ljubljan Medical center Ljuljn SPS Interna klinika Klinič ni odelk za gastroenterolgijo Drugi klinič ni odelki SPS Kirurš ka klinika Klinič ni odelk za bdominalno kirurgijo Klinič ni odelk za nevrokirurgijo Klinič ni odelk za maksilofacialno in oralno kirurgijo Klinič ni odelk za plastič no kirurgijo in opekline Klinič ni odelk za toraklno kirurgijo Klinič ni odelk za urolgijo Drugi klinič ni odelki SPS Ginekolš ka klinika SPS Nevrolš ka klinika SPS Pediatrič na klinika Dermatovenrolš ka klinika Klinika za infekcijske bolezni in vroč inska stanja Klinika za otrinolaringolgijo in cervikofacialno kirurgijo Oč esna klinika Ortopedska klinika Drugi klinič ni odelki 71 348 369 1984 41 9 6 6 18 563 58 189 39 39 30 27 29 52 12 32 10487 654 350 283 132 15 619 18 6 47 82 68 148 27 10 25 29 16 18 190 13 1 31 490 654 1345 39,5 37,9 40,9 31,2 43,7 6,7 71,2 12,3 57,6 26,3 46, 58,2 64,1 74, 53, 6,7 83,0 25,0 91,7 96,9 47,1 40,1 10,0 Skupaj Totl 64 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo Tabela 9. – Table 9. Nadljevanje – Contiued *Odstotki niso rač unani pri š tevilh pod 15 Percentages are not calculated for les than 15 cases Sploš na bolniš nica Jesnice Sploš na bolniš nica Izola Sploš na bolniš nica Maribor Sploš na bolniš nica Murska Sobota Sploš na bolniš nica dr. Franc Derganc Nova Gorica Sploš na bolniš nica Nov mesto Sploš na bolniš nica dr. Jož eta Potrč a Ptuj Sploš na bolniš nica Slovenj Gradec Sploš na bolniš nica Trbovlje Bolniš nica za ginekolgijo in pordniš tvo Kranj Bolniš nica Topolš ica Bolniš nica za ginekolgijo in pordniš tvo Postojna Bolnica Sež an Ortopedska bolnica Valdoltra Psihiatrič na klinika Ljubljan Psihiatrič na bolniš nica Begunje Psihiatrič na bolniš nica Idrija Zasebne ordinacije Privte clinics Drugi zdravstveni zavodi Other health instiutions Bolniš nica Golnik Cancer Incidence in Slovenia 204 65 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia Sploš ne in specialistič ne bolniš nice Genral nd special hospitals Sploš na bolniš nica Brež ice Sploš na bolniš nica Celj 45, 4,5 40,1 3,9 41, 52,0 43,5 34,1 52,9 5,6 74,6 52,0 7,4 - - - - 35,4 75,3 6,5 4,2 45,1 45,3 257 310 15 487 365 506 85 375 68 27 126 25 31 1 0 0 0 653 27 51 13 801 5603 17 138 607 165 150 263 37 128 36 15 94 13 24 1 0 0 0 231 17 340 50 361 2539 Bolniš nice Š tevilo novih Napoteni a OI primerov Š tevilo %* Hospitals Number of new Refred to the IO cases Number %* Tabela 10.Š tevilo in odstotek* novih primerov rak (brez registrianih samo iz dravniš kih porč il o vzroku smrti) po stadiju, lokacij in spolu - Slovenija 204 Table 10. Number and percentage* of new cancer cases (without cases registerd from death certificates only) by stage, by site and by sex - Sloveni 204 Stadij Š ifraPrimarna Spol Š teviloLokaliziran Reg.razš iritevOd. razš iritevNeznan MKB lokacija primerovŠ tevilo %*Š tevilo %* Š tevilo %* Š tevilo %* Stage ICDPrimary SexNumber Localized Reional Distant Unkown code site of casesNumber %* Number %* Number %t* Number %* Tongue, other & unspecified parts Mouth, other & unspecified parts Druge in eopredeljne velike ž lez slinavke Othr & unspecifid major salivary glands Druga in slabo predeljna mest n ustnici, v ustni votlini in farinksu Other and il-defied sites in the lip, oral cvity an pharynx C0Vse lokacije- Al sites96 Ustnica Lip Baz jezika s of tongue Jezik, drugi dli Dlesn Gum Ustno dno Flor f muth Nebo Palte Usta, drugi dli Parotidna ž leza Prti glnd Tonzila Tsil Orofarinks rphrynx Nazofarinks sphrynx Piriformni sinus yrifr si s Hipofarinks yphrynx Pož iralnik Oesophagus Ž elodec Stmah Tanko č revo Sml intstine C15 C16 C17 C14 C12 C09 C10 C13 C08 C05 C06 C1 C0 C03 C04 C01 C02 C07 Rektosigmoidna zveza Rectosi oi junction Debelo č revo ColnC18 C19 6 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo M+Ž 10487475645,430128,72352,239 3,7 53927 42, 15829,4129824,1294,2 Ž 5094247948,7142 27,9102720,21643,2 M26 238,5 13,8 0 0, 27, Ž 1 10 – 1 – 0 – 0 – M15 2 13, 1386,7 0 0, 00, Ž 4 0 – 4 – 0 – 0 – M14 7 – 5 – 2 – 0 – Ž 5 2 – 2 – 0 – 1 – M10 0 – 10 – 0 – 0 – Ž 2 0 – 1 – 1 – 0 – M31 1 35, 2064,5 0 0, 00, Ž 5 2 – 3 – 0 – 0 – M13 5 – 8 – 0 – 0 – Ž 3 2 – 1 – 0 – 0 – M16 743,8 850, 1 6,3 00, Ž 6 3 – 3 – 0 – 0 – M4 0 – 4 – 0 – 0 – Ž 5 2 – 2 – 1 – 0 – M0 0 – 0 – 0 – 0 – Ž 3 1 – 1 – 1 – 0 – M40 820, 317,5 0 0, 12,5 Ž 7 1 – 6 – 0 – 0 – M36 5 13,9 3083, 1 2,8 00, Ž 4 0 – 4 – 0 – 0 – M5 0 – 4 – 1 – 0 – Ž 3 1 – 2 – 0 – 0 – M38 2 5,3 3592,1 1 2,6 00, Ž 6 0 – 6 – 0 – 0 – M26 6 23,1 1869,2 1 3,8 13,8 Ž 0 0 – 0 – 0 – 0 – M0 0 – 0 – 0 – 0 – Ž 0 0 – 0 – 0 – 0 – M68 12 17,6 2435,3 2638,2 68, Ž 9 2 – 3 – 3 – 1 – M290 57 19,71640, 9 34,1 186,2 Ž 17 37 21,6 6839,8 5129,8 158, M13 2 – 6 – 4 – 1 – Ž 7 2 – 3 – 1 – 1 – M36 41 1,22160,4 9526,0 92,5 Ž 36 4 13,12059,5 752,3 175,1 M59 7 1,9 3457,6 1525,4 35,1 Ž 58 10 17,2 3560,3 132,4 00, Tabela 10. – Table 10. Nadljevanje – Contiued Stadij Š ifraPrimarna Spol Š teviloLokaliziran Reg.razš iritevOd. razš iritevNeznan MKB lokacija primerov Stage ICDPrimary SexNumber Localized Reional Remote Unkown code site of cases Rektum Ž olč nik Galblader Trebuš na slinavka Pancreas Obnosni sinusi Acesory sinuses C25 C26 C24 C31 C30 C23 Sapnik Trchea Sapnica in pljuč a Bronchus and lung Timus C3 C34 C37 Grlo LarynxC32 Anus in anlni kanl nus nd nal cnal Jetra in itrahepatič ni vodi Liver nd intrhetic bile ucts Drugi in eopredeljni deli bilarnega trakta Biliary tract, other and unspecified parts Druga in slabo predeljna mest v prevnih organih Other and il-defined digstive organs Nosna votlina in srednje uho asl cavity and midle ar C21 C2 RectuC20 Thyus Srce, mediastinum, plevra Heart, eistinu, leur Druga in slabo predeljna mesta v dihlih in prsnih organih Other and il-defined sites in the rspi- ratory system an intrathoraci organs Kosti, sklepni hrustanec udov Bone and articulr crtilage of limbs Kosti, sklepni hrustanec, drugje Bone and articular cartilage of thr n unspecified prts C38 C40 C41 C39 Mezoteliom esothelioa Kaposijev sarkom Kposi' srcoa C45 C46 Maligni melanom kož e linant elnoa of skin Druge maligne neoplazme kož e Skin, other alignomas C43 C4 Cancer Incidence in Slovenia 204 67 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia Number %* Number %* Nuber %t* Number %* M286 4 15,418062,9 5719, 51,7 Ž 175 4324,61057, 2514,3 63,4 M1 0 – 1 – 0 – 0 – Ž 14 9 – 4 – 0 – 1 – M84 32 38,1 1619,0 2327,4 1315, Ž 38 6 15,8 718,4 174,7 821, M12 1 – 5 – 5 – 1 – Ž 45 7 15,6 817,8 255,6 51,1 M35 4 1,4 1234,3 1234,3 720, Ž 32 7 21,9 134, 618, 825,0 M13 4 3,5 4539,8 5750,4 76,2 Ž 138 9 6,5 5338,4 614,2 1510,9 M1 0 – 0 – 0 – 1 – Ž 2 0 – 0 – 1 – 1 – M3 1 – 1 – 0 – 1 – Ž 5 0 – 5 – 0 – 0 – M9 1 – 8 – 0 – 0 – Ž 7 0 – 6 – 1 – 0 – M9 5454,5 4545, 0 0, 00, Ž 15 640, 960, 0 0, 00, M6 1 – 3 – 2 – 0 – Ž 3 0 – 2 – 1 – 0 – M894146 16,331234,93964,3 394, Ž 287 4 15,310536, 1284,6 103,5 M1 0 – 1 – 0 – 0 – Ž 2 1 – 0 – 1 – 0 – M5 0 – 3 – 1 – 1 – Ž 1 0 – 0 – 0 – 1 – M0 0 – 0 – 0 – 0 – Ž 0 0 – 0 – 0 – 0 – M9 4 – 3 – 1 – 1 – Ž 5 1 – 2 – 1 – 1 – M3 1 – 1 – 1 – 0 – Ž 5 2 – 2 – 0 – 1 – M167128 76, 2917,4 3 1,8 74,2 Ž 18014379,4 2513,9 7 3,9 52,8 M73171898,2 9 1,2 3 0,4 10,1 Ž 85 82997,0 192, 0 0, 50,6 M2 940,9 940,9 313,6 14,5 Ž 1 6 – 4 – 1 – 0 – M1 1 – 0 – 0 – 0 – Ž 0 0 – 0 – 0 – 0 – Š tevilo %*Š tevilo %* Š tevilo %* Š tevilo %* Tabela 10. – Table 10. Nadljevanje – Contiued Stadij Š ifraPrimarna Spol Š teviloLokaliziran Reg.razš iritevOd. razš iritevNeznan MKB lokacija primerov Stage ICDPrimary SexNumber Localized Regional Remote Unkown code site of cases Vulva Nož nica Vagin Maternič ni vrat Crvix uteri Maternič no telo Corpus uteri Maternica, neopredeljno Uterus, unspecifie Jajč nik Ovry Posteljica Placnt Penis Pis Prostat Prstte Modo Testis C52 C53 C54 C5 C56 Drugi in eopredeljni ž enski spolni organi Other and uspecified parts of feml genital organs C57 C58 C60 C61 C62 Periferni ž ivci in avtonmno ž ivč evje Pripheral erves ad autonmic nrvous ystem Peritonej in retroperitonej Rtrpritoum and pritoneum Drugo vezivno in ehko tkivo Other cnective and sft isue Dojka Brest Ž ensko zunanje spolvilo C47 C48 C49 C50 C51 Drugi in eopredeljni seč niorgani Other ad unscifid uriary r s Oko in oč esni adneksi C68 C69 Uretr Seč ni mehur C6 C67Bladr Drugi in eopredeljni moš ki spolni organi Other and unspecified male gnitl organs Ledvica rzen meha Kiney, excpt rnl pelvis Ledvič ni meh Rnal pelvis Sč vod C63 C64 C65 Eye and adnex Menige i s Mož gani Brain C70 C71 68 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo Number %* Number %* Number %t* Number %* M1 0 – 1 – 0 – 0 – Ž 3 0 – 3 – 0 – 0 – M12 2 – 3 – 3 – 4 – Ž 16 0 0, 1062,5 637,5 00, M21 73,3 152,4 2 9,5 14,8 Ž 2 1045, 1045, 1 4,5 14,5 M5 2 – 2 – 1 – 0 – Ž 107554550,743140,1 92 8,6 70,7 M– – – – – – – – – Ž 5 3156,4 240, 1 1,8 11,8 M– – – – – – – – – Ž 5 4 – 1 – 0 – 0 – M– – – – – – – – – Ž 1951 56,9 7538,5 8 4,1 10,5 M– – – – – – – – – Ž 28521 74, 4616,1 23 8,1 41,4 M– – – – – – – – – Ž 6 2 – 0 – 4 – 0 – M– – – – – – – – – Ž 167 2 13,2 84,813279,0 53,0 M – – – – – – – – – Ž 4 0 – 0 – 3 – 1 – M– – – – – – – – – Ž 1 0 – 0 – 1 – 0 – M10 6 – 3 – 1 – 0 – Ž – – – – – – – – – M73148265,912817,5 67 9,2 547,4 Ž – – – – – – – – – M10 4848,0 44,0 7 7,0 11,0 Ž – – – – – – – – – M2 1 – 1 – 0 – 0 – Ž – – – – – – – – – M153 9058, 2617,0 3019,6 74,6 Ž 102 6159,8 2019,6 1514,7 65,9 M15 746,7 853, 0 0, 00, Ž 14 4 – 8 – 2 – 0 – M8 6 – 2 – 0 – 0 – Ž 2 2 – 0 – 0 – 0 – M20915373,2 3918,7 12 5,7 52,4 Ž 72 5779,2 912,5 5 6,9 11,4 M1 1 – 0 – 0 – 0 – Ž 1 0 – 1 – 0 – 0 – M14 10 – 4 – 0 – 0 – Ž 13 10 – 3 – 0 – 0 – M2 2 – 0 – 0 – 0 – Ž 3 3 – 0 – 0 – 0 – M72 7198,6 00, 1 1,4 00, Ž 58 5798,3 1 1,7 0 0, 00, Š tevilo %*Š tevilo %* Š tevilo %* Š tevilo %* Tabela 10. – Table 10. Nadljevanje – Contiued Stadij Š ifraPrimarna Spol Š teviloLokaliziran Reg.razš iritevOd. razš iritevNeznan MKB lokacija primerov Stage ICDPrimary SexNumber Localized Regional Remote Unkown code site of cases Stadij (An– Arbor) Š ifraPrimarna Spol Š tevilo I I I + IV Neznan MKB lokacija primerov Stage ICDPrimary SexNumber I I I + IV Unkown code site of casesNumber %* Number %* Number %* Number %* *Odstotki niso rač unani pri š tevilh pod 15 Percentages are not calculated for les than 15 cases Hodgkinova bolezn 26 31,5 830,8 15 ki's diseas 20 210, 1260, 5 Ne-Hodgkinov limfom 14 2320,2 2521,9 56 on-okin's lyphoa 132 3929,5 2619,7 51 C81 C82- 85 57, 25,0 49,1 38,6 10 16 0 0, 15,0 8, 12,1 Hrbtni mozeg, mož ganski ž ivci in drugi deli CŽ S Spial cor, cranial nerves and other prts of CNS Š č itnica Thyroid glnd Nadledvič na ž leza Arnal gl d Druge ndokrine ž lez in sorne strukture Other docrine glands and rlate structures Druga in slabo predeljna mesta Other d il-defin sits Metastaz in eopredeljna mlign neoplazma bezgvk Metastsi and unspecifid mlignant eoplasm of lymph nodes Metastaze dihal in prebavil tstss of resiratory and igestiv rgns Metastaze, drugje tstss of thr sites Maligna neoplazma brez opredeljneg est Malignat oplasm without specifiction f site C72 C73 C74 C75 C76 C7 C78 C79 C80 Cancer Incidence in Slovenia 204 69 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia Number %* Number %* Number %t* Number %* M2 2 – 0 – 0 – 0 – Ž 3 3 – 0 – 0 – 0 – M29 1448,3 137,9 413,8 00, Ž 106 72 67,9 2624,5 8 7,5 00, M4 2 – 0 – 1 – 1 – Ž 0 0 – 0 – 0 – 0 – M0 0 – 0 – 0 – 0 – Ž 0 0 – 0 – 0 – 0 – M5 1 – 1 – 3 – 0 – Ž 10 0 – 2 – 5 – 3 – M20 0 0, 00, 1 5,0 1995,0 Ž 15 0 0, 00, 0 0, 1510,0 M54 0 0, 00, 5410,0 00, Ž 50 0 0, 00, 5010,0 00, M21 0 0, 00, 2110,0 00, Ž 19 0 0, 00, 1910,0 00, M49 0 0, 00, 4910,0 00, Ž 23 0 0, 00, 2310,0 00, Š tevilo %*Š tevilo %* Š tevilo %* Š tevilo %* Š tevilo %* Š tevilo %* Š tevilo %* Š tevilo %* M Ž M Ž 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 5– 60– 65– 70– 75– 80+ Tabela 1. Š tevilo umrlih za rkom po lkacij, spolu in starosti - Slovenija 204* Table 1. Number of cancer deaths by site, sex and age - Slovenia 204*by by Š ifraPrimarna Vse Starosti Age Vse lokacije Al sites Base of tongue Jezik, drugi deli Tongue, othr & unspcified parts Flor of mouth Usta, drugi deli Mouth, othr & unspecified parts Parotidna ž leza Druge in eopredeljne velik ž lz slinavk Othr & unspecified major salivary glads Piriformni sinus Druga in slabo predeljna mest ustnici, v ustni votlini in farinks Other ad il-defined sites in t lip, orl cavity an pharynx Smal intestine Debelo č revo Rektosigmoidna zveza ctsi i juction C0Ustnica Lip C01z jzika C02 C03DlesnGum Ustn dnC04 NeboC05Palte C06 C07rti glnd C08 TonzilaC09Tsil OrofarinksC10rphrynx NazofarinksC1sphrynx C12yrifr si s C13Hipofarinksyphrynx C14 C15Pož iralnikOesophagus C16Ž elodecStmah C17Tnko č rvo C18Coln C19 RektumC20ct Anus in anlni kanl s d al calC21 70 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo MKBlokcij starosti ICDPrimary Al codesite ages Spol Sex – C0 C97 Ž 100000000000000010 M200000000001001000 Ž 000000000000000000 M600000000003111000 Ž 000000000000000000 M100000000010000000 Ž 000000000000000000 M400000000010021000 Ž 200000000000100001 M100000000000100000 Ž 000000000000000000 M100000001000223021 Ž 200000000000100010 M300000000110010000 Ž 000000000000000000 M000000000000000000 Ž 100000000000010000 M000000000000000000 Ž 000000000000000000 M3500000000237783401 Ž 400000000000001120 M200000000001000100 Ž 200000000000000002 M000000000000000000 Ž 000000000000000000 M2100000010115324310 Ž 500000000001110011 M400000000002011000 Ž 200000000002000000 M83000000103813411512106 Ž 1400000000001204124 M231000002116107152549423835 Ž 135000000011559519192447 M500000000100002101 Ž 200000000000000011 M190000000012581272639383 Ž 149000000030110591227275 M41000000000022491086 Ž 400000000010202110915 M14300000000348121229311727 Ž 1060000000105417717232 M100000000000000100 Ž 100000000000000001 M200000000000000110 M+Ž M Ž 507572126142140801893573565086818948341083 282420259119481020123134432540431452 2533010151021328156125174249354403631 ICDPrimary Al codesite ages Sex 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 5– 60– 65– 70– 75– 80+ Tabela 1. – Table 1. Nadljevanje – Contiued Š ifraPrimarna Vse Starosti Age C25Pancreas C26 C30 C31 C32GrloLarynx C3SapnikTrchea C34Sapnica in pljuč aBrohus d lng C37TimusThys C38 Srce, mediastinum, plevra Hart, isti , lur C39 Druga in slabo predljena mest v dihlih in rsnih orgnih Othr an il-defied sites in the respirtory systm an intrathraci orgns C40Kosti, sklepni hrustanec udovBne and articlr crtilage of limbs C41 Ksti, sklepni hrustanec, drugje Bone and articlr crtilae f thr n unspecified prts C43 Maligni melanom kož e li ant elna of skin C4Druge maligne neoplazme kož eSkin, other maligs C45Mezoteliosthlima C46Kaposijev sarkomsi' srca C47 Periferni ž ivci in avtonmno ž ivč vj Trebuš n slinavka Druga in slabo predeljna mest v prevnih organih Othr and il-defied digestive organs Nosna votlina in srednje uho asl city d mi l ar Obnosni sinusi Acesory si ses Peripheral nd authonmic nrvous ystem Peritonej in retroperitonejC48Retroperitoneum and peritoneum Drugo vezivno in ehko tkivoC49Other conective and soft isue DojkaC50Brest Ž ensko zunanje spolviloC51Vulva Ž olč nikC23Galblader C24 Drugi in eopredeljni deli bilarnega trakta Biliry trct, other nd unspecified parts Jetra in itrahepatič ni vodiC2Livr d intr tic bile ducts Cancer Incidence in Slovenia 204 71 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia M900000000100127171512188 Ž 501000000002433391312 M100000000000111503 Ž 34000000000110323131 M2400000000001108239 Ž 2500000000010231666 M1600000000461015119211614 Ž 127000000002215715232547 M100000000001100126 Ž 1400000001000001318 M100000000100000000 Ž 000000000000000000 M200000000000001100 Ž 200000000000000101 M620000000231581271473 Ž 900000000000131121 M400000000001001200 Ž 000000000000000000 M7920000002410347282981218410678 Ž 2490000000211251922837495 M100000000000001000 Ž 100000000000001000 M1200000110101202112 Ž 400000000001000012 M000000000000000000 Ž 000000000000000000 M100000000000001000 Ž 400000000001100011 M600001000001101011 Ž 600000010001000103 M4900011112466383472 Ž 47001002002321536913 M900000010000021005 Ž 1200000000000000048 M1600000000025241011 Ž 1300000010000331140 M000000000000000000 Ž 000000000000000000 M000000000000000000 Ž 000000000000000000 M500000100001102000 Ž 500000000100002110 M910010000000020032 Ž 100000001012010312 M100000000000000010 Ž 37500000024827432347574785 M– – – – – – – – – – – – – – – – – – Ž 1800000000000212229 MKBlokcij starostiSpol Age Š ifraPrimarna Starosti MKBlokcij ICDPrimary codesite Vse starosti Al ages Spol Sex 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 5– 60– 65– 70– 75– 80+ Tabela 1. – Table 1. Nadljevanje – Contiued Drugi in eopredeljni ž enski spolni organiC57Other and uspecified parts of mle genital organs C58Psteljicalacnt C60 Penis is C61Prostatrstte C62 Modo Testis C63 Drugi n eopredljeni moš ki spolni organi Other and uspecified male gnitl organs Ledvica rzen mehaC64Kiney, excpt rnl pelvis Ledvič ni mehC65Rnal pelvis Seč vodC6Urter Seč ni mehurC67Bladr Drugi n eopredljeni seč ni oraniC68Other nd unspecified urinary organs Oko in oč esni adneksiC69Eye ad adex MenigeC70i s Druge ndokrine ž lez in sordne struktureC75Other ndocrine glands and relatd structurs Druga in slabo predljena mestC76 Othr and il-defined sites Mož ganiC71Brain C72 Hrbtni mozeg, mož ganski ž ivci in drui deli CŽ S Spinal cor, cranial nerves and other prts of CNS Š č itnicaC73 Thyroid glnd Nadledvič na ž lezaC74Arnal gl d C53Cervix uteri Maternič no telo C54Corpus uteri Maternica, neopredeljno C5Uterus, unspecifie Nož nica C52Vagin Matrnič ni vrat Jajč nikC56Ovry 72 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo M– – – – – – – – – – – – – – – – – – Ž 300000000000100002 M– – – – – – – – – – – – – – – – – – Ž 4800000012559057356 M– – – – – – – – – – – – – – – – – – Ž 570000000023221358814 M– – – – – – – – – – – – – – – – – – Ž 40000001022032841210 M– – – – – – – – – – – – – – – – – – Ž 1360000101136913241622020 M– – – – – – – – – – – – – – – – – – Ž 1000000000000021124 M– – – – – – – – – – – – – – – – – – Ž 000000000000000000 M500000001000111100 Ž – – – – – – – – – – – – – – – – – – M2680000000002192028486991 Ž – – – – – – – – – – – – – – – – – – M900001212010001100 Ž – – – – – – – – – – – – – – – – – – M100000000000000100 Ž – – – – – – – – – – – – – – – – – – M65000010100232127171010 Ž 50000000000343257917 M200000000020000000 Ž 100000000000000010 M200000000010010000 Ž 000000000000000000 M96000000000146516151930 Ž 30000000000110245512 M100000000010000000 Ž 000000000000000000 M000000000000000000 Ž 100000000000000001 M200000000000000200 Ž 900000000001021113 M4701000100135877734 Ž 610000011213106391582 M300000000001100100 Ž 200000000000011000 M500000000000010400 Ž 1300000000000102145 M610000000001111010 Ž 300000000001011000 M200000100001000000 Ž 200000000000000011 M500000000000110102 Ž 29000000001110301220 Tabela 1. – Table 1. Nadljevanje – Contiued Age C84 Limfomi celic T in kož ni lif celic T Periphral nd cutaneous T-cl lymphomas C85 Druge in eopredeljne vrste ne-Hodgkinvega limfoma Other and unspecified types of non-Hogkin's lymphoma C8 Maligne imunoproliferativne bolezni Malignant imunoprolife rtive diseases C90 Difuzni plazmocitom in maligne neplaze plzmocitov Multiple myeloma nd malignant plas cel neoplsms C91Limfatič na levkemijaLyphoid lukai C92Mieloič na levkemijaylid lukai C81 Hodgkinova bolezn ki's diseas C82 Folikularni e-Hodgkinov limfm Folicular non-Hodgkin's lymphom C83 Difuzni e-Hodgkinov limfom Difuse non-Hodgkin's lypha Leukaemia, unspecified cl typ C93Moncitna levkemijaytic luai C94 Druge opredeljne levkemije Othr lukaemias of specified cls C95 Levkemija z neopredeljnim clič ni tipom Metastaz in eopredeljna mlign neoplazma bezgavkC7 Mtstsi nd unspecified malignant neoplsm of lymph nodes Metastaze dihal in prebavil C78tstss of resiratory nd digestive rgans Metastaze, drugjeC79tstss of thr sites Maligna neoplazma brez opredeljneg est C80Malignant eoplasm without specifiction f site Cancer Incidence in Slovenia 204 73 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia M100000000000000001 Ž 100000000000000100 M2800000000100323667 Ž 2400000000001113567 M1400000000003123032 Ž 900000000001000314 M4300000000131548579 Ž 50000000011432186131 M400000000000021001 Ž 300000010000000101 M200000000010000001 Ž 000000000000000000 M800000000000020042 Ž 100000001000003313 M200000001000000010 Ž 200000000000000200 M39110000002003368312 Ž 3000000010031046810 M000000000000000000 Ž 100000000000000100 M2900000000011433755 Ž 43000000000002289715 M3100000000102145738 Ž 26100000100000042513 M2910001011001174462 Ž 2310000200001002467 M500000000001012100 Ž 300000000000001101 M000000000000000000 Ž 000000000000000000 M400000001000101010 Ž 100000000101000027 Š ifraPrimarna Vse Starosti MKBlokcij starosti ICDPrimary Al codesite ages Spol Sex 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 5– 60– 65– 70– 75– 80+ MKBlokacija ICDPrimary codesite Spol Sex 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 5– 60– 65– 70– 75– 80+ D3 CŽ S, benigna neoplazma Benig oplsm f brin nd othr parts f CNS D43 CŽ S, neopredeljno NS, ucrtain or uknown Maligne neoplazme na več neodvisnih (ri rnih) mestih C97Maligat neoplass of independant (rimry) multil sites D32 Menige, benigna neopalzma Bi noplasm of mniges C96 Druge in eopredljen maline nelazme liftič nega, krvotvornega in sordne tkiva Other & uspecified malignant noplasms of lymphoid, haeopetic & relate tisues Tabela 1. – Table 1. Nadljevanje – Contiued Š ifraPrimrn Starosti Age *Vir: Inš tiut za varovanje zdravja Source: Instiute f Public Hlth 74 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo M100000000000000010 Ž 200000000000001100 M50000000100314512821 Ž 400000000001211412712 M000000000000000000 Ž 100000000000000010 M000000000000000000 Ž 200000000010001000 M900000000000002331 Ž 600000100000100121 Zgoraj neupoš tevani Nt icld above Vse starosti Al ages Tabela 12.Š tevilo vseh ž ivih bolnikov z rakom po spolu in izbrani primarni lokaciji - Slovenija, 31. 2. 04 Table 12. Prevalence of cancer patients by sex and by selcted primary site - Slovenia, Decmber 31, 204 Š ifraPrimarna MKBlokcij Skupaj Moš ki Ž enske ICDPrimary ales FemalesTotal codesite C0 – Vse lokacije Skupaj C96Al sites Total Usta in ž relo Mouth and pharynx Pož iralnik Oesophagus Ž elodec Stmah Debelo č revo Coln Rektum in rektosigmoidna zveza Rectu and rectosi oi junction Jetra in itrahepatič ni vodi Liver and intrahepatic bile ducts Ž olč nik in ž olč evodi Galblader and biliary tract Trebuš na slinavka Pancres Grlo Larynx Sapnik, sapnici in pljuč a Trche, brohus and lung Maligni melanom kož e linant elnoa of skin Druge maligne neoplazme kož e Skin, other malignoms Vezivno in ehko tkivo Conectiv and sft isue Dojka Brest Maternič ni vrat Crvix uteri Maternič no telo Corpus uteri Jajč nik Ovry Prostat rstte Modo Testis Ledvica z ledvič nim ehom Kiney with ral pelvis Seč ni mehur Bladr Centralni in avtonmni ž ivč ni sitem trl d utoic nervous yste C64 -65 C67 C70 -72 C54 C56 C61 C62 C4 C48 -49 C50 C53 C25 C32 C3 -34 C43 C19 -20 C2 C23 -24 C0 -14 C15 C18 C16 Š č itnica Thyroid glnd C73 Hodgkinova bolezn C81 kin's diseas C82 -85 ne-Hodgkinovi limfomi non- kin's lypha Difuzni plazmocitom in maligne neoplazme plazmocitov Multile yel a nd linant ls cl neplasms C90 LevkemijeC91 -95 2695 102 165 156 320 129 1732 6032 172 896 1863 253 1253 52 98 349 362 1263 2936 1367 1430 146 513 14 768 152 261 98 Leukaeias 857 290 1367 809 - 2936 258 6 107 5629 801 14 82 91 1471 71 85 2398 130 103 1597 241 409 751 19 520 - - 289 23 621 1263 349 362 294 9832 1526 6904 95 49 83 81 124 31 1603 3685 42 26 671 873 359 761 142 469 - - Cancer Incidence in Slovenia 204 75 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia l IZBOR PUBLIKACIJ, ki so jih sodelavci Epidemiolgije in Registra rk objavil v zanjih petih ltih (tudi v sodelvnju z drugimi raziskovalci) SELCTION OF PUBLICATIONS, published by the mebers of Epidemiolgy and Cancer Registry in the last five years (also in coperation with other resarchers) 76 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo 202 -Capocaccia R, Colonna M, Corazziari I et al. and the EUROPREVAL Working Group. Measuring cancer prevalence in Europe: the EUROPREVAL project. Ann Oncol 2002; 13(6): 831–9. -Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002; 360(9328): 187–95. -Debeljak A, Triller N, Pompe Kirn V et al. Strokovna izhodišèa za internistièno obravnavo bolnika s pljuènim rakom. Zdrav Vestn 2002; 71(6): 385–90. -Eæimoviæ P, Pompe Kirn V. Second primary cancers in laryngeal cancer patients in Slovenia, 1961-1996. Eur J Cancer 2002; 38(9): 1254–60. -Lambert R, Guilloux A, Pompe Kirn V et al. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer 2002; 97(6): 811–8. -Micheli A, Mugno E, Krogh V et al. and the EUROPREVAL Working Group. Cancer prevalence in European registry areas. Ann Oncol 2002; 13(6): 840–65. -Pompe Kirn V. Epidemiological features of laryngeal cancer in Slovenia. Zdrav Vestn 2002; 71: Suppl 3: 59–63. -Pompe Kirn V: Rak v Sloveniji - število in preživetje bolnikov. In: Frankiè D ed. Prepoznavanje in zdravljenje raka. Strokovno izpopolnjevanje magistrov farmacije v letu 2002, Ljubljana 2002. Ljubljana: Lekarniška zbornica Slovenije, 2002: 5–8. -Pompe Kirn V. Preživetje bolnikov z rakom v Sloveniji - novosti iz Registra raka za Slovenijo za obdobje 1988-1997. Onkologija 2002; 6(1): 28–31. -Primic Žakelj M. Rak danes in rak šest desetletij nazaj. In: Skela Saviè B, eds. Razvoj onkologije in onkološke zdravstvene nege. Kakovost v zdravstveni negi. 29. strokovni seminar, Ljubljana 2002. Zbornik. Ljubljana: Sekcija medicinskih sester v onkologiji pri Zbornici zdravstvene nege Slovenije - Zvezi društev medicinskih sester in zdravstvenih tehnikov Slovenije, 2002: 19–24. -Uršiè Vršèaj M, Primic Žakelj M, Kirar Fazarinc I. Epidemiologija raka materniènega vratu v Sloveniji in v svetu ter nacionalni program ZORA. In: Možina A ed. Zgodnja detekcija raka materniènega vratu : kolposkopski teèaj, Ljubljana 2002. Zbornik predavanj. Ljubljana: Klinièni center - Ginekološka klinika, 2002: 5–7. 203 -Benedièiè Pilih A, Pompe Kirn V, Kokol P, Povalej P, Arzenšek J. Kožni melanom v Sloveniji in potreba po preventivi. In: Miljkoviæ J ed. Dermatološki dnevi. Strokovno izpopolnjevanje iz dermatologije z mednarodno udeležbo, Maribor 2003. Maribor: Splošna bolnišnica, 2003: 27–37. -Berrino F, Capocaccia R, Gatta G et al, eds. Survival of cancer patients in Europe: the EUROCARE-3 study. Ann Oncol 2003; 14(5). -Lutz JM, Francisci S, Pompe Kirn V et al and EUROPREVAL Working Group. Cancer prevalence in Central Europe: the EUROPREVAL study. Ann Oncol 2003; 14(2): 313–22. -Pompe Kirn V. Rak v številkah : da bi ga bolje razumeli in lažje obvladovali. Okno 2003; 17(1): 27–9. -Pompe-Kirn V, Zakotnik B, Zadnik V. Preživetje bolnikov z rakom v Sloveniji 1983–1997. Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2003. -Primic Žakelj M, Arko D, Rener M, Žgajnar J. Rak dojk v Sloveniji: epidemiologija in presejanje. Zdrav Vestn 2003; 72: Suppl 2: II–179–II–181. -Primic Žakelj M, Zadnik V. Epidemiologija raka dojk. In: Takaè I, Arko D eds. 30 let Centra za bolezni dojk v Mariboru. Simpozij z mednarodno udeležbo, Maribor 2003. Zbornik predavanj. Maribor: Splošna bolnišnica, 2003: 15–27. -Primic Žakelj M, Zadnik V. Rak dojk: razširjenost in nevarnostni dejavniki.In: Štabuc B, ed. Veè znanja o raku, manj smrti. Seminar, Strunjan 2003. Ljubljana; Koper: Zveza slovenskih društev za boj proti raku; Obalno društvo za boj proti raku, 2003: 55–63. -Primic Žakelj M, Zadnik V. Staranje prebivalstva in rak. In: Skela Saviè B ed. Starost in rak. 30 strokovni seminar, Ljubljana 2003. Ljubljana: Sekcija medicinskih sester v onkologiji pri Zbornici zdravstvene nege - Zvezi društev medicinskih sester in zdravstvenih tehnikov Slovenije, 2003: 5–11. -Uršiè Vršèaj M, Primic Žakelj M, Kirar Fazarinc I. Epidemiologija raka materniènega vratu v Sloveniji in v svetu ter nacionalni program ZORA. In: Možina A, ed. Zgodnja detekcija raka materniènega vratu in kolposkopski teèaj in Praktièna kolposkopija in ambulantno zdravljenje prekanceroze, Ljubljana 2003. Zbornik predavanj. Ljubljana: Klinièni center; Ginekološka klinika; Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo, 2003: 92–5. -Zadnik V, Šelb J: Osnovni vzroki smrti s kazalniki umrljivosti v Sloveniji v letu 2001. Zdrav Vestn 2003; 72(7–8): 429–4. 204 -Benedièiè Pilih A, Pompe Kirn V, Kokol P, Povalej P. Kožni melanom v Sloveniji in potreba po preventivi. In: Bešiæ N, Anderluh F, Benedik J et al eds. Novosti v onkologiji in smernice za obravnavo bolnic z rakom dojk in bolnikov z malignim melanomom. 17. onkološki vikend. Laško: Kancerološko združenje Slovenskega zdravniškega društva, 2004: 107–9. Cancer Incidence in Slovenia 204 7 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia -de Vries E, Boniol M, Dore JF, Coebergh JW, Pompe Kirn V and Eurocare Working Group. Lower incidence rates but thicker melanomas in Eastern Europe before 1992: a comparison with Western Europe. Eur J Cancer 2004; 40: 1045–52. -Jazbec J, Eæimoviæ P, Jereb B. Second neoplasms after treatment of childhood cancer in Slovenia. Pediatr Blood Cancer 2004; 42: 574–81. -Kirar Fazarinc I, Primic Žakelj M. Stanje na podroèju presejanja raka dojk in vzpostavitev organiziranega programa v Sloveniji. Radiol Oncol 2004; 38: Suppl 1: S21–5. -Kirar Fazarinc I, Primic Žakelj M. Izvajanje Državnega programa ZORA in kazalci organiziranega presejanja raka materniènega vratu v Sloveniji. In: Bešiæ N, Anderluh F, Benedik J et al eds. Novosti v onkologiji in smernice za obravnavo bolnic z rakom dojk in bolnikov z malignim melanomom. 17. onkološki vikend. Laško: Kancerološko združenje Slovenskega zdravniškega društva, 2004: 105–6. -Norièiè G, Repše S, Pompe-Kirn V. Rezultati zdravljenja raka debelega èrevesa in danke v Sloveniji - analiza leta 1997. Gastroenterolog 2004; 8: Suppl 2: 287–9. -Primic Žakelj M. Smernice za zgodnje odkrivanje raka. In: Skela Saviè B, Logonder M, Lokar K eds. Ukrepajmo danes, da bomo živeli jutri. 31. strokovni seminar Sekcije medicinskih sester v onkologiji. Moravske toplice: Zbornica zdravstvene nege Slovenije-ZDMSZTS, 2004: 28–33. -Primic Žakelj M, Kirar Fazarinc I. Cervical cancer screening a Slovenian experience. In: Better health outcomes through public health approaches in primary health care. Fourth international forum on common access to health care. Brdo pri Kranju: Ministry of Health, 2004: 1–5. -Primic Žakelj M, Ravnihar B and Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83000 women with breast cancer from 16 countries. Lancet 2004; 363: 1007–16. -Primic Žakelj M, Zadnik V. Kajenje in rak v Sloveniji. In: Štabuc B, Primic Žakelj M, Zdešar A eds. Kajenje in rak. 12. seminar "In memoriam dr. Dušana Reje". Ljubljana: Zveza slovenskih društev za boj proti raku, Onkološki inštitut, Inštitut za varovanje zdravja RS, Rdeèi križ Slovenije, 2004: 36–42. -Primic Žakelj M, Zadnik V. Epidemiologija raka dojk v svetu in v Sloveniji. Radiol Oncol 2004; 38: Suppl 1: S1–S7. -Primic Žakelj M, Zadnik V, Škrlec F. Nekaj osnovnih podatkov in zanimivosti iz novega letnega poroèila Registra raka za Slovenijo. Onkologija 2004; 8: 22–4. -Tyczynski JE, Bray F, Pompe Kirn V et al. Lung cancer mortality patterns in selected Central Eastern and Southern European countries. Int J Cancer 2004; 109: 598–610. -Tyczynski JE, Pleško I, Primic Žakelj M et al. Breast cancer mortality patterns and time trends in 10 new EU member states: mortality declining in young women, but still increasing in the elderly. Int J Cancer 2004; 112: 1056–64. -Zadnik V, Primic Žakelj M. Vpliv dejavnikov tveganja in genetske nagnjenosti na pojavljanje raka dojk pri mladih ženskah. In: Bešiæ N, Anderluh F, Benedik J et al eds. Novosti v onkologiji in smernice za obravnavo bolnic z rakom dojk in bolnikov z malignim melanomom. 17. onkološki vikend. Laško: Kancerološko združenje Slovenskega zdravniškega društva, 2004: 114–5. 205 -Bray F, Carstensen B, Moller H, Zappa M, Žakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005; 14: 2191–9. -Brennan P, Scelo G, Hemminki K, Mellemkjaer L, Tracey E, Pompe-Kirn V, et al. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer 2005; 93: 159–66. -Hemminki K, Scélo G, Boffetta P, Mellemkjaer L, Tracey E, AndersenA et al. Second primary malignancies in patients with male breast cancer. Br J Cancer 2005; 92: 1288–92. -Kobal AB, Horvat M, Prezelj M, Pompe-Kirn V, Zadnik V, Osredkar J, et al. Vpliv elementarnega živega srebra na peroksidacijo l ipidov in funkcijsko sposobnost posameznih tarènih organov pri prebivalcih mesta Idrija in delavcih rudnika : zakljuèno poroèilo raziskovalnega projekta (skrajšana verzija). Idrij Razgl 2005; 50: 20–30. -Norèiè G, Repše S, Pompe-Kirn V. Rak debelega èrevesa in danke v Sloveniji - razlike v kirurškem zdravljenju in preživetju bolnikov. Zdrav vestn 2005; 74:št. 12, 767–70. -Pompe Kirn V. Podrobnejši pregled trenda incidence raka šèitnice v obdobju 1983–2002 v Sloveniji. Onkologija 2005; 9: 12–4. -Primic Žakelj M. Epidemiology of breast cancer: incidence and mortality trends, prevention and control. 3rd Sarajevo breast cancer conference. Sarajevo: ESO, 2005: 15–27. -Primic Žakelj M. Evropske smernice za presejanje žensk za raka materniènega vratu. In: Možina A, ed. HPV in prepreèevanje raka materniènega vratu Kje smo in kako naprej? (HPV infection and cervical cancer prevention - Where are now, what to do next?) Mednarodni znanstveni simpozij. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo, 2005: 9–13. -Primic Žakelj M. Prenovljeni evropski kodeks proti raku. In: Štabuc B, ed. Poroèilo Zveze in regijskih društev za boj proti raku Slovenije: leto 2004. Ljubljana: Zveza društev za boj proti raku Slovenije, 2005: 6–11. -Primic Žakelj M. Zgodnje odkrivanje pogostejših rakov pri starejših. In: Turk J, ed. Zdrava poznejša leta. Ljubljana: Društvo za zdravje srca in ožilja Slovenije, 2005: 97–110. -Primic Žakelj M, Zadnik V. Epidemiologija raka dojk v Sloveniji in v svetu. In: Štabuc B, ed. Poroèilo Zveze in regijskih društev za boj proti raku Slovenije: leto 2004. Ljubljana: Zveza društev za boj proti raku Slovenije, 2005: 13–6. -Primic Žakelj M, Zadnik V. Presejanje in zgodnje odkrivanje raka. In: Štabuc B, ed. Zgodnje odkrivanje raka - izzivi za prihodnost. XIII. seminar "In memoriam dr. Dušana Reje", Zbornik. Ljubljana: Zveza slovenskih društev za boj proti raku, 2005: 8–13. -Primic Žakelj, Zadnik V. Raziskovalno delo službe epidemiologija in registri raka na Onkološkem inštitutu. In: Bilban M, ed. Cvahtetovi dnevi javnega zdravja 2005. Ljubljana: Medicinska fakulteta, 2005: 125–34. 78 Incidenca rka v Slovenij 204 Onkolš ki inš tiut Ljubljan, Register ak za Slovenijo -Primic Žakelj, Zadnik V, Žagar T. Epidemiološki podatki o raku materniènega vratu v Sloveniji. In: Takaè I, ed. 50 let laboratorija za ginekološko citologijo v Mariboru. Mednarodni znanstveni simpozij. Maribor: Splošna bolnišnica, 2005: 151– -Primic-Žakelj M, Zadnik V, Žagar T. Is cancer epidemiology different in Western Europe to that in Eastern Europe? Ann Oncol 2005; 16 Suppl 2: ii 27–9. -Quaglia A, Vercelli M, Lillini R, Mugno E, Coebergh JW, Quinn M, and ELDCARE Working Group. Socio-economic factors and health care system characteristics related to cancer survival in the elderly. A population-based analysis in 16 European countries (ELDCARE project). Crit Rev Oncol Hematol 2005; 54: 117–28. -Zadnik V: Evropska raziskava vplivov dejavnikov tveganja na zbolevanje za rakom dojk pri mladih ženskah: podatki za Slovenijo. In: Bilban M, ed. Cvahtetovi dnevi javnega zdravja 2005. Ljubljana: Medicinska fakulteta, 2005: 135–49. -Zadnik V, Primic Žakelj M. Epidemiologija želodènega raka. In: Omejc M, Repše S, eds: Kirurgija želodca - standardi in novosti. Simpozij. Ljubljana: Klinièni oddelek za abdominalno kirurgijo, SPS Kirurška klinika, Klinièni center, 2005: 122–7. -Žagar T, Primic Žakelj, Zadnik V. Povezovanje Registra raka za Slovenijo s sorodnimi državnimi podatkovnimi zbirkami. In: Tkaèik B, Urbas M, eds. Komuniciranje z dajalci in uporabniki statistiènih podatkov ter podpora EMU in Lizbonski strategiji. 15. statistièni dnevi. Ljubljana: Statistièni urad Republike Slovenije, Statistièno društvo Slovenije, 2005: 268–7. -Žagar T. Lifetables for Slovenia 19822004. Rostock: Max Planck, 2005: 1–94. http://www.lifetable.de/cgi-bin/country.plx?country=Slovenia. 206 -Allemani C, Sant M, De Angelis R, Marcos-Gragera R, Coebergh JW and EUROCARE Working Group. Hodgkin disease survival in Europe and the U.S.: prognostic significance of morphologic groups. Cancer 2006; 107: 352–60. -Hertl K, Primic Žakelj M, Žgajnar J, Kocijanèiè I. Performance of opportunistic breast cancer screening in Slovenia. Neoplasma 2006; 53: 237–41. -Mellmkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E et al. Risk of second cancer among women with breast cancer. Int J Cancer 2006; 118: 2285–92. -Mitry E, Ciccolallo L, Coleman MP, Gatta G, Pritchard-Jones K and EUROCARE Working Group. Incidence of and survival from Wilms' tumour in adults in Europe: data from the EUROCARE study. Eur J Cancer 2006; 42: 2363–8. -Pompe-Kirn V, Primic Žakelj M. Ali vemo, koliko je raka prostate v Sloveniji in kaj vpliva na razvoj te bolezni? Onkologija 2006; 10: 9–13. -Pompe-Kirn V. Obolevnost za rakom dojk med ženskami, vkljuèenimi v pilotno študijo. Onkologija 2006; 10: 96–8. -Primic Žakelj M, Zadnik V, Pogaènik A, Uršiè-Vršèaj M. Presejanje za raka materniènega vratu v Sloveniji in državni program ZORA. Radiol Oncol; 2006: 40: Suppl 1: s143–s148. 60. -Primic Žakelj M, Krajc M, Mauèec Zakotnik J. Presejanje za raka dojk - kje smo danes. Radiol Oncol 2006; 40: Suppl 1: s25–s30. -Primic Žakelj M, Zadnik V, Žagar T. Breast cancer risk factors. Lijeè Vjesn 2006; 128, Suppl 3: 49–50. -Primic Žakelj M, Zadnik V, Žagar T. Epidemiologija raka debelega èrevesa in danke (Epidemiology of colorectal cancer. In: Repše S, Štor Z eds. Kirurgija raka debelega èrevesa in danke: standardi in novosti. Zbornik simpozija (Standards & novelties: proceedings of the symposium, Ljubljana 2006. Ljubljana: Kirurška šola, Klinièni oddelek za abdominalno kirurgijo, Kirurška klinika, Klinièni center, 2006: 14–20. -Primic Žakelj M, Zadnik V, Žagar T. Ali se uèinki programa ZORA že kažejo v incidenci invazijskega raka materniènega vratu. In: Možina A ed. Dan ginekološke onkologije: rak jajènikov. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo: Ginekološka klinika, Klinièni center, 2006: 55–6. -Pogaènik A, Primic Žakelj M. Ali je kakšen napredek na podroèju laboratorijske dejavnosti pri analizi BMV? In: Možina A ed. Dan ginekološke onkologije: rak jajènikov. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo: Ginekološka klinika, Klinièni center, 2006: 57. - – -Scélo G, Boffetta P, Hemminki K, Pukala E, Olsen JH, Andersen A et al. Associations between small intestine cancer and other primary cancers: an international population-based study. Int J Cancer 2006; 118: 189–96. - – -Strojan P, Šmid A, Èizmareviè B, Žagar T, Auersperg M. Verrucous carcinoma of the larynx : determining the best treatment option. Eur J Surg Oncol 2006; 32: 984–8. -Steliarova-Foucher E, Kaatsch P, Lacour B, Pompe-Kirn V, Eser S, Miranda A et al. Quality, comparability and methods of analysis of data on childhood cancer in Europe (1978–1997) : report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006; 42: 1915–51. -Vercelli M, Lillini R, Capocaccia R, Micheli A, Coebergh JW, Quinn M and ELDCARE Working Group. Cancer survival in the elderly: effects of socio-economic factors and health care system features (ELDCARE project). Eur J Cancer 2006; 42: 234–42. -Zadnik V, Primic Žakelj M. Breme želodènega raka v svetu in Sloveniji (The burden of stomach cancer worldwide and in Slovenia). In: Zbornik predavanj XI I. podiplomskega teèaja kirurgije, 10.–11. februar 2006. Ljubljana: Kirurška klinika, Klinièni center, 2006: 77–80. -Zadnik V, Reich BJ. Analysis of the relationship between socioeconomic factors and stomach cancer incidence in Slovenia. Neoplasma 2006; 53: 103–10. Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scelo G, Pukkala E et al. Second primary cancers in thyroid cancer patients : a multinational record linkage study. J Clin Endocrinol Metab 2006; 91: 1819 25. Shen M, Boffetta P, Olsen JH, Andersen A, Hemminki K, Pukkala E et al. A pooled analysis of second primary pancreatic cancer. Am J Epidemiol 2006; 163: 502 11. - Zadnik V. Geografska analiza razporejanja incidence raka. Onkologija 2006; 10: 92–5. -Zadnik V, Žagar T, Primic Žakelj M. The geographical variation of cervical cancer screening efficiency in Slovenia. In: Batagelj V, Ferligoj A, Žiberna A eds. Data science and classification : program and abstracts. Ljubljana: Center of Methodology and Informatics, Institute of Social Sciences at Faculty of Social Sciences, 2006: 173. -Zadnik V, Žagar T, Primic Žakelj M. Estimating the efficiency and geographical variability of cervical cancer incidence in Slovenia. In: Stare J, Vidmar G eds. International Conference Applied Statistics 2006, September 17-20, 2006, Ribno (Bled), Slovenia. Program and Abstracts. Ljubljana: Statistical Society of Slovenia, 2006: 74–5. Cancer Incidence in Slovenia 204 79 Instiute of Oncolgy Ljubljan, Cancer Registry of Slovenia -Žagar T, Primic Žakelj M, Zadnik V. Pretok in uporaba informacij v Registru raka - najstarejšem zdravstvenem registru v Sloveniji. Bilt ekon organ inform zdrav 2006; 22: 6. – -Žagar T, Zadnik V, Pohar M, Primic Žakelj M. Complete yearly life tables by sex for Slovenia, 1982–2004, and their use in public health [Popolne letne tablice umrljivosti za Slovenijo po spolu, 1982–2004, in možnosti uporabe v javnem zdravju]. Radiol Oncol 2006; 40: 115 24.